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Abstract 
Kinase suppressor of Ras-1 (KSR1), originally identified as a novel protein kinase in the Ras-
Raf cascade, plays a role in activation of mitogen-activated protein kinases (MAPKs). 
Although efforts have been devoted to study the role of KSR1 in certain tumour types, its 
biological functions in breast cancer have remained largely undefined. 
A SILAC-based proteomic analysis was conducted to identify the KSR1-regulated phospho-
proteins in breast cancer. Our results revealed that KSR1 overexpression decreases deleted in 
breast cancer 1 (DBC1) phosphorylation. We then demonstrated that KSR1 decreases 
transcriptional activity of p53 by reducing phosphorylation of DBC1, which leads to a 
reduced interaction of DBC1 with sirtuin 1 (SIRT1); this in turn enables SIRT1 to deacetylate 
p53.  
We further examined the correlation between KSR1 expression and clinical outcome in breast 
cancer. Our results showed that patients with breast cancer with high KSR1 in our cohort 
(n>1000) had better disease free- and overall survival. Moreover, in KSR1-transfected stable 
cells, fewer and smaller size colonies were formed in comparison to parental cells, while an in 
vivo study demonstrated that the growth of xenograft tumours overexpressing KSR1 was 
inhibited. Mechanistically, the tumour suppressive action of KSR1 is BRCA1 dependent, 
which was shown by in vitro 3D matrigel and soft agar assays. KSR1 regulates BRCA1 
ubiquitination through elevated BRCA1-associated RING domain 1 (BARD1) expression and 
increased BRCA1-BARD1 interaction. 
Deregulation of tyrosine kinases (TKs) signalling can contribute to tumourigenesis. A 
combined approach of RNAi and SILAC-based quantitative proteomics was employed to 
decode the TKs-regulated proteomes upon silencing individually each 65 validated TKs in 
MCF7 breast cancer cells. Bioinformatics analysis identified 10 new distinctive clusters based 
on similarity in the TKs-regulated proteomes. The biological relevance of our proteomic study 
in interpreting the TKs-regulated proteomes supports the essential role of TKs in regulating 
all aspects of cellular activities.  
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CHAPTER 1: 
INTRODUCTION 
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1.1 Cancer 
1.1.1 Cancer is a major cause of disease and death 
Cancer is a major health problem and remains a leading cause of death around the globe. In 
2012, 14.1 million people were newly diagnosed with cancer (excluding non-melanoma skin 
cancer), and 8.2 million died from cancer worldwide [1]. It is predicted that the number of 
annual cancer cases will increase from 14 million to 22 in the next two decades [1]. Lung, 
liver, stomach, colorectal and breast cancers are responsible for causing the most cancer-
related deaths each year [1, 2]. Data from the World Health Organization (WHO) shows that 
five leading behavioural and dietary risks including high body mass index, low fruit and 
vegetable intake, lack of physical activity, tobacco and alcohol use are responsible for about 
30% of cancer deaths [1, 2]. 
More specifically, in 2011 in the UK, more than 331,000 people were diagnosed with cancer 
[3-7]. The European Age-Standardised (AS) incidence rates for all cancers (excluding non-
melanoma skin cancer) in the UK increased by 23% in males and by 43% in females during 
the period 1975-1977 to 2009-2011. However, there has been a slowdown in the rate of 
increase over the past ten years, with the AS incidence growing by 3% in males and 7% in 
females (Figure 1) [3-7]. Approximately 159,000 people died from cancer in the UK in 2011 
[8]. Despite an increase in cancer incidence, cancer mortality is decreasing in the UK. 
Between 1990-1992 and 2009-2011, the European AS mortality rates decreased by 26% in 
males and 20% in females. In the last ten years, the rate of reduction has started to decelerate, 
with the AS mortality rates declining by 12% and 9% in males and females, respectively 
(Figure 2). A further 17% decrease of cancer deaths is expected between 2011 and 2030 in 
the UK [9, 10]. 
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Figure 1 Cancer incidence in the UK. 
All cancers excluding non-melanoma skin cancer, European Age-Standardised Incidence Rates, 
UK, 1975-2011. Modified from Cancer Research UK website, 2014. 
Figure 2 Cancer mortality in the UK. 
All cancers, European Age-Standardised Mortality Rates, UK, 1971-2011. Modified from Cancer 
Research UK website, 2014. 
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1.1.1.1 Breast cancer 
Breast cancer is the second most common cancer after lung cancer worldwide. In females, it is 
the most frequent malignancy both in more and less developed regions with an estimated 1.67 
million people newly diagnosed globally in 2012, accounting for 25% of all cancers [1]. 
Breast cancer is the fifth cause of death from all cancers (522,000 deaths). However, in 
females, it is the most common cause of cancer death in less developed regions (324,000 
deaths, 14.3% of all) and the second cause in more developed regions (198,000 deaths, 15.4%) 
after lung cancer [1]. In the UK, breast cancer is the most common cancer in women with a 
lifetime risk of 1 in 8 females being diagnosed with breast cancer [3-7]. More than 49,500 
women and 400 men in the UK were diagnosed with breast cancer in 2010. Since 1970s, 
breast cancer incidence rates in women have increased by almost 70% in the UK, partly 
owing to the awareness of early signs and symptoms and mammography screening, which 
lead to early detection. Around 11,700 females and 80 males died from breast cancer in the 
UK in 2011 [8]. Female breast cancer death rates have fallen by 40% in the UK since the mid-
1980s, despite increases in incidence rates. Numerous factors have contributed to better 
survival rates of breast cancer patients, including early diagnosis, improvements in surgery 
practice and radiation-therapy delivery, development of systemic chemotherapy, endocrine 
therapy, and targeted therapies. Despite that, breast cancer still remains the second most 
common cause of death from cancer in women. A better understanding of the mechanisms 
underlying carcinogenesis, tumour progression and metastasis, resistance to therapies will 
help us develop more effective treatments and continue to improve patient prognosis.  
1.1.2 The hallmarks of cancer 
Cancer is believed to stem from one single cell. Oncogenic transformation from a normal cell 
into a malignant cell in humans is a multistage process. Typically, these steps are manifested 
in genetic changes that contribute to the progressive conversion of normal human cells into 
malignant derivatives [11, 12]. 
Due to the remarkable progress in cancer research over the past decades, our understanding of 
the biology of cancer has greatly improved. Scientists have now realized that tumours are 
more than a mass of sustaining proliferative cancer cells. Importantly, they are multifaceted 
entities comprising a collection of distinct cell types, including normal cells forming tumour-
related stroma, which function actively to contribute to the initiation, development and 
metastasis of tumour cells. The conceptual progress has allowed Hanahan and Weinberg to 
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revisit their original elaboration of hallmarks of cancer and to recognise the emerging 
hallmark traits. Together with the initial six, they have recently summarised in total ten 
biological capabilities and enabling characteristics attained during the multistep development 
from normal cells to human tumours [11, 12]. These hallmarks are: 
 Self-sufficiency in growth signals leading to sustaining proliferation  
 Resistance to cell death signals 
 Avoidance of anti-growth signals 
 Uncontrolled replicative immortality 
 Sustained angiogenesis replicative immortality 
 Activation of invasion and metastasis 
 Instability and mutation of genome 
 Deregulation of cellular energy metabolism 
 Tumour-promoted inflammation 
 Escaping from immune destruction 
 
 
 
 
Figure 3 Hallmarks of cancer. 
Biological capabilities that were proposed by Hanahan and Weinberg as hallmarks of cancer are 
shared in common by all human cancers. Modified from Hanahan and Weinberg, 2011 
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Notably, protein kinases play a fundamental role in all aspects of cell organization and 
behaviour, whereas deregulation of protein kinases can contribute to the development of 
almost all hallmarks of cancer [13]. A detailed description of protein kinases, particularly 
tyrosine kinases (TKs) is presented in sections 1.2 and 1.4, respectively.  
 
Focusing on the main scope of this thesis, the origins of protein phosphorylation and the 
classifications of protein kinases in the human kinome is discussed. Particularly, I will 
describe the biological function of an interesting group in the human kinome, termed 
“pseudokinases”, as well as summarize the current understanding of one member from this 
group, kinase suppressor of Ras 1 (KSR1). In the last section, TKs are reviewed, highlighting 
with a few examples regarding their structural and functional importance, and their 
involvement in carcinogenesis. 
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1.2 Protein kinases 
Ever since the discovery of reversible phosphorylation regulating the activity of glycogen 
phosphorylase, mounting evidence has shown that the reversible phosphorylation of proteins 
is essential to the modulation of almost all aspects of cell function [14]. Protein kinases are 
conserved enzymes that are capable of transferring a phosphate group from a phosphate 
contributor onto a receiver amino acid in a target protein. In general, the contributor is the γ 
phosphate of adenosine-5'-triphosphate (ATP), or another nucleoside triphosphate, but 
different enzymes may have other phosphate donors. Due to the fact that most protein kinases 
have more than one substrate, classification of protein kinases is thus based on the receiver 
amino acid specificity rather than protein substrate specificity and two main families are 
hence defined as serine/threonine (Ser/Thr) and tyrosine (Tyr) kinases [15, 16]. 
Phosphorylation can lead to activation or inhibition of biological activity, enhancement or 
decrease of molecule movement and facilitation or disruption of protein-protein interaction, 
depending on the target substrates and associated networks. 
1.2.1 The origins of phosphorylation  
The first evidence of protein kinase activity was reported in 1954, which described that an 
enzyme present in liver mitochondrial can phosphorylate casein [17]. Shortly after, two 
different groups identified that a phosphorylation/dephosphorylation mechanism was involved 
in the conversion of phosphorylase b to phosphorylase a [18-20]. One of the groups led by 
Fischer and Krebs showed that the b form could be converted to the a form in cell-free muscle 
extracts dependent of Mg
2+
 and ATP and an enzyme named as phosphorylase kinase by the 
authors [18, 19]. Subsequently, this kinase was revealed to facilitate the transfer of the γ-
phosphoryl group of ATP to a specific serine residue on phosphorylase b [14, 21].  
It was not easy to purify protein kinases in the early days. In 1959, phosphorylase kinase was 
the first protein kinase purified from rabbit muscle [22]. After nine years, another protein-
serine kinase, the cyclic adenosine monophosphate (cAMP)-dependent protein kinase (also 
known as protein kinase A (PKA)), was purified from rabbit skeletal muscle [23]. In 1979, the 
first protein-tyrosine kinase, pp60
v-src
, was purified using ion exchange or immunoaffinity 
chromatography [24], followed by purification of  the epidermal growth factor (EGF) receptor 
kinase from shed plasma membrane vesicles [25]. With the development of molecular cloning 
and gene sequencing in the late twentieth century, a great body of evidence supported that a 
large family of eukaryotic protein kinases exists, and the burgeoning numbers of protein 
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kinases identified or characterized further suggested that the mammalian genome may encode 
as many as a thousand different protein kinases [26, 27]. The achievement of human genome 
sequence finally allows scientists to be able to identify all human protein kinases, catalogued 
as human kinome by Manning and colleagues. A total of 518 putative protein kinases 
constituting about 1.7% of all human genes have been characterized [27]. The human kinome 
will be discussed in details in the next part of this introduction (Section 1.2.3).  
1.2.2 Kinase domain structure 
The exponentially increasing rate of identified protein kinases resulting from molecular 
cloning and sequence has uncovered the fact that all protein kinases share prominent sequence 
similarity in their catalytic domains [26]. The first evidence of this similarity came from a 
surprising discovery that a region of approximately 300 amino acids in the catalytic subunit of 
the cAMP-dependent protein kinase and pp60
v-src
 was related [28]. This finding indicates that 
the cAMP-dependent protein kinase and pp60
v-src
 may originate from the same ancestral 
protein kinase. It is thus reasonable to conclude that some if not all eukaryotic protein-
serine/threonine and protein-tyrosine kinase genes arose from a single archetypal gene given 
the identified sequence similarities [26]. Soon catalytic domains consisting of 250-300 amino 
acid residues within protein kinases were characterized and subsequently the first systematic 
classifications of protein kinases on account of their homologous kinase domains (catalytic 
domains) were presented by Hanks and Hunter [16]. Their monumental work that analysed 
and aligned the amino acid sequences of reported protein kinases allowed the identification of 
conserved structural features responsible for their enzymatic activity. These revolutionarily 
conserved domains in turn revealed the common mechanism underlying the regulation of 
transferring the γ phosphate of a purine nucleotide triphosphate to the hydroxyl groups of 
their associated substrates, even if diversities of structures, regulation modes, and substrate 
specificities among the protein kinases exist [16].  
In 1991, Knighton and colleagues solved the first crystal structure of the cAMP-dependent 
protein kinase (PKA), the hallmark for all successive structural studies of kinases [29]. A 
great body of elegant work subsequently dissected the crystal structures of other protein 
kinases including cyclin-dependent kinase 2 (CDK2), the mitogen-activated protein kinase 
(MAPK) or extracellular-signal regulated kinase 2 (ERK2) and the tyrosine kinase c-SRC 
[29-34]. These comprehensive studies uncovered that classical protein kinases have a 
canonical catalytic domain of ~250 amino acids in length, consisting of a small N-terminal 
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lobe of β-sheets and a larger C-terminal lobe of α-helices [35]. From the crystal structures of 
identified protein kinases, Hanks and Hunter summarized that the conserved kinase domains 
contain 12 canonical subdomains that fold into a common catalytic core structure and two 
main subdivisions within the superfamily: the protein-serine/threonine kinases and the 
protein-tyrosine kinases [16]. The three main roles endorsed to the kinase domains of protein 
kinases to exert catalytic activity are: a) allowing interaction and orientation of the ATP 
phosphate donor as a complex with Mg
2+
; b) allowing interaction and orientation of the 
protein (or peptide) substrate; c) allowing the transfer of the γ-phosphate from ATP to the 
receiver hydroxyl residue (serine, threonine, or tyrosine) of the protein substrate [16].  
The common mechanism and fold shared by protein kinases are described here as an example 
of the basic catalytic cycle for substrate phosphorylation by a kinase (Figure 4). Firstly, ATP 
binds in a cleft between the N-terminal and C-terminal lobes to enable the adenosine moiety 
to place in a hydrophobic pocket with the phosphate backbone positioned towards the outside 
of the solution. Then, the protein substrate integrates along the cleft and this consequently 
allows the conserved residues within the kinase catalytic domain to catalyse the transfer of γ-
phosphate of ATP to the hydroxyl oxygen of the Ser, Thr or Tyr residue of the substrate. 
Finally, after phosphorylation, the substrate and ADP are released from the active site [35].  
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1.2.3 Human kinome 
Protein phosphorylation is the most common type of post-translational modification in the 
signal transduction of eukaryotic cells. Through phosphorylation of substrates, protein kinases 
modulate almost every aspect of cellular processes, including development, metabolism, 
transcription, differentiation, cell cycle progression, proliferation and apoptosis [27, 35]. 
Given their essential role in signal transduction, protein kinases are one of the largest families 
of genes in eukaryotes and have been extensively studied [36-40]. Moreover, scientists have 
estimated that about 30% of all cellular proteins are phosphorylated on at least one residue 
and assumedly there are approximately 700,000 potential phosphorylation sites (P-sites) for 
any given kinase [35, 41, 42]. With the advent of comprehensive information from human 
genome sequence, a total of 518 human protein kinases, constituting about 1.7% of all human 
genes, have been identified, which are catalogued as “human kinome” by Manning and 
Figure 4 The common mechanism and fold of protein kinases. 
A. A representative catalytic cycle of substrate phosphorylation by a protein kinase. Starting clock-
wise from top left, ATP binds to a cleft between the N-terminal and C-terminal lobes that is the 
active site of the kinase. Subsequently, the complex is joined by the substrate binding to the active 
site. After it is bound, the active domain within the kinase catalyses the transfer of the γ-phosphate 
of ATP (red) to a Ser, Thr or Tyr residue of the substrate. Once phosphorylation is completed, the 
substrate and ADP are then detached from the kinase. The order of the steps may vary depending 
on different kinases. For instance, some kinases bind to their protein substrates first and followed 
by ATP and others release ADP before releasing the protein substrate. B. A similar protein fold 
shared by protein kinase are presented here. It comprises two lobes: one lobe consists of mainly β-
sheet structure (blue) and the other lobe consists of α-helices (green, orange and yellow). This lobe 
structure produces an ATP-binding cleft that creates the active site. The representative fold is 
shown by the crystal structure of CDK2 (Protein Data Bank (PDB) ID: 1QMZ). ATP is modelled 
bound in the cleft (red ball and stick model). This figure is adapted from published work from 
Ubersax et al, 2007. 
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colleagues [27]. It has now been widely recognised that mutations and dysregulation of 
protein kinases result in impaired cellular function and play a critical role in virtually every 
human disease, particularly in malignancies [43, 44]. The complete mapping of human protein 
kinases (kinome) has greatly improved our understanding of the origins of human diseases 
and benefited us in identifying therapeutics targets against them. 
1.2.3.1 Classification and phylogeny of the human kinome 
The classification of protein kinases has greatly increased over the past twenty years. In 1995, 
Hanks and Hunter classified protein kinases into five broad groups, 44 families, and 51 
subfamilies, based on the comparison of the sequences in the catalytic fragment [16]. To 
further advance our understanding of kinase function and evolution, the milestone work by 
Manning and colleagues has catalogued and classified the complete complement of protein 
kinases in the human genome and added four new groups, 90 families, and 145 subfamilies 
[27]. These new classifications are clustered primarily by comparing the sequences of their 
catalytic domains, assisted by information of similarities in sequence and domain structure 
outside of the catalytic domains, defined biological functions, and a conserved classification 
of the yeast, worm, and fly kinomes [38]. 
The human kinome is catalogued into seven main groups, including PKA, PKG and PKC 
families (AGC); calcium (Ca
2+
)/calmodulin (CaM)-dependent protein kinases (CAMK); 
casein kinase 1 (CK1); containing CDKs, MAPKs, glycogen synthase kinase 3 (GSK3), 
Cdc2-like kinase (CLK) families (CMGC); homologs of the yeast Sterile 7, Sterile 11 and 
Sterile 20 kinases (STE); tyrosine kinases (TK);  tyrosine kinase-like (TKL) (Figure 5). Other 
small groups such as atypical protein kinases are not discussed here due to limited studies 
available. Moreover, most family members within each main kinase group share 
evolutionarily conserved sequences, structure, as well as functions. 
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Figure 5 The phylogenetic tree of the complete superfamily of human protein kinases. 
A total of 518 human protein kinases are classified based on similarity between the protein 
sequences of these catalytic domains. Each kinase is at the tip of a branch, and the similarity 
between various kinases is inversely related to the distance between their positions on the tree 
diagram. Most kinases fall into small families of highly related sequences, and most families are 
part of larger groups. The seven major groups are labelled and coloured distinctly. Other kinases 
are shown in the centre of the tree, coloured gray. This figure is adapted from published work from 
Manning et al, 2002. 
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The AGC kinase group of protein kinases comprises 60 members, including PKA, PKG and 
PKC families [16, 27]. From the information of the solved kinase domain structures so far, it 
is now recognised that the structures of active AGC kinases are highly similar [45]. In the 
bilobal kinase fold, ATP, which serves as the phosphate donor during phosphorylation, is 
forked between a small N-lobe and a large C-lobe. The activation segment of the kinase 
containing catalytic elements such as the Asp-Phe-Gly (DFG) motif for phosphoryl transfer is 
located in the C-lobe, adjacent to the ATP-binding site, whereas through αC helix the 
activation segment connects to the N-lobe [46]. Upon phosphorylation, conformational 
changes within the active and regulatory elements coordinate the formation of a set of 
interactions required for the catalytic activity of the kinase [47, 48].  As one of the most 
studied kinase groups, the AGC family are implicated in multiple important cellular functions 
and their dysregulation contributes to the pathogenesis of many human diseases, including 
cancer [45]. 
The CAMK group of protein kinases comprises a number of important and well-studied 
subgroups including CaMKs (CaMKI, CaMKII, CaMKIV and CaMKK), check point kinases 
(CHKs), AMP-activated protein kinases (AMPKs) and microtubule affinity-regulating 
kinases (MARKs) [27]. Although the CAMK group is named after Ca
2+
/CaM-dependent 
protein kinase, only some of the CAMK group protein kinases are known to be activated by 
Ca
2+
/CaM binding to a domain located near the C-terminus to the catalytic domain, such as 
CaMKI, CaMKII, CaMKIV, CaMKK and MLCK [16, 49]. Studies of structure and regulation 
of CaMKs have provided insights in understanding this interesting group of kinases. CaM is a 
ubiquitous 16-17 kD protein enclosing four helix-loop-helix motifs that can bind Ca
2+
 with 
high specificity and affinity. CaM has two globular domains with two Ca
2+
 binding sites 
individually and coupled by a flexible α-helix. Upon Ca2+ binding to CaM,  a conformational 
change is induced, thus exposing hydrophobic residues to allow interaction of the Ca
2+
/CaM 
complex with other proteins such as Ser/Thr protein kinases [50]. Moreover, when there is no 
Ca
2+
/CaM in the system, the CaMKs are auto-inhibited. Apart from activation by Ca
2+
/CaM, 
phosphorylations including auto-phosphorylation or phosphorylation by some other kinase 
can also modulate their kinase activity [50]. 
The CMGC group includes key kinases such as CDKs, ERKs, GSKs, CLKs and CK2s, which 
have a diversity of functions in cell cycle control, stress-response, cell survival and 
metabolism regulation. Some members of this group tend to phosphorylate substrates at sites 
lying in proline (Pro)-rich environments and are known as proline-directed kinases [16]. For 
35 
 
example, studies from the CDK family such as Cdc2 and CDK2 indicate a requirement of 
phosphate acceptors lying directly N-terminal to a Pro residue, which is similar in the case of 
MAPK family [16]. However, some other kinases may not obey the proline-directed 
specificity, such as the CK2 family that shows a strong preference for Ser residues positioned 
N-terminal to a cluster of acidic residues [16]. Further structural analysis will improve our 
understanding regarding the regulation of this well-conserved group and shed light on their 
biological function as well. 
The CK1 group is a small family originally known as casein kinase 1 but now renamed as cell 
kinase 1, comprising CK1s, vaccinia related kinases (VRKs), and tau-tubulin kinases 
(TTBKs). Casein kinase 1 subgroup is a family of monomeric serine/threonine (Ser/Thr)-
selective protein kinases, which is the most extensively studied within this group [27]. To date, 
casein kinase 1 family has been shown to be important in regulating various cellular processes 
including DNA replication, DNA damage response, circadian rhythms, Wnt signalling, 
membrane trafficking, cytoskeleton maintenance and RNA metabolism [51-53]. Both in vitro 
and in vivo studies have shown that the CK1 family prefers pre-phosphorylated substrates. 
Indeed, their most preferable motif contains a phospho-residue in the N-3 position, such as 
pSer/pThr-X-X-Ser/Thr, where pS/pT is a phospho-serine or phospho-threonine, X can be any 
amino acid, and the underlined residues refer to the target site. It is indicated that the priming 
phosphoryl group may cooperate with a basic pocket on the surface of the kinase, thus placing 
the substrate for phosphorylation [54]. 
The STE group consists of MAPK cascade families (Ste7/mitogen-activated protein kinase 
kinase (MAP2K), Ste11/MAP3K and Ste20/MAP4K), which could serially activate each 
other and then consequently phosphorylate the MAPK family [27]. Specifically, the Ste7 
family also known as MEK kinases can directly phosphorylate MAPKs and are typically 
dual-specificity kinase; Ste11 members also known as MEKK kinases can phosphorylate Ste7 
kinases; a number of Ste20 members can activate Ste11 kinases and then transduce the signal 
down the cascade [55]. These families are named after members of the canonical pheromone-
responsive MAPK cascade in yeast. Distinctive members of Ste7 and Ste11 kinases are 
associated with different MAPKs as substrates, such as ERK, c-Jun amino terminal kinase 
(JNK). This highly interactive cascade plays an important role in multiple cellular processes 
and its deregulation contributes to human diseases, particularly cancers [55].  
The TK group is extensively studied and diverse, and has about 90 members, the largest 
number of distinct families of any group [27]. There are two main subgroups: one is classified 
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as receptor tyrosine kinases (RTKs), which localize in the plasma membrane and are activated 
by binding of an extracellular molecule; the other is known as cytoplasmic tyrosine kinases 
(CTKs), containing SRC homology 2 (SH2) and/or SH3 domains essential for activation by 
activated receptor tyrosine kinases motility [56]. A detailed description about the structure 
and function of TKs is presented in a separate chapter below (Section 1.4). TKL group has 
approximately 43 members, and is also a very diverse group of families that resemble both 
tyrosine and serine/threonine kinases. This group comprises the mixed-lineage kinase (MLK), 
Lim domain-containing kinase (LIMK), testis-specific kinase (TESK), Raf, receptor-
interacting protein kinase (RIPK) and serine/threonine kinase receptors (STKR) families, 
which are mainly involved in regulating cellular proliferation, survival, differentiation, 
function, and motility [56]. 
Interestingly, there are about 50 human kinases predicted to be inactive kinases and classified 
as pseudokinases owing to their lack of one or more conserved catalytic residues required for 
enzymatic activity [27]. They have been postulated to function as scaffolding proteins or 
allosteric regulators in signal transduction. A more detailed discussion about this group in 
human kinome is found in the below section 1.2.4.   
1.2.4 Pseudokinases 
The term “pseudokinase” originated from the concept that these protein kinases lack one or 
more conserved residues which are crucial for enzymatic activities compared with classic 
protein kinases such as PKA, therefore they are not predicted to be able to phosphorylate 
substrates. Based on sequence analysis, the excellent work conducted by Manning and 
colleagues demonstrated that approximately 50 protein kinases in the human kinome are 
classified as pseudokinases, which require the intact three motifs (the Val-Ala-Ile-Lys 
(VAIK), the His-Arg-Asp (HRD), the DFG) for ATP and peptide binding, and 
phosphotransfer to exert the catalytic activity (Figure 6) (reviewed by Boudeau and Alessi, 
Zeqiraj and Aalten [57-59]). Interestingly, kinase suppressor of Ras 1 (KSR1), which is the 
main focus of my PhD project, has been classified as a pseudokinase. Its structure and 
associated biological functions is extensively described in section 1.3.  
It appears that these pseudokinases are widely situated in every branch in phylogenetic tree, 
which hints that from the evolution perspective, they might function similarly as active 
protein kinases. Increasing evidence from structural investigation suggests that this might be 
the case. For example, with-no-K(Lys) kinase (WNK) in which the key lysine residue in 
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VAIK motif in subdomain II of the catalytic domain was missing was shown that it can 
function actively by using another neighbouring lysine in the β strand 2 [60, 61]. Ca2+/CaM-
dependent serine protein kinase (CASK) is another good example where despite the absence 
of key enzymatic residues in DFG motif indispensable for Mg
2+
 binding, CASK can still 
implement itself in a constitutively active conformation, which can exhibit the capability of 
autophosphorylation and phosphorylating specific substrate, the synaptic protein neurexin-1. 
Unlike other kinases which require Mg
2+ 
for activity, CASK works independently of Mg
2+
 
which surprisingly inhibits its catalytic activity [62, 63]. The elucidation of receptor tyrosine 
protein kinase ERBB3 crystal structure challenged the concept that it was an inactive 
pseudokinase, since ERBB3 lacks the intact conserved motif HRD required for 
phosphorylation. In fact, in order to promote phosphoryl transfer, ERBB3 can adopt itself in 
an active conformation through a unique mechanism by its kinase-defective domain [64, 65]. 
 
 
 
 
 
 
 
Figure 6 Similarity in sequences of pseudokinases. 
Multiple sequence alignment of pseudokinases comparing three conserved motifs (VAIK, HRD 
and DFG) in the catalytic domain essential for enzymatic activity. Highlighted in black are the 
indicated missing motifs for each pseudokinase. This figure is modified from published work from 
Zhang et al, 2012. 
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No matter what functions these pseudokinases perform either as scaffold proteins, allosteric 
regulators or active kinases, emerging evidence has shown that they are greatly involved in 
cell proliferation, differentiation, apoptosis and metastasis in malignancies [43]. Here we are 
discussing some examples of well-established pseudokinases.  
1.2.4.1 Pseudokinases that have kinase activity 
1.2.4.1.1 ERBB3 
ERBB3 belongs to the human epidermal growth factor receptor (EGFR) family of receptor 
tyrosine kinases, which includes EGFR, ERBB2, ERBB3 and ERBB4. A group of growth 
factors as extracellular ligands bind to these receptors to form dimmers with a preference for 
heterodimers leading to the activation of downstream signalling pathways in cell proliferation 
and differentiation, whereas, abnormal activation contributes to pathogenesis of many cancers 
[66, 67]. Among these diverse homodimer and heterodimer complexes, ERBB2-ERBB3 is 
shown to be the most active form [68]. The uniqueness of ERBB3 is that it has long been 
shown to be kinase-inactive because of amino acids substitutions within the conserved kinase 
domain compared with the other members in this family. Thus, ERBB3 functions 
allosterically as a catalytic partner to activate the other family members [69, 70]. 
A recent study showed that the kinase domain of ERBB3 was able to bind ATP and to trans- 
autophosphorylate its intracellular region by forming a heterodimer between the intact 
intracellular kinase domain and the kinase domain [64]. However, compared to other EGFR 
family members, kinase activity of ERBB3 was significantly decreased and no 
phosphorylation ability on exogenous peptides was shown. Moreover, Shi and colleagues 
demonstrated that although ERBB3 lacked several key conserved residues, it might employ a 
distinctive mechanism to transfer the phosphoryl group by using the existing kinase-like 
conformation instead of the catalytic base aspartate [64, 65]. A further study suggested that 
although the kinase activity of ERBB3 was far lower than the other members such as EGFR, 
it may be adequate to activate phosphatidylinositol-3-OH kinase (PI3K)/Akt pathway and 
contribute to the resistance of tyrosine kinase inhibitors (TKIs) [71]. Considering that ERBB3 
may play a critical role in overcoming the resistance to EGFR or ERBB2 inhibitors in cancers, 
more detailed functional and mechanistic studies are still needed to focus on the interaction 
between family members and identification of unique substrates. 
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1.2.4.1.2 CASK 
CASK is a pseudokinase belonging to the membrane-associated guanylate kinase protein 
family (MAGUK) which function as multiple domain adaptor (scaffolding) proteins [72]. 
CASK was originally described in C. elegans and in Drosophila (Caki) [73, 74]. CASK is one 
of 10 subfamilies consisting of a PDZ domain, a catalytically inactive guanylate kinase (GUK) 
domain and a SH3 domain [75]. Resulting from its numerous domains, CASK acts as a 
scaffold protein and plays a role in protein organization. In mammals, it is located at cell 
junctions and synapses and is thought to play a critical role in brain development and central 
nervous system function [76, 77]. It can bind to more than 20 cellular proteins in different 
subcellular regions of neurons and form protein complexes for the interaction with the trans-
membrane protein neurexin at pre-synaptic sites leading to downstream events [78]. 
Mutations lead to brain malformation, mental retardation and neonatal lethality [79]. In a 
single study, it was demonstrated that CASK functions as an active protein kinase that 
phosphorylates neurexins providing further evidence to suggest that at least some 
„„pseudokinases‟‟ retain kinase activity in addition to scaffold properties [62]. 
1.2.4.1.3 ILK  
Integrin-linked kinase (ILK) is a serine/threonine kinase which was originally discovered 
using a yeast two-hybrid screen system and found to interact with the cytoplasmic domain of 
β1 integrin [80]. It has an N-terminal ankyrin repeat domain, a pleckstrin-homology (PH)-like 
domain and a C-terminal catalytic domain [81]. The ankyrin repeat domain binds to LIM 
found in scaffold protein domains of the particularly interesting new cysteine-histidine rich 
protein (PINCH) family. The C-terminal domain reacts with parvin forming the ILK-PINCH-
Parvin (IPP) complex, which forms a scaffold with other factors [82].  ILK has a role to play 
in adhesion of cells by linking integrin (transmembrane receptor) to the actin cytoskeleton [82, 
83]. 
The argument as to whether ILK is a pseudokinase or possesses kinase activity  has recently 
been discussed in an excellent review by Hannigan et al, as there has been some debate in 
recent years  relating to its true function [84]. In some studies, no substrates were found for 
ILK and it was considered to be a pseudokinase as it lacks the HRD and DFG motifs in its 
kinase domain which are required for phosphate group transfer [82]. Furthermore, the crystal 
structure of the kinase domain, particularly its molecular folds differ from those of active 
kinases [83]. However, ILK has been shown to phosphorylate a variety of different substrates, 
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including GSK3 and Akt [85]. Taking everything into consideration, it is most plausible that 
ILK is a true kinase and therefore requires re-classification, while it is likely to have a novel 
mode of activity resulting from changes to its catalytic domain. 
ILK has many important functions in signal transduction pathways associated with cell 
survival, migration, cell adhesion and extracellular matrix, differentiation, cell survival and 
angiogenesis and is essential for embryonic development and tissue homeostasis, as 
deregulation leads to abnormal tissue development [81]. 
1.2.4.2 Pseudokinases that exert allosteric regulation and scaffolding function 
1.2.4.2.1 STRADα 
STE-20-related adaptors α and β (STRADα and STRADβ) isoforms (also known as STLK5 
and STKL6), which belong to the STE20 protein kinase family, also lack kinase activity [57]. 
These pseudokinases are upstream components in signal-transduction pathways controlling a 
wide range of biological processes. The function of STRADα is to allosterically activate the 
tumour suppressor Liver Kinase B1 (LKB1) in a complex with mouse protein 25 α (MO25α) 
scaffolding protein, resulting in the activation of AMPK family members. Similarly, the 
STRADβ and MO25β isoforms also stabilise LKB1 [86, 87]. Activation of AMPK leads to 
the regulation of cellular energy status, fatty acid synthesis, cell polarity and proliferation. 
The kinase domain structure of STRADα consists of N and C lobes with a cleft between them 
making up the active site. The activation loop is found in the C terminal lobe and it is 
phosphorylated at specific sites when the kinase is in an active state, allowing substrate 
binding. In turn, LKB1 is activated by binding to STRADα thus not relying on activation by 
phosphorylation. Direct interaction of their kinase domains, strongly suggests an allosteric 
mechanism of activation [88]. ATP and MO25α binding to STRADα changes its kinase 
domain to an active-like kinase conformation that is characterized by extending its A-loop, 
allowing STRADα to bind LKB1. This results in the kinase domain of LKB1 to adopt an 
active kinase conformation, which is further stabilized by the binding of MO25α to the A-
loop of LKB1 [89]. Moreover, its cellular distribution is determined by STRADα and MO25α.  
Re-localization of LKB1 is induced by STRADα from the nucleus to the cytoplasm [90]. 
Mutant forms of STRADα that are unable to bind MO25α and ATP fail to activate LKB1 [91, 
92]. 
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1.2.4.2.2 Tribbles family 
Tribbles was first shown as a regulator in coordinating mitosis and morphogenesis during 
Drosophila development. Through promoting the degradation of Cdc25/String, tribbles 
blocked mitosis at a critical point to control cell cycle progression [93-95]. There are three 
mammalian trb isoforms (trb1, trb2 and trb3) homologues to the Drosophila tribbles and they 
all share the highly conserved kinase domain, which lacks catalytic residues.  
Despite the conserved structure of the tribble family members, their actions differ: trb1 and 
trb2 are mainly involved in the development of leaukemia, while trb3 is upregulated in non-
haematopoietic malignancies. Dedhia et al generated mice using hematopoietic stem cells 
expressing all three tribbles isoforms separately. Only those overexpressing trb1 or trb2 
developed acute myeloid leukaemia (AML). In addition, this data also showed that trb1 and 
trb2, but not trb3, have the ability of promoting the degradation of CCAAT/enhancer-binding 
protein-α (C/EBPα) by resulting in their differential functions in leukaemogenesis [96].  
1.2.4.2.3 TRRAP 
Transformation/transcription domain-associated protein (TRRAP), a large 434 kDa protein, is 
a member of the phosphatidylinositol 3-kinase-related kinase (PIKK) family that shares a high 
homology to the PI3Ks [97, 98]. TRRAP was originally discovered in 1998 where it was 
found to interact with c-Myc and E2F oncoproteins [99]. In humans, it is one of six family 
members, which also include mammalian target of rapamycin (mTOR), ataxia-telangiectasia 
mutated (ATM), ataxia-telangiectasia and Rad3-related (ATR), DNA-dependent protein 
kinase catalytic subunit (DNA-PKcs) and suppressor of morphogenesis in genitalia (SMG-1) 
[100].   
TRRAP has been reported to act as a scaffold protein for numerous regulatory factors 
including GCN5, p53, BRCA1, E2F and c-Myc [101, 102]. It acts as a mediator, being part of 
several different histone acetyltransferase (HAT) complexes [102-106]. In turn, these 
complexes act as a platform for different regulatory factors. Transcriptional profiling revealed 
that TRRAP knockdown affected numerous signalling pathways and cell cycle components. 
In one study TRRAP was associated with repair of DNA double-strand breaks [102]. 
Collectively, TRRAP plays a role in forming part of the complex necessary for c-Myc 
oncogene activation and is involved in the regulation of tumour suppressor gene p53. 
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1.2.4.3 Future perspectives 
Our knowledge of this enigmatic family of protein kinases has increased in recent years where 
approximately 10% of these proteins have been classified as pseudokinases. Their initial 
classification was largely based on sequence analysis and the discovery that pseudokinases 
lacked at least one highly conserved amino acid from their kinase domain. It appears that 
pseudokinases can have different functions, having regulatory roles. Some provide a 
molecular platform, steering enzymes and their substrates into critical positions allowing 
cellular reactions to proceed, and others are able to activate kinases by allosteric changes of 
their “substrates”.  In addition, some pseudokinases, although they have evolved “inactive” 
kinase domains, still exhibit catalytic activity by various unique mechanisms, indicating they 
are evolutionary counterparts of protein kinases. New experimental facts will in future allow a 
more precise classification of pseudokinases.  
New insights gained from structure analysis of WNK, CASK and ERBB3 suggest that it 
would be interesting to re-evaluate the remaining pseudokinases to delineate possible novel 
mechanisms in regulating phosphorylation. Thus, uncovering the three-dimensional structure 
of pseudokinases will improve our understanding of the intramolecular interactions in 
signalling transduction and possibly classify some pseudokinases to active protein kinases. 
Re-instating known active domains within pseudokinases may shed more light on their 
functions. In addition, further evidence on elucidating the pathways they participate in and 
their protein partners they cooperate with may reshape our perspectives on their biological 
functions. 
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1.3 Kinase suppressor of Ras 1 (KSR1) 
KSR1 was originally identified nearly 20 years ago as a novel protein kinase evolutionarily 
conserved in the Ras signalling pathway functioning between Ras and Raf in Drosophila and 
Caenorhabditis elegans [107-109]. Interestingly, in C. elegans, deletion of KSR1 alleles 
repressed activated Ras showing by a blockade of inducting multiple vulvas, but did not affect 
wild-type counterparts. Similarly, in Drosophila, defects in KSR1 inhibited the effect of 
activated Ras, but not activated Raf, indicating that KSR1 functions either downstream of Ras 
and upstream of Raf or in parallel pathways [110]. By comparing the sequences between 
mammalian and Drosophila KSR1, similarity through the kinase domain has been observed 
[107]. However, instead of a lysine at its subdomain II, which is required for kinase activity, 
an arginine residue is invariantly present in the mouse and human sequences. Owing to this 
fact, mammalian KSR1 are extensively referred to as a pseudokinase. Subsequently, the role 
of KSR1 as a scaffolding protein was revealed. Murine KSR1 (mKSR1) was first reported to 
cooperate with activated Ras to facilitate MEK and MAPK activation thereby promoting 
Xenopus oocyte maturation and cellular transformation [111]. In this report, the authors 
concluded that the activity of KSR1 is Ras-dependent and it can also interact with Raf. 
However, KSR1 is not a Raf kinase, but a crucial part of this signalling complex, even though 
it can bind to Raf. In addition, KSR1 was observed to translocate from the cytoplasm to the 
plasma membrane in the presence of activated Ras, during which it forms a complex 
involving Raf-1, MEK1 and 14-3-3. This in turn leads to the activation of Raf-1, which is 
independent of its enzymatic activity, highlighting its role as a scaffold in the MAPKs 
pathway [112, 113]. Meanwhile, the notion KSR1 as an active kinase was described from the 
finding that tumour necrosis factor alpha (TNFα) and ceramide were shown to significantly 
increase KSR1 autophosphorylation and its capacity to phosphorylate and activate Raf-1 
[114]. Emerging evidence thus supports dual activity of KSR1 as an active kinase as well as a 
scaffold protein in the Ras-Raf-MAPK pathway. Here the recent advances in unravelling its 
structure and function, especially in cancers are discussed. 
1.3.1 KSR1 structure 
The KSR family proteins are conserved from invertebrates to mammals, and two mammalian 
members namely KSR1 and KSR2 have been identified [107, 115]. From sequence 
comparison, the similarity of amino acids between KSR1 and KSR2 is approximately 61% 
[115]. As the aim of this project is about the function of KSR1, we will focus mainly on 
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KSR1. It is closely related to the Raf kinase family containing five conserved areas (CA) 
named CA1-CA5 [107].  
CA1 domain is located in the N-terminus of 40 amino acids exclusive to KSR1 but lacking in 
KSR2 [115]; CA2 is a proline-rich domain with unrevealed function; CA3 is a cysteine-rich 
atypical C1 motif mediating its membrane recruitment with phospholipids and this domain is 
essential for its activity to enhance Ras-dependent signalling and localization to the plasma 
membrane [113, 116]. The function of KSR1 C1 domain was further studied through 
elucidating its three-dimensional solution structure using nuclear magnetic resonance (NMR) 
[116]. This domain is similar to the C1 domains of Raf-1 and PKCγ, although not functionally 
interchangeable between them. Moreover, it does not directly bind to Ras indicating its 
distinctive role comparing with Raf-1 and PKCγ [116]. CA4 is a serine/threonine-rich region 
with an FXFP motif that interacts with ERK [111, 117, 118]; CA5 missing the conserved 
lysine residue at subdomain II required for phosphorylation is kinase-like domain [107, 117]. 
Notably, in Drosophila and C. elegans, the lysine residue is conserved and exists within the 
kinase domain for phosphotransfer reaction [107-109]. One recent study identified another 
domain composed of a coiled coil (CC) and a sterile α motif (SAM) at the N-terminus of 
KSR1. In fact, by binding directly to micelles and bicelles, the CC-SAM domain can guide 
KSR1 to certain sites at plasma membrane upon growth factor stimulus. Furthermore, nuclear 
magnetic resonance spectroscopy and in vitro assays demonstrated that the helix α of the CC 
motif is essential for modulation of membrane binding, indicating that combined with the 
atypical C1 domain, CC-SAM domain is indispensable for KSR1 cellular translocation [119]. 
A schematic depiction of KSR1 structure is shown in Figure 7.  
 
 
 
45 
 
 
 
 
 
 
 
 
 
 
1.3.2 KSR1 as a scaffold protein 
The function of KSR1 as a scaffold protein has been well described in numerous cellular 
contexts upon various stimulations, although in some cases contradictory downstream effects 
have been reported comparing to the initial notion of a positive regulator in the Ras-Raf-
MAPKs pathway. Murine KSR1 was first described to cooperate with activated Ras to 
stimulate Xenopus oocyte maturation and cellular transformation through elevated MEK and 
MAPK activity [111]. In the same study, authors also observed an interaction between 
mKSR1 with Raf at the plasma membrane in a Ras-dependent manner [111]. This finding was 
also verified by another study showing that KSR1 increased Raf activity via its cysteine-rich 
CA3 domain binding to Raf [113]. Cell fractionation assays revealed that KSR1 can form a 
complex with 14-3-3 in both the membrane and cytoplasmic fractions of cell lysates and with 
Raf in the membrane fraction, through which it can positively modulate the Ras pathway in 
vertebrate organisms [112].  
Conversely, an inhibitory effect of KSR1 on Ras-induced transformation was reported. KSR1 
was shown to cooperate with MEK1/2, but not Ras or Raf-1, and this interaction resulted in 
an inhibition of proliferation of embryonic neuroretina cells induced by Ras [120]. Yu and 
Figure 7 Schematic depiction of KSR1 structure and identified binding sites. 
Five conserved domains are identified in the KSR family members: CA1, a domain unique to the 
KSR1 protein; CA2, a proline-rich region; CA3, a cysteine-rich domain; CA4, a serine/threonine-
rich region, and CA5, a putative kinase domain (Therrien et al, 1995 and Morrison et al, 2001). 14-
3-3 proteins bind to two phosphoserine residues (Ser297 and Ser392) located on either side of the 
CA3 domain (Cacace et al, 1999). G protein γ subunits (Gγ) bind to the CA3 domain (Bell et al, 
1999). ERK1/2 (MAPK) interacts with an FxFP motif in the CA4 domain (Cacace et al, 1999; 
Muller et al, 2001). MEK1/2 (MEK), Raf, Hsp90 and p50cdc37 (Hsp90/p50) interact with the CA5 
domain (Denouel-Galy et al, 1998; Yu et al, 1998; Stewart et al, 1999 and reviewed by Morrison, 
2001). A new identified domain comprises of a coiled coil (CC) and a sterile α motif (SAM) 
required for membrane biding (Koveal et al, 2012). This figure is modified from published work 
from Morrison, 2001 and Koveal et al, 2012. 
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colleagues described that KSR1 can directly interact with MEK1 and ERK, and expression of 
KSR1 in COS-7 cells inhibited serum-stimulated MAPK activation [121]. Moreover, ectopic 
expression of KSR1 decreased MAPK activation induced by growth factors, activated Ras 
and Ras effectors in fibroblasts [122]. KSR1 was also able to suppress EGF and Ras-induced 
phosphorylation of ternary complex factors (TCF), which are substrates of MAPK. However, 
no effects of KSR1 on activation of MAPK itself were observed [123]. Bell and colleagues 
demonstrated that KSR1 can cooperate with G-protein βγ subunits, which mediates the 
translocation of KSR1 to the plasma membrane. In COS-7 cells, expression of wild-type 
KSR1 repressed G-protein βγ-induced MAPK activation [124]. Furthermore, KSR1 was 
shown to form a multimolecular signalling complex comprised of heat shock protein 90 
(HSP90), HSP70, HSP68, p50CDC37, MEK1/2 and 14-3-3 in human embryonic kidney 293T 
cells. This study also reported that KSR1 did not affect the MEK activity or activation but the 
membrane fraction of MEK, indicating the scaffolding role of KSR1. KSR1 was also shown 
to function as a scaffold protein in the Ras-Raf-MAPK pathway in vivo [125]. In fact, the 
MAPK activation was decreased in KSR1-null mice and high-molecular-weight complexes 
comprising KSR, MEK, and ERK were not detected in the depletion of KSR1 [125].  
Interestingly, it appears that the expression levels of KSR1 determine its biological effects on 
the downstream signalling pathways, which further supports its role as a scaffold protein in 
modulating various pathways. Indeed, at a higher expression, KSR1 acted to decrease Ras-
induced activity, but increased the Ras signalling pathway when lower levels were expressed 
in Xenopus oocytes [126]. A following study in KSR1
-/-
 mouse embryo fibroblasts (MEFs) 
confirmed this observation when re-introducing a titration of KSR1 abundance. With low 
KSR1 expression, ERK activity was enhanced as well as cell growth and RasV12 oncogenic 
transformation. Conversely, all these effects were markedly reduced with higher KSR1 
expression highlighting the importance of expression levels of a molecular scaffold in the 
modulation of cellular signalling [127]. Moreover, the similar phenomenon of its scaffolding 
role was also implicated in regulating adipogenesis in MEFs [128]. While removal of KSR1 
inhibited adipogenesis in vitro, re-introduction of low levels of KSR1 restored adipogenesis. 
Optimal levels of KSR1 were shown to be necessary for organizing activation of ERK and 
ribosomal protein S6 kinase (RSK) with C/EBPβ synthesis essential for the adipogenic 
program. However, increased levels of KSR1 were able to suppress adipogenesis through 
indirectly regulating peroxisome proliferator-activated receptor gamma (PPARγ) [128].  
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More studies have revealed a dynamic interplay that KSR1 is involved in as an allosteric 
regulator in Ras-Raf-MAPKs signalling cascade. In non-stimulated cells, Cdc25C-associated 
kinase 1 (C-TAK1) phosphorylates KSR1 at S392, which creates the binding site for 14-3-3, 
resulting in sequester of KSR1 in the cytosol, where it constitutively interacts with MEK and 
ERK. Upon growth factor stimulation, activated Ras triggers the dephosphorylation of KSR1 
at S392 by protein phosphatase 2A (PP2A), leading to the release of 14-3-3 from its binding 
sites. This in turn allows KSR1 to translocate to the cell membrane, where KSR1 forms a 
complex with Raf, MEK and ERK. KSR1 thus potentially enhances the phosphorylation of 
Raf, MEK, and ERK, facilitates the upstream signalling transduction as well as multiple 
substrates phosphorylation in the cytoplasm and nucleus, and through this manner regulates 
proliferation, cell cycle and apoptosis [129-131] (Figure 8). A series of follow-up studies 
added complexity to the molecular scaffold KSR1-involved signalling regulation. Douziech 
and co-workers reported that connector enhancer of KSR (CNK)  together with Hyphen 
(HYP), a novel SAM domain-containing protein, can recruit KSR1 to Raf before signal 
activation. Subsequently, the interaction of this ternary can enhance KSR1‟s capability to 
facilitate the Ras-dependent Raf-activation indicating a potential role of KSR1 as an allosteric 
modulator of Raf catalytic function [132]. CK2 was identified as an element of the KSR1 
scaffold complex contributing to Raf kinase activity [133]. The basic surface region of the 
KSR1 atypical C1 domain was shown to be required for CK2 binding to KSR1 and 
interruption of KSR1/CK2 complex caused a significant inhibition of growth factor induced 
Raf activation [133]. The Ras effector protein impedes mitogenic signal propagation (IMP) 
was capable of deactivate KSR1 or disturbing KSR1 homooligomerization and B-Raf/c-Raf 
hetero-oligomerization in order to regulate assembly of mitogenic signalling complexes and 
MAPK activation [134, 135]. 
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Recent advances in KSR1 structure further demonstrated its involvement in multiple scaffold 
complexes. Upon growth factor stimulation, a functional CA1 region of KSR1 was reported 
to be required for the assembly of a ternary complex with B-Raf and MEK, resulting in 
activation of MEK and ERK. This in turn allows ERK to phosphorylate KSR1 and B-Raf on 
several feedback Ser/Thr P-sites, which leads to the dissociation of KSR1 from the plasma 
membrane [136]. This finding again highlights the scaffolding role of KSR1 in the signalling 
dynamics, where KSR1 behaves as both a stimulator and an inhibitor in ERK cascade 
activation regulating the intensity and duration of the signalling. Using structural biology 
analysis, Rajakulendran and colleagues generated the KSR1-Raf side-to-side heterodimer. In 
forming this complex, KSR1 can directly regulate Raf activation, despite missing catalytic 
Figure 8 Schematic model for the function of KSR1. 
In quiescent cells, KSR1 remains in the cytoplasm with 14-3-3 binding at S297 and S392 
phosphorylated by C-TAK1. KSR1 also constitutively interacts with MEK and ERK. Upon 
stimulation by growth factors such as EGF, KSR1 is dephosphorylated by PP2A at S392 resulting 
in the release of 14-3-3 and exposure of the CA3 domain on KSR1. This leads to cell membrane 
translocation where KSR1 forms an active complex with phosphorylated Raf, MEK and ERK. The 
activated ERK can in turn phosphorylate various substrates in the cytoplasm and nucleus regulating 
proliferation, cell cycle and apoptosis. This figure is modified from published work from Zhang et 
al, 2012 
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function. Moreover, mutations in the dimer interface of KSR1 suppressed the activity of Raf 
[137]. A-kinase-anchoring protein (AKAP)-Lbc was lately identified to coordinate with 
KSR1 in forming the central parts of the MAPKs signalling. Together with KSR1, the 
complex enables signal transmission from Raf, through MEK, and on to ERK1/2 efficiently 
[138]. The scaffolding role of KSR1 is further supported by the observation that Raf 
inhibitors can trigger KSR1/B-Raf complex formation, which is dependent on conserved 
dimer interface residues in each partner but not relying on interaction of B-Raf to activated 
Ras [139]. In addition, this study demonstrated that KSR1 was able to compete with C-Raf for 
inhibitor-induced dimerisation to B-Raf, thereby modulating downstream ERK signalling 
[139].  
1.3.3 KSR1 as an active kinase 
A body of evidence supports the notion of KSR1 as an active kinase, despite suggestions of 
an incomplete catalytic domain. Zhang and colleagues first showed mouse KSR1 is 
competent to autophosphorylate as a 100 kDa membrane-bound molecule [114]. Moreover, 
TNFα and ceramide can induce the kinase activity of KSR1 to autophosphorylate and 
transactivate Raf-1 at Thr269 in vivo and in vitro [114]. Shortly, EGF was shown to be able to 
stimulate the kinase activity of KSR1 in a two-stage in vitro kinase assay when 
overexpressing Flag-tagged KSR1 in COS-7 cells. Its enzymatic activation of c-Raf-1-
dependent activity was only observed in full-length KSR1, but not kinase inactive and C- and 
N-terminal deletion mutants. In addition, endogenous KSR1 isolated from A431 cells 
expressing high levels of activated EGF receptor was also shown a constitutive enrichment of 
catalytic activity [140]. Direct phosphorylation of Raf-1 by KSR1 was demonstrated to be 
essential for TNFα-induced ERK1/2 activation in intestinal epithelial cells, revealing a 
protective role of KSR1 in the inflammatory process, which required its regulatory kinase 
activity [141, 142]. Conversely, by overexpressing a dominant-negative kinase-inactive KSR1 
in young adult mouse colon cells, decreased cell survival and increased apoptosis were 
observed upon TNFα treatment [143]. Moreover, kinase-dead KSR1 also suppressed nuclear 
factor κB (NF-κB) activation and ERK/MAPK activation in the same context further 
supporting its regulatory role as a kinase [143].  
New biochemical techniques such as protein purification and molecular modelling have 
enabled further aspects of KSR1 function to be probed, generating new perspectives on its 
catalytic function. In order to demonstrate that KSR1 is an active kinase for Raf-1, Zafrullah 
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and colleagues generated a specific monoclonal antibody against phospho-Raf-1 (Thr269).  
Using this antibody, the immuno-purified KSR1 was shown to be capable of phosphorylating 
FLAG-Raf-1 and kinase-dead FLAG-Raf-1(K375M) but not Raf-1(K375M/T269V), altered 
with a Thr269 to valine substitution [144]. The authors further purified KSR1 to homogeneity 
and confirmed that KSR1 can phosphorylate BSA-conjugated Raf-1 peptide at Thr269 [144]. 
Consistently, recombinant wild-type KSR1, but not kinase-inactive KSR1, can 
autophosphorylate on its serine residues, phosphorylate myelin basic protein (MBP) as a 
generic substrate, and directly activate MEK1 through phosphorylation, regulating cell 
survival in response to TNFα [145]. In addition, the authors overexpressed FLAG-tagged 
wild-type KSR1 (+KSR1) and KSR1 (+D683A/D700A) in KSR1
-/-
 colon epithelial cells and 
observed that only FLAG immunoprecipitates from cells encoding wild-type KSR1 were able 
to phosphorylate MEK1, suggesting MEK1 is an in vitro substrate of KSR1 [145]. 
Furthermore, in order to distinguish between the scaffold and kinase function of KSR1, Hu 
and co-workers generated a mutant (A587F) by adding a bulky phenylalanine at the ATP 
binding pocket of KSR1 to impair ATP binding. However, this mutant can still maintain a 
closed, active conformation, but is unable to interact with ATP. Indeed, the KSR1 mutant was 
not able to phosphorylate MEK, although it can constitutively bind to its partner as a scaffold. 
On the other hand, the wild-type KSR1 was shown to phosphorylate MEK induced by c-Raf, 
indicating a requirement of an active kinase activity in this process [146]. At the same time, 
structural and biochemical studies were utilized to understand the interaction between KSR2 
and MEK1. Crystal structure analysis of the kinase domain of KSR2 illustrated that the side-
to-side interaction between KSR2 with MEK1 is through their respective activation segments 
and C-lobe αG helices. Upon ATP bound to KSR2 catalytic site, KSR2 was shown to 
phosphorylate MEK1 by in vitro assays and chemical genetics [147]. Moreover, BRaf can 
form a side-to-side heterodimer with KSR2 (KSR2-BRaf), in which BRaf can allosterically 
increase the kinase activity of KSR2. The KSR2-BRaf complex thereby facilitates MEK 
phosphorylation by BRaf achieved via the KSR2-involved transmission of a signal from BRaf 
to allow conformational adjustment of MEK for phosphorylation [147]. The notion 
highlighting that KSR coordinates with a regulatory Raf molecule in cis to trigger a 
conformational alteration of MEK, assisting phosphorylation of MEK by another enzymatic 
Raf molecule in trans sheds new light on our understanding the function of KSR family 
members [147].  
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1.3.4 Regulation of KSR1 
Given the fact that KSR1 is an important player in the Ras-Raf-MAPKs pathway, extensive 
efforts have been devoted to study the mechanisms regulating KSR1 protein as well as 
associated biological effects. Amongst these are post-translation modifications of KSR1 and 
the protein-protein interactions with other regulatory molecules.  
1.3.4.1 Phosphorylation and protein-protein interaction 
Phosphorylation was first shown to affect KSR1 function and its interaction with binding 
partners. Cacace and colleagues identified five phosphorylation sites, two of which (Ser297 
and Ser392) are constitutively phosphorylated, whereas phosphorylations of Thr260, Thr274, 
and Ser443 are induced by activated Ras. Indeed, in serum-starved medium, Ser297 and 
Ser392 of KSR1 stayed constitutively phosphorylated, regulating its binding capacity to the 
14-3-3 family proteins. Upon Ras activation, three other sites Thr260, Thr274, and Ser443 
were shown phosphorylated by MAPK and subsequently were blocked by MEK inhibitor 
PD98059 [126]. Similarly, Volle and co-workers demonstrated that murine KSR1 remained 
phosphorylated in cells and in an immune complex on at least 10 distinct serines and 
threonines [148]. In this study, all the phosphorylated sites identified are restricted to the N-
terminus of KSR1 excluding the kinase domain. Interestingly, wild-type mouse KSR and the 
kinase-inactive KSR (R598M) proteins were shown to have identical phosphorylated sites in 
intact cells and in the immune complex, indicating that the kinase domain of KSR1 does not 
contribute to the phosphorylation of KSR1 itself [148]. 
As shown here, phosphorylation plays an important role in subcellular localization of KSR1 
resulting in regulation of associated signalling pathways. In quiescent cells, C-TAK1 was 
shown be able to constitutively interact with KSR1 and phosphorylate KSR1 on Ser392 
leading to 14-3-3 binding and cytoplasmic sequestration of KSR1 [129].  Upon growth factor 
activation, de-phosphorylation of KSR1 by serine/threonine protein phosphatase PP2A was 
shown to trigger a disassociation of KSR1 and 14-3-3 allowing KSR1 membrane 
translocation and regulation of Ras-Raf-MAPKs signalling [131]. On the other hand, Brennan 
and colleagues first observed nuclear fluorescence of KSR1 in cells expressing GFP-KSR1. 
Subsequently, the authors showed that of the phosphorylated sites identified, mutations of 
Thr274 and Ser392 caused the re-shuttle of nuclear localisation of KSR1 indicating a role of 
phosphorylation in modulating KSR1 nucleocytoplasmic distribution [149]. Moreover, when 
fluorescent forms of KSR1 and MEK were co-transfected in cells, it was shown that each 
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protein facilitated the cytoplasmic localization of the other highlighting the notion that MEK 
interaction is also crucial in regulation of  KSR1 subcellular distribution [149]. Intriguingly, 
NM23-H1, a tumour metastasis suppressor, was described to associate with KSR1 in 293T 
cells and MDA-MB-435 breast carcinoma cells. In vitro kinase assays demonstrated that 
autophosphorylated recombinant Nm23-H1 phosphorylated KSR1 on Ser392 and Ser434, 
whereas Ser392 mutation of KSR1, either alone or in combination with Ser297 inhibited the 
phosphorylation ability of Nm23-H1 [150]. Moreover, NM23-H1 overexpression prompted 
an increase in Hsp90 binding to cytoplasmic KSR1 and enhanced degradation of KSR1 
protein in MDA-MB-435 breast carcinoma cells [151]. Tso and colleagues reported that an 
elevated level of Nm23-H1 and -H2 and an increase in phosphorylated KSR in the nuclear 
fractions were observed in HEK293 cells stable expressing regulator of G-protein signalling 
19 (RGS19), indicating RGS19 as a new regulator of Nm23H1/2-mediated KSR1 
phosphorylation [152]. Recently, one report showed that VRK2A can interact with KSR1 and 
MEK1 by forming a stable high molecular size (600-1,000 kDa) complex on the surface of 
the endoplasmic reticulum (ER). VRK2A silencing led to a dissociation of these high 
molecular size complexes, whereas VRK2A overexpression increased KSR1 abundance in the 
particulate fraction and inhibited ERK1/2 incorporation into the complex upon EGF 
stimulation [153]. The finding that KSR1 complex regulated by VRK2A in the ER can affect 
MAPK signalling output provides a new mechanism of KSR1 subcellular modulation and its 
associated downstream effects. 
In addition, Yoder and co-workers reported that high Zn
2+
 levels can enhance KSR1 
phosphorylation in mammalian tissue culture cells, which was not affected by EGF stimulus 
and a MEK inhibitor (PD98059) [154]. The observed effect on KSR1 phosphorylation was 
also shown to be Zn
2+
 specific as adding high concentrations of Co
2+
, Cu
2+
, Mg
2+
 or Ca
2+
 did 
not achieve the same result [154]. To better understand the biological effects of KSR1 
phosphorylation in regulating the Ras-Raf-MAPKs pathway, mutations of Ser392 and Thr274 
of KSR1 (KSR1.TVSA) were generated and used for multiple functional analyses [155]. 
KSR1.TVSA resulted in constant ERK activation and cell cycle progression with either 
platelet-derived growth factor (PDGF) or EGF treatment. It was also shown that KSR1.TVSA 
cells grew faster and a higher density than wild-type KSR1 cells, and KSR1.TVSA was more 
stable than wild-type KSR1 [155].  
Very recently, Sibilski and colleagues reported Tyr728 as a novel regulatory phosphorylation 
site of KSR1, which is phosphorylated by lymphocyte-specific protein tyrosine kinase (LCK, 
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a member of SRC family) suggesting a potential link between SRC kinases and MAPK 
signalling via KSR1 [156]. Moreover, the authors revealed that Tyr728 is essential in 
retaining the conformation of the KSR1 kinase domain obligatory for its interaction with 
MEK. Phosphorylation of Tyr728 initiated rearrangements of conformation in the MEK 
interface and reorganized structural elements required for catalytic activity of KSR1. 
Phosphorylation of Tyr728 may negatively affect Raf-mediated MAPK activation resulting in 
an inhibition in cell proliferation [156].  
1.3.4.2 Transcription regulation 
1, α25-dihydroxyvitamin D3 (1,25D), was reported to able to selectively increase KSR1 gene 
expression in human leukaemia HL60 cells, whereas other inducing agents including retinoic 
acid or dimethyl sulfoxide did not [157]. Importantly, the authors revealed that a vitamin D 
responsive element (VDRE) exists in the promoter region of the human KSR1 gene, allowing 
vitamin D receptor (VDR) to bind, in a 1,25D-dependent manner [157]. This finding suggests 
a new mechanism of regulating KSR1 in the transcriptional level as well as an involvement of 
KSR1 in 1,25D-induced monocytic differentiation of human myeloid leukaemia cells [157]. 
The same group showed that oncoprotein Cot1 inhibited KSR1 and 1, 25-Dihydroxyvitamin 
D3-induced differentiation of human AML cells [158]. In fact, silencing Cot1 resulted in a 
marked increase in KSR1 mRNA in HL60 and U937 cells and overexpression of Cot1 caused 
a decrease in KSR1 abundance induced by 1,25D [158]. 
1.3.5 The physiological role of KSR1 
Expression profiles of KSR1 protein and gene were determined by western blotting and RT-
qPCR in the normal adult mouse. Western blotting showed that KSR1 protein is higher 
expressed in the adult brain and lower expressed in bladder, ovary, testis, and lung, whereas it 
is not detected in other adult tissues. However, KSR1 transcripts are identified in all adult 
tissues except liver shown by RT-PCR [159]. Another study later also reported that KSR1 
mRNA is expressed in neutrophils, macrophages, thymus, and spleen in mice [160]. 
In addition, a splice variant of murine KSR1 (B-KSR1) highly expressed in brain-derived 
tissues was characterized and it is evident in mouse brain throughout embryogenesis [161]. 
Introduction of B-KSR1 in PC12 cells caused an increase in nerve growth factor (NGF)-
induced neuronal differentiation and EGF-induced neurite outgrowth, which required MEK 
binding and activation [161]. This finding demonstrates that B-KSR1 may be important in 
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Ras-dependent neuronal differentiation and involved in regulating the mature central nervous 
system [161].  
To study the in vivo function of KSR1, mouse models of homozygous deletion for KSR1 were 
generated [125, 162]. The data revealed KSR1
-/-
 mice were viable and phenotypically normal, 
and did not develop any major defects, although a distinctive hair follicle phenotype was 
observed in one study, similar to EGFR deficient mice [125, 162]. Consistently, both groups 
reported that there were no main histological abnormalities of the major organs in young mice 
or in adults up to 1 year of age, and the weight, behaviour, and brood size were also 
unaffected in the mice [125, 162]. However, in comparison to MEFs from wild-type KSR1 
mice, MEK and ERK activation was attenuated in MEFs derived from KSR1
-/-
 mice, as well 
as in KSR1 depleted T cells [125].  
KSR1 was also shown to be essential for maximal ERK activation induced by UV light, 
ionizing radiation, or the DNA cross-linking agent mitomycin C (MMC) [163]. Of note, in the 
absence of KSR1, cells underwent but did not recuperate from MMC-induced G2/M arrest, 
whereas restoration of KSR1 enabled KSR1
-/-
 cells to return to cell cycle upon MMC 
treatment [163]. Cells expressing a mutated form of KSR1 unable to bind ERK showed no 
recovery from MMC-induced cell cycle arrest, indicating a requirement of the KSR1-ERK 
interaction. Moreover, only cells expressing KSR1 were capable of re-programming from 
MMC-induced cell cycle arrest, as in KSR1
-/-
 cells constant activation of ERK was not 
adequate to promote cell cycle re-initiation upon MMC-treatment [163]. 
1.3.6 KSR1 in cancers 
1.3.6.1 KSR1 in solid tumours 
As KSR1 plays an essential role in the Ras-Raf-MAPKs module, which is one of the well-
known oncogenic pathways, studies are beginning to explicate its biological characteristics in 
different cancers. Polyomavirus middle T-antigen (MT) can trigger oncogenic potentials in a 
Ras-dependent manner through the involvement of the adaptor protein, Shc, and the lipid 
kinase, phosphatidylinositol 3-kinase [164, 165]. An initial study reported that in MT
+
KSR1
+/- 
mice, the onset of tumour formation was 35±8 days whereas the tumour was not detected until 
65±9 in MT
+
KSR1
-/- 
mice
 
[125]. This indicates that the absence of KSR expression can slow 
tumour formation although it might not be indispensable in this mouse model. Interestingly, 
Lozano and colleagues showed that in a v-Ha-Ras-mediated skin cancer mouse model, KSR1 
contributed to tumourigenesis as 70% of Tg.AC transgenic mice in a KSR1
+/+
 background 
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developed papillomas, whereas only 10% in a KSR1
-/-
 background demonstrated papillomas 
[162]. It has been noticed that the discrepancies from the two models may be due to different 
genomic background and distinctive tumourigenesis signals. As in Tg.AC transgenic mice, c-
Raf-1/MAPK cascade is predominant requiring KSR1, MT-driven mammary tumourigenesis 
relying on SRC and PI3K is KSR1 independent. This finding also supports the notion that 
KSR1 is selectively required for some forms of oncogenic Ras-transduced MAPK mediated 
tumourigenesis [162].  
Subsequent work from the same group reported that targeting KSR1 by continuous infusion 
of phosphorothioate antisense oligonucleotides (AS-ODNs) reduced tumour growth of K-Ras-
dependent human PANC-1 pancreatic and A549 NSCLC xenografts in nude mice, suggesting 
inhibition on KSR1 as a potential therapeutic target in Ras-dependent malignancies [166]. To 
further assess the correlation between ODNs update and therapeutic effects, an ultrasensitive 
noncompetitive hybridization-ligation enzyme-linked immunosorbent assay (NCHL-ELISA) 
was developed to quantify KSR1 ODNs uptake in plasma and tumour tissues [167]. The 
ELISA assay was performed to measure plasma and tumour KSR1 ODN levels in PANC-1 
derived pancreatic cancer mice and showed that tumour suppression associated with KSR1 
ODN uptake in tumour tissues not in plasma [167]. Introduction of KSR1 into KSR1
-/- 
MEFs 
induced cell proliferative and oncogenic potential and removal of KSR1 inhibited Ras(V12)-
dependent transformation [127]. Furthermore, the increase in transformation by ectopic 
expression of KSR1 required an optimal concentration range of KSR1, as it started to inhibit 
the proliferative action and activity of Ras-Raf-MAPKs cascade at higher levels [127]. KSR1 
is also involved in cell sensitivity to cisplatin-induced apoptosis. Specifically, in comparison 
to wild type MEFs, KSR1 depletion in MEFs correlated with reduced ERK activation by 
cisplatin and elevated resistance to cisplatin-stimulated apoptosis. Expression of KSR1 into 
KSR1
-/-
 MEFs and MCF7 cells increased ERK activation and sensitivity to cisplatin [168].  
A screen to characterize KSR1 expressions and the effects on drug sensitivity using a 
collection of cancer cell lines and the NCI60 anticancer drugs supported an important role of 
KSR1 in defining cellular sensitivity [169]. The results showed that KSR1 expression levels 
varied nearly 30-fold difference between the highest and lowest expressing cell lines in the 
NCI60 [169]. In comparison to KSR1
-/-
 MEFs, reintroduction of KSR1 expression in MEFs 
enhanced resistance of cells to tunicamycin and cytochalasin H [169]. In EGFR-driven A431 
squamous cell carcinoma (SCC) cells, targeting KSR1 was shown to down-regulate elevated 
tissue factor (TF), which is involved in tumour cell survival, growth, and angiogenesis [170]. 
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Conversely, overexpression of KSR1 in A431 cells resulted in an increase in TF expression 
and tumourigenicity in mice and this effect was suppressed by pan-EGFR inhibitor, CI-1033, 
suggesting the fact that the oncogenic potentials of KSR1 and TF are EGFR dependent [170]. 
In addition, KSR1 was also observed to play an important role in targeting Ras-mediated 
radioresistance. Indeed, silencing KSR1 or overexpressing kinase-inactive KSR1 abolished 
ionizing radiation-induced Raf/MEK/ERK2 cascade activation, improved the cytotoxic effect 
of radiation, gained radiosensitization and facilitated clonogenic death in A431 cancer cells 
[171]. In mouse models, pharmacologic deletion of KSR1 by infusing KSR1 AS-ODN 
resulted in radiosensitization in EGFR-dependent A431 SCC and in oncogenic K-Ras-driven 
A549 human NSCLC [171].  
Additionally, through modulation of peroxisome proliferative activated receptor gamma 
coactivator 1 alpha (PGC1α) and oestrogen-related receptor alpha (ERRα), KSR1 was 
demonstrated to induce oncogenic Ras-dependent anchorage-independent growth [172]. 
Interestingly, the authors showed that KSR1 required the presence of H-RasV12 to regulate 
the expression of metabolic regulators PGC1α and ERRα [172]. In comparing KSR1 cDNA 
expression between normal endometrium and endometrial carcinoma (ECC), Llobet and co-
workers performed a cDNA array and reported that KSR1 was up-regulated in ECC, validated 
using RT-qPCR. Moreover, tumour tissue microarray (TMA) confirmed that KSR1 protein 
was significantly elevated in endometrial carcinoma in comparison to normal endometrium 
[173]. Deletion of KSR1 by small hairpin RNA led to decrease in both proliferation and 
anchorage-independent cell growth of endometrial cancer cells. Importantly, KSR1 silencing 
re-sensitized TRAIL- and Fas-induced apoptosis in resistant endometrial cell lines, which 
might partly be regulated through down-regulation of FLICE-inhibitory protein FLIP [173]. 
Recently, our kinome screen using RNA interference to identify novel regulators of ERα 
revealed a potential involvement of KSR1 in breast cancer, which led to a main part of my 
PhD study on its function and associated signaling  in breast cancer  [174]. 
1.3.6.2 KSR1 in non-solid tumours 
The work to study the rationale for deltanoids in therapy for myeloid leukaemia revealed a 
KSR1-involved signalling associating with MAPK and C/EBP. Upon deltanoid activation of 
VDR, KSR1 expression and the activity of MAPK pathway were up-regulated, partially 
contributing to monocytic differentiation of human myeloblastic HL60 cells [175]. As 
discussed in the previous part, oncoprotein Cot1 was shown to down-regulate KSR1 
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expression and 1,25-Dihydroxyvitamin D
3
-induced differentiation of human AML cells, thus 
providing extended information of KSR1‟s involvement in non-solid tumours [158].  
KSR1 was recently indicated to contribute to activating protein tyrosine phosphatase, non-
receptor type 11 (PTPN11)-induced granulocyte-macrophage colony-stimulating factor (GM-
CSF) hypersensitivity, the characteristic phenotype of juvenile myelomonocytic leukaemia 
(JMML). To address this, bone marrow progenitors from WT and KSR1
-/-
 mice expressing 
WT Shp2, and PTPN11 gain-of-function mutants (Shp2E76K, or Shp2D61Y) were assessed. 
Increased KSR1 activation and enhanced interaction between KSR1 and active ERK were 
observed in Shp2D61Y- and ShpE76K-expressing macrophage progenitors. While KSR1 loss 
partially suppressed Shp2E76K-induced GM-CSF hypersensitivity, the similar effect was not 
observed in Shp2D61Y-expressing cells suggesting a distinctive role of KSR1 in GM-CSF 
hypersensitivity in different mutants [176]. In bone marrow-derived mast cells from KSR1-
deficient mice, KSR1 depletion caused a decrease in kit-ligand-mediated proliferation and 
degranulation, as well as a decline in migration [177]. It was shown that effect of KSR1 loss 
on migration was through activation of p21-activated kinase, a modulator of F-actin 
polymerization key to mast cell migration [177]. 
Furthermore, KSR1 depletion in B cells resulted in a reduction in proliferation and an increase 
in cytokine deprivation-induced apoptosis. Although overexpression of Myc restored the 
proliferation capability of KSR1-null B cells, the inactivation of KSR1 in Myc overexpressing 
mice led to an enhancement in B cell apoptosis as well as an impediment in the onset of B cell 
tumourigenesis, further suggesting that KSR1 modulates the cooperation of Ras/MAPK 
signalling pathway and Myc to drive oncogenic transformation and lymphoma development 
[178]. Together, these results indicate a significant role of KSR1 in various cancers and it 
might be a potential therapeutic target in Ras-dependent cancers. However, in breast cancer, 
which seems to have few Ras mutations, the role of KSR1 remains to be thoroughly 
investigated.   
1.3.7 KSR1 in other biological processes 
1.3.7.1 KSR1 in immune system 
Several lines of evidence demonstrate that KSR1 is an important regulator of immune 
functions. In particular, KSR1 null mice displayed impairment in MEK and ERK activities, 
thus, resulting in a marked reduction in T cell proliferation [125]. Moreover, KSR1 
overexpression suppressed the DP to SP transition during positive selection in reaggregate 
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fetal thymic organ culture (rFTOCs) and structural analysis of KSR1 displayed that an 
interaction between KSR and MEK was required for the action of KSR overexpression in this 
system, supporting that KSR coordinates Ras signalling to ERK activation during positive 
selection of T cells [179]. To address the role of KSR1 in ERK activation upon 
proinflammatory stimuli and its function in physiological inflammatory process in vivo, 
Fusello and colleagues first showed that a defect in ERK activation by osmotic shock or after 
stimulation with proinflammatory cytokines or LPS was observed in KSR1-deficient [160]. 
The results from arthritis development after arthritogenic antiserum induction revealed that in 
comparison to KSR1 wild-type mice, KSR1-null counterparts displayed a significant decrease 
in the ankle and forepaw swellings [160].  
Several studies have documented the protective role of KSR1 against cytokine-induced 
apoptosis in intestinal epithelium inflammatory conditions [142, 143]. Initial in vitro studies 
showed that inactivation of KSR1 resulted in a decrease in survival and an increase in 
apoptosis of TNF-treated cells through modulating NF-κB activation, cIAP2 expression and 
MAPK kinase activity, supporting KSR1 as an essential regulator for TNF-stimulated survival 
pathways in intestinal epithelial cell lines [143]. To examine the function of KSR1 in 
regulating intestinal cell fate during cytokine-mediated inflammation, KSR1-deficient mouse 
model was generated [142]. The authors showed that KSR1 depletion caused an increased 
susceptibility to chronic colitis and an enhancement of TNF-induced apoptosis in mouse 
colon epithelial cells in vivo, correlated with an inability to initiate antiapoptotic signals 
including Raf-1/MEK/ERK, NF-κB, and Akt [142]. The aforementioned effects can be 
inverted by introducing wild-type KSR1, but not kinase-inactive further confirming a 
potential requirement of a catalytic activity of KSR1 [142].  
Lin and colleagues described that MAPK activity is digital upon T-cell-receptor stimulation 
and the system output of the MAPK cascade in T cells is highly fluctuated and modulated by 
upstream signalling of the MAPK module, thus regulating various biological functions [180]. 
However, it appears that although KSR1 was shown to modulate the threshold required for 
MAPK activation in T cells, it did not affect the fundamental system outputs [180]. Filbert 
and co-workers examined hymocyte selection in KSR1-deficient mice and showed although 
negative selection in the HY model was marginally diminished in KSR1-null mice, positive 
selection in two different TCR transgenic models, HY and AND, was normal. These results 
suggest that KSR1 may be essential for full ERK activation in thymocytes but not for 
thymocyte selection [181]. In addition, Gringhuis and colleagues demonstrated that KSR1 
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was involved in forming a signalosome complex together with LSP1, CNK and the kinase 
Raf-1, consequently coordinating the C-type lectin DC-SIGN tailored cytokine production in 
response to distinct pathogens [182]. 
As for natural killer (NK) cells, it was shown that the loss of KSR1 in NK cells perturbed 
NK-cell cytolytic capacity. Upon T cell activation, KSR1 was recruited to NK lytic synapse 
that in turn regulated the localisation of active ERK to the synapse [183]. KSR1
-/-
 interleukin 
10 (IL10)
-/-
 double knockout mice were shown to be susceptible to an early manifestation of 
colitis by the age of 4 weeks [184]. Additionally, elevated expression of interferon gamma 
(IFN-γ) in T cells was detected in the double knockout mice and the inhibition of IFN-γ was 
able to reduce the extent of severity in colitis [184]. Moreover, KSR1 has been shown to be a 
protective factor against bacterial infection. In fact, KSR1-deficient mice were highly 
vulnerable to pulmonary Pseudomonas aeruginosa infection, comparing to wild type mice. 
Mechanistically, upon infection, KSR1 was capable of inducible nitric oxide synthase (iNOS) 
and Hsp90 recruitment resulting in increased iNOS activity and NO release to eliminate 
bacteria [185]. In lipopolysaccharide (LPS)-induced acute lung injury model, a very similar 
response to LPS was observed in both KSR1-deficient and wild-type mice, suggesting a 
dispensable role of KSR1 in LPS-induced ERK activation in alveolar macrophages [186]. 
Interestingly, a recent study has established a relationship between MAPK and mTOR 
pathways through the involvement of KSR1 in T cells. Although KSR1 modulates mTOR 
complex 1 (mTORC1) activity, KSR1 deficiency has no obvious effects in mTOR -dependent 
T cell differentiation [187]. 
1.3.7.2 KSR1/2 in metabolism 
Both KSR members are involved in the maintenance of cellular metabolism in which 
metabolic abnormalities were evident in KSR1 and 2 deficient mouse models. Phenotypically, 
KSR1
-/-
 mice exhibited adipocyte hypertrophy while KSR2
-/-
 counterparts were obese and 
glucose intolerant [128, 188]. As for the role of KSR1 in adipogenesis, the initiation of 
adipocyte differentiation relied indirectly on suitable amounts of KSR1 that orchestrated the 
temporal coordination of Raf/MEK/ERK and RSK signalling, and in this manner, controlled 
the activities of adipogenic transcription factors such as C/EBP and PPARγ [128].  
KSR1 has been recently implicated in regulating glucose tolerance and insulin sensitivity via 
the interplay between KSR1 and MARK2. Klutho and colleagues reported an elevated 
glucose disposal rate in response to exogenous insulin, increased glucose tolerance, and 
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resistance to diet-induced obesity were observed in mice lacking MARK2 [189]. Interestingly, 
disruption of KSR1 in MARK2-null mice reversed the increased sensitivity to exogenous 
insulin resulting from MARK2 removal. As shown, the mode of action in which MARK2 acts 
as a negatively modulator in insulin sensitivity relies on the direct phosphorylation on S392 of 
KSR1 [189]. Furthermore, KSR1 and its associated PP2A/KSR1/ERK signalling haven been 
shown to play a role in pravastatin normalized contraction induced by ET-1 in aortic smooth 
muscle in type 2 diabetic rats [190]. 
Comparing to a potential involvement of KSR1 in metabolism regulation, KSR2 seems to be 
an essential modulator in energy expenditure and insulin sensitivity supported by several 
elegant studies below. Costanzo-Garvey and colleagues have revealed a direct interaction 
between the two KSR members and AMPK, a prominent energy sensor for metabolic 
processes [188]. The disruption of KSR2-AMPK interaction prevented AMPK activation and 
phosphorylation that is imperative to induce fatty acid oxidation and regulate glucose uptake. 
Mechanistically, in wild-type KSR2
+/+
 mice, KSR2 can cooperate with AMPK to suppress 
acetyl-CoA carboxylase (ACC) and increase the expression of PGC1α-dependent OXPHOS 
genes, and consequently repression of ACC can thus inhibit malonyl CoA synthesis a 
negative regulator of CPT1. Hence, increased CPT1 activity and OXPHOS gene expression 
can facilitate the oxidation of fatty acids and decrease their storage as triglycerides (TG) [188]. 
However, KSR2 loss can result in an impairment of AMPK function, a reduction of OXPHOS 
gene expression, and deregulation of ACC activity, eventually causing obesity [188]. Of note, 
a recent study has revealed that KSR2 controls tumour metabolism and cell growth in an 
AMPK dependent manner. Particularly, the forced expression of KSR2 in KSR1 null MEFs 
resulted in augmented proliferation and induction of anchorage independent growth. On the 
other hand, the introduction of AMPK restores the transformed phenotype and tumour 
metabolic activities upon KSR2 depletion [191]. 
To investigate the role of KSR2 in humans and identify KSR2 variants in obese individuals, a 
comprehensive study was performed by sequencing 2,101 individuals with severe early-onset 
obesity and 1,536 controls [192]. Pearce and colleagues identified multiple rare variants in 
KSR2 in individuals with severe early-onset obesity, which can potentially cause impaired 
Raf-MEK-ERK signalling or decreased the interaction between KSR2 and AMPK. 
Furthermore, when transfecting KSR2 variants in cells, impaired glucose oxidation and 
palmitate-stimulated fatty acid oxidation (FAO) were observed in comparison to wild-type 
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KSR2 counterparts [192]. These findings highlight a fundamental role of KSR2 in obesity, 
insulin resistance, and impaired cellular fuel oxidation. 
Collectively, these studies have underlined the significance of KSR members in regulating 
cellular metabolism and energy homeostasis and KSR1/2 could be potential therapeutic 
interventions in metabolic disorders, such as obesity. 
1.3.7.3 KSR1 in central nerve system 
Several studies have investigated the function of KSR1 in regulating associated signalling in 
the nervous system. Shalin and colleagues first revealed an important role of KSR1 in 
coordinating hippocampal signal transduction as well as in synaptic plasticity and memory 
formation [193]. In this study, shortages in contextual and cued associative fear conditioning, 
passive avoidance, and the Morris water maze were observed in KSR1-depletion mice, as well 
as decreased theta burst stimulation (TBS)-induced long-term potentiation (LTP) indicating a 
potential cellular mechanism for the observed behavioral phenotype [193]. Mechanistically, 
the authors showed that the action of KSR1 is through specifically enhancing activation of a 
membrane pool of ERK that is triggered by PKC activation but not by cAMP/PKA dependent 
pathway, revealing a new mechanism of KSR1-regulated ERK activation in specific learning 
and plasticity paradigms [193]. 
Szatmari and colleagues studied the contribution of KSR1 associated ERK1/2 activation in 
neutral survival signalling. In cultured rat cortical neurons, it was shown that brain-derived 
neurotrophic factor (BDNF) increased KSR1 interaction with activated ERK1/2, whereas 
KSR1 depletion using a short hairpin RNA decreased ERK1/2 activation induced by BDNF 
and reduced the BDNF protection against camptothecin (CPT)-mediated apoptosis, but not 
trophic deprivation-induced apoptosis. On the other hand, KSR1 overexpression enhanced 
BDNF protection against CPT-induced apoptosis [194]. A similar observation was shown in 
cortical neurons upon another neuroprotective stimulus, forskolin, which is a cAMP-elevating 
drug. As reported, Forskolin increased ERK1/2 activation in a PKA dependent manner, 
accompanied by an increase in association between KSR1 and active ERK1/2, while the 
inhibition effect of Forskolin on CPT-induced apoptosis was dependent of KSR1 and ERK1/2 
[194]. These findings reveal a crucial role of KSR1 in the anti-apoptotic activation of ERK1/2 
by BDNF or cAMP/PKA signalling. 
Moreover, it has been shown that KSR1 and its phosphorylation by downstream kinase 
ERK1/2 contribute to maintaining physiological levels of synaptic plasticity in hippocampal 
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neurons. Canal and co-workers first showed that KSR1 was phosphorylated by ERK1/2 at 
multiples sites in HEK239T cell and further characterization of the KSR1 phosphorylation 
sites revealed a feedback regulation of ERK1/2 activity by KSR1. In fact, ERK1/2 activity 
was considerably decreased after 20 and 60 min and depleted after 4 h of EGF treatment in 
control or KSR1 wild-type cells, whereas KSR1 mutants on the feedback phosphorylation 
sites endured a constant activation of ERK1/2, even at 4 hours, indicating a role of feedback 
phosphorylation of KSR1 in controlling ERK1/2 signalling [195]. Furthermore, 
electrophysiological recordings in hippocampal neurons expressing wild-type or feedback-
deficient KSR1 revealed that the potentiation of excitatory postsynaptic currents was 
restrained by KSR1 feedback phosphorylation highlighting the function of feedback 
phosphorylation of KSR1 as a keeper to prevent excessive ERK1/2 signalling in the 
postsynaptic compartment [195]. 
1.3.8 Closing remarks 
Comprehensive insights regarding the structural and functional studies of KSR1 have started 
to redefine our previous knowledge, as it is becoming obvious now that the original 
classification of KSR1 as a pseudokinase may not be representative of its exact biological 
behaviour. Advances made in the last few years have changed our perspectives in the 
functions of KSR1, whereas a more complicated conception of KSR1 as a scaffold protein 
and an active kinase is established. Nevertheless, numerous gaps remain to be filled in order 
to understand the complexity of KSR1 biological actions. First of all, physiological substrates 
of KSR1 and its catalytic activity need to be identified and further validated in differential 
cellular contexts, as well as its subcellular localization where it performs associated functions. 
Moreover, as a scaffold protein, it is crucial to determine its binding partners in dynamic 
scenarios since the subsequent interaction will ultimately contribute to various biological 
outcomes. Finally, the inquiry as to whether KSR1 is an attractive therapeutic target in 
malignancies that are confined to be Ras-dependent tumours requires further clarification. 
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1.4 Tyrosine kinases (TKs) 
TKs are enzymes that catalyse the transfer of phosphate from ATP to tyrosine residues in 
substrates. This group lies in the largest branch in the human kinome phylogenetic tree, which 
is comprised of 90 members [27]. TKs are divided into two main classes: RTKs and CTKs. 
Receptor TKs are transmembrane proteins with a ligand-binding extracellular domain, a 
membrane spanning segment and a catalytic intracellular kinase domain, whereas non-
receptor TKs lack transmembrane domains and are normally localized in the cytosol, the 
nucleus, or the inner surface of the plasma membrane [56]. Like all the other canonical 
protein kinases, the catalytic domains of all TKs have a bilobar structure, with an N-terminal 
lobe binding ATP and magnesium, a C-terminal lobe enclosing an activation loop, and a cleft 
between the lobes to which polypeptide substrates bind [196]. 
1.4.1 Receptor tyrosine kinases (RTKs) 
In the human kinome, there are 58 known RTKs, which are categoried into 20 subfamilies 
(Figure 9) [27, 197]. These subclasses are classified based on sequence similarity and 
characteristic structural features such as two cysteine-rich repeat arrangements in the 
extracellular domain of monomeric subclass I receptors, disulfide-linked heterotetrameric 
α2β2 structures with similar cysteine-rich sequences in subclass II receptors, and five or three 
immunoglobulin-like repeats in the extracellular domains of subclass III and IV receptors, 
respectively [196]. Due to their structural characteristics, the ligand binding domain and the 
kinase activity of RTKs are isolated by the plasma membrane. Thus, receptor activation 
induced by extracellular ligand binding  must be transduced through the membrane barrier to 
activate the intracellular domain functions [196].  
1.4.1.1 Activation of RTK extracellular domain by ligands 
With recent advances in structural studies of RTKs, our knowledge and understanding have 
developed from the classic mechanism for ligand-induced dimerization to diverse regulations 
of their activation by growth factor ligands. The original conceptual idea is that the activation 
of RTKs and associated signalling potentials is through ligand-induced dimerization [198]. In 
the absence of ligands, some RTKs are monomeric and disabled with an inactive 
conformation of their kinase domains. Upon ligands binding to the extracellular domain, a 
subsequent conformational alteration is induced resulting in receptor oligomerization, which 
stabilizes a specific contact between adjacent cytoplasmic domains and disrupts the 
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autoinhibitory interaction. This eventually triggers an activation of catalytic function essential 
for activating multiple downstream signalling pathways [196, 197]. 
 
  
Figure 9 Receptor Tyrosine Kinase Families. 
In the human kinome, there are 58 identified RTKs, which contain 20 subfamilies. Illustrated are 
schematic structures presented with the family members listed beneath each receptor. Structural 
domains in the extracellular regions, identified by structure determination or sequence analysis, are 
marked according to the key. The intracellular kinase domains are shown as red rectangles. 
Abbreviations of the prototypic receptors: EGFR, epidermal growth factor receptor; InsR, insulin 
receptor; PDGFR, platelet-derived growth factor receptor; VEGFR; vascular endothelial growth 
factor receptor; FGFR, fibroblast growth factor receptor; CCK, colon carcinoma kinase; EphR, 
ephrin receptor; Axl, a Tyro3 PTK; TIE, tyrosine kinase receptor in endothelial cells; RYK, 
receptor related to tyrosine kinases; DDR, discoidin domain receptor; Ret, rearranged during 
transfection; ROS, RPTK expressed in some epithelial cell types; LTK, leukocyte tyrosine kinase; 
ROR, receptor orphan; MuSK, muscle-specific kinase; LMR, Lemur; STYK1, 
serine/threonine/tyrosine kinase 1. This figure is adapted from published work from Lemmon and 
Schlessinger, 2010. 
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Evidence from solved crystal structures of the ligand-binding domains upon RTKs bound to 
their relevant ligands strongly supports this ligand-modulated dimerization in many cases, 
such as the Flt1-vascular endothelial growth factor (VEGF) receptor [199, 200], the 
NGF/neurotrophin receptor TrkA [201], Eph receptors [202], Axl  [203], Tie2 [204] and the 
stem cell factor receptor KIT [205]. All of these studies reveal a consistent mechanism that a 
bivalent ligand cooperates simultaneously with two receptor molecules and effectively 
interplays them into a dimeric complex [197]. 
Furthermore, recent progress in uncovering more complete extracellular regions of RTKs has 
added into our understanding of the mechanisms for ligand-induced dimerization. Lemmon 
and Schlessinger have recently categorized and summarized the mechanism into two extremes 
and two intermediate cases [197]. As shown in Figure 10A, TrkA/NGF is an example of one 
extreme, where receptor dimerization is exclusively “ligand mediated” and the two receptors 
make no direct contact. As an alternative, the other extreme is shown by the example of 
ERBB/growth factor, whose dimerization is entirely “receptor mediated” and the ligand has 
no influence on forming the dimer interface (Figure 10D). On the other hand, in some cases 
such as KIT/stem cell factor and FGFR/growth factor, a combination of ligand-mediated and 
receptor-mediated components is shown as the main mechanism for dimerization (Figure 10B 
and 10C). Above all, dimerization of most RTKs falls into one of these four modes and more 
comprehensive studies of other RTK families are needed to provide new insight into this field.  
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1.4.1.2 Activation of intracellular kinase domain 
The extracellular signalling of RTKs initiated by ligand-induced dimerization subsequently 
results in the activation of the intracellular tyrosine kinase domain (TKD), thereby 
transducing the activated signal down the cascade. Multiple excellent examples from KIT, 
FGFR, the insulin receptor and EGFR have illustrated a comprehensive picture of the 
activation mechanism that albeit varies in different cases [13, 197]. Although the crystal 
structures of activated TKDs in most RTKs with N-lobe and a C-lobe are similar, the inactive 
Figure 10 Receptor Tyrosine Kinase Dimerization. 
In general, RTKs interact as dimers when ligands (red) bind to their extracellular regions. The 
bound ligand can form all, a portion, or none of the dimer interface, and it activates the receptors 
by stabilizing a specific relationship between two individual receptor molecules. A. A nerve 
growth factor dimer (red) interacts with two TrkA molecules without any direct contact between 
the two receptors (Wehrman et al, 2007). B. A stem cell factor dimer (red) interacts with two KIT 
molecules. Additionally, two Ig-like domains (D4 and D5), re-orienting upon receptor activation, 
interact across the dimer interface. Hence, a combination of ligand-mediated and receptor-mediated 
dimerization modes is used by KIT (Yuzawa et al, 2007). C. Two fibroblast growth factor receptor 
(FGFR) molecules interact with one another through the Ig-like domain D2, where the molecule 
heparin or heparin sulfate proteoglycans (white sticks) also bind (Schlessinger et al., 2000). In 
addition, each fibroblast growth factor molecule (red) associates with Ig-like domains D2 and D3 
of both FGFR molecules. D. Dimerization of ErbB receptors is inter-mediated completely by the 
receptor. Through binding to two sites (DI and DIII) of the same receptor molecule, the ligand 
initiates conformational changes in EGFR from a previously blocked dimerization site in domain 
II. This figure is adapted from published work from Lemmon and Schlessinger, 2010. 
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forms of TKDs, as well as regulatory mechanisms vary significantly across receptors [206]. 
Owing to the diversities in regulating the catalytic activities of RTKs, it is therefore likely for 
them to be activated in a variety of distinctive manners. Generally, in each case, TKD is 
exclusively cis-autoinhibited by numerous intramolecular contacts specific for its receptor, 
whereas upon receptor dimerization induced by its ligand, cis-autoinhibition is unrestricted, 
thus promoting RTK activation [13, 197]. Here are some brief descriptions of the 
aforementioned examples.  
Juxtamembrane (region between the transmembrane helix and the cytoplasmic kinase domain) 
autoinhibition is the most known regulatory mechanism for catalytic activity of RTKs. 
Although juxtamembrane region may vary substantially in length and sequence among RTKs, 
it frequently comprises tyrosine phosphorylation sites essential for regulating catalytic activity  
and downstream signalling protein recruitment [207]. For the past decade, biochemical and 
structural studies of RTKs have provided strong evidence to support this mechanism, 
represented by Eph family RTKs [208], MuSK [209], Flt3  [210] and KIT [211]. Indeed, in 
each of these examples, the juxtamembrane region contacts directly with certain parts of the 
TKD, such as the activation loop, and contribute to maintain an autoinhibited conformation. 
Subsequent phosphorylation of the tyrosine residues of this region promoted by ligand-
induced dimerization releases juxtamembrane autoinhibition and stimulates receptor 
activation [197, 207]. Moreover, deletions of residues Lys550 to Glu561 or other mutations 
within the juxtamembrane region of KIT can interrupt the autoinhibitory interactions, prevent 
the region from maintaining the inactive kinase structure, thus causing a constitutive aberrant 
kinase activation [212]. 
The activation loop of the receptor TKD also contributes to RTK autoinhibition revealed by 
structural studies of the insulin receptor and FGFR1. In the case of insulin receptor, a crucial  
tyrosine (Tyr1162) in the activation loop of the insulin receptor TKD positions into the active 
site, and this direct contact with the active site of the kinase prevents both ATP and protein 
substrates from accessing to the active site. Therefore, the insulin receptor TKD maintains 
inactive in cis by its own activation loop. However, upon insulin binding to the receptor, 
phosphorylation of Try1162 and other two sites in TKD interrupts the cis-autoinhibitory 
interactions, which allows the receptor to adopt a conformational change from cis-
autoinhibition to an active state for catalytic function [206, 213]. Similarly, tyrosines in the 
activation loop of FGFR1 act through an indirectly intramolecular interaction to stabilize the 
inactive conformation of the kinase, thus blocking the protein-substrate-binding site. Once 
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FGF binds to the receptor, tyrosines in the activation loop become phosphorylated, which 
subsequently disrupts the cis-autoinhibitory configuration enabling an active transformation 
for kinase activity [214, 215]. 
Another form of reversible cis-autoinhibition is regulated through a region in the C-terminal 
of kinases. For instance, tyrosine sites in the C-terminal tail of Tie2 prevent substrate access 
to the active site [216]. Autophosphorylation of the tyrosines sites in the Tie2 C-terminal tail 
may destroy these autoinhibitory interactions and hence activate Tie2 [197]. Furthermore, 
crystallographic and mutational studies of the EGFR/ERBB family have revealed an allosteric 
mechanism for activation of TKDs [66]. Interestingly, the asymmetric dimer interface formed 
between the C-lobe of one TKD, (called the “Activator”) and the N-lobe of the second TKD, 
(called the “Receiver”) is essential for EGFR activation. Thus, conformational changes in the 
N-lobe of the Receiver kinase induced by this direct contact disrupt the cis-autoinhibitory 
structure observed in the monomer. Eventually, the characteristic active configuration of the 
Receiver kinase is employed in the absence of phosphorylation of its activation loop. 
Likewise, another member of the family, ERBB4 kinase, adopts an asymmetric dimer 
conformation essentially identical to the mechanism observed for activation of the EGFR 
[217].  
Above all, RTKs have developed a variety of de novo autoinhibitory mechanisms to inhibit 
basal-level activity. Upon binding to ligands, a set of characteristic conformational changes 
occur in multiple regions of RTKs including extracellular and intracellular domains, which 
subsequently allows RTKs to adopt an active form to perform their enzymatic activity and 
activate numerous downstream signalling pathways. The prevalence of mutations within the 
key domains such as juxtamembrane region in RTKs results in constitutively active forms of 
these receptors independent of ligand binding, contributing to many human diseases 
particularly malignancies [13, 212].  
1.4.1.3 RTKs in cancers 
RTKs are central regulators of intracellular signal-transduction pathways mediating almost all 
aspects of cellular processes, including proliferation, survival, differentiation, apoptosis, 
metabolism and motility [13]. Deregulation of RTK signalling by amplification 
(overexpression), mutations or alterations in structure can result in aberrant kinase activity 
contributing to various human disorders, especially malignant transformation. Considering 
their vital role in tumourigenesis, RTKs have become one of the most important groups of 
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drug targets, and plenty of inhibitors or targeted antibodies have been tested and some are 
already used in clinics [218].  
In the human kinome, almost all 20 subfamilies of RTKs have been implicated in regulating 
various signalling pathways in different cancers and they mainly function as dominant 
oncogenes [13]. For example, EGFR is amplified/overexpressed or mutated in a number of 
tumours including breast, oesophageal, glioblastoma, liver, prostate, ovarian and NSCLC, and 
activated EGFR signalling represents one of the main oncogenic signatures in these cancers 
[44, 219-221]. In PDGFR family, PDGFRα is amplified or mutated in gastrointestinal stromal 
tumour (GIST), glioblastoma, ovarian carcinoma, whereas PDGFRβ is mutated or 
overexpressed AML and CMML [13, 212, 222, 223]. Abnormal activity of FGFR family 
particularly due to genetic alterations has been extensively implicated in the development of a 
range of cancers. Amplifications in breast, ovarian, bladder, and mutations in melanoma, and 
translocations of FGFR1 in leukaemia are frequently observed [224-229]. FGFR2 
amplifications and mutations are often seen in gastric, breast and endometrial cancer [230-
232], whereas FGFR3 is overexpressed or mutated in bladder and cervical cancer [233-235].  
Like the ones in the larger groups of RTKs described above, members of the smaller families 
have also been implicated in oncogenesis. For instance, anaplastic lymphoma kinase (ALK) 
has been shown as an important oncogenic driver in several solid and hematologic tumours 
and has thus emerged as a biomarker and potential therapeutic target for certain population of 
patients. Indeed, numerous alterations of ALK including amplification, mutation, 
translocation and structural rearrangement have been implicated in contribution to tumour 
initiation and development in lung, breast, oesophageal, colorectal cancer, neuroblastoma and 
anaplastic large cell lymphoma [236-239]. Moreover, activation of RET via gain-of-function 
mutations or through aberrant expression has been greatly implicated in heritable and sporadic 
tumours. Initial studies revealed that the germline oncogenic RET mutations are associated 
with multiple endocrine neoplasia type 2, which is an autosomal dominant multi-tumour 
syndrome characterized by early onset medullary thyroid carcinoma [240-242]. Recently, 
RET has been shown to be expressed in over 50% of pancreatic ductal carcinoma and more 
frequently in high grade and metastatic tumours [243, 244]. In breast cancer, increased RET 
activity can result in an increase in cell proliferation and survival, and elevated levels of RET 
expression in vivo in breast tumours have been linked with resistance to endocrine therapies 
[245-248]. 
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Mounting evidence has supported the oncogenic potential of RTKs in a wide range of cancers. 
Here, an example of the most established RTK family-EGFR/ERBB in cancer is presented. 
1.4.1.3.1 EGFR/ERBB family in cancer 
There are four members in the ERBB family: EGFR, ERBB2, ERBB3 and ERBB4, which all 
share the conserved RTK‟s structural features with an extracellular ligand binding region, a 
single membrane spanning region, and a cytoplasmic tyrosine kinase domain [249]. In general, 
like other typical RTKs, activation of ERBB receptors is through ligand-induced dimerization. 
Upon ligand binding, the formation of homo- and heterodimers of ERBB receptors is induced 
and thus the intrinsic kinase domain is exposed and activated, resulting in phosphorylation of 
the regulatory tyrosine residues within the cytoplasmic tail. These phosphorylated residues in 
turn function as binding sites and initiate the recruitment of a variety of molecules essential 
for the activation of multiple intracellular signalling pathways [250, 251]. Based on their 
specificity of binding to different ERBB receptor, the EGF family ligands are divided into 
three groups: the first comprises EGF, TGF-α, amphiregulin and epigen, which attach 
specifically to EGFR; and the second includes betacellulin, heparin-binding EGF (HB-EGF) 
and epiregulin, which display dual specificity by binding both EGFR and ERBB4. The third 
group includes the NRGs, which are comprised of two subgroups based on their capacity to 
bind ERBB3 and ERBB4 (NRG1 and NRG2) or only ERBB4 (NRG3 and NRG4) [249, 252]. 
Notably, although none of the EGF ligands bind ERBB2, it can be activated through forming 
heterodimers with the other ligand-bound receptors in the family and in fact it is the preferred 
heterodimerization partner for the other activated ERBBs [253].  
Of the four EGFR receptors, enormous evidence has demonstrated an influential contribution 
of EGFR, ERBB2 and ERBB3 to the initiation, development and progression of various types 
of human cancer, but the role of ERBB4 in oncogenesis remains to be determined. As the 
involvement of ERBB3 in cancer has been discussed in the previous chapter, this part will 
focus on EGFR and ERBB2.  
Deregulation of EGFR by amplification, overexpression, mutation or structural alterations are 
frequent in human malignancies and associated with its oncogenic capacity. Elevated 
expression of EGFR gene is detected in numerous cancers including brain, breast, ovary, 
cervix, bladder, oesophagus, stomach, colon and lung, and is frequently associated with 
higher grade, higher proliferation and reduced survival. [56, 249, 250]. In addition to 
overexpression, activating EGFR mutations are crucial drivers of transformation and exist in 
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certain tumours. In particular, in NSCLC samples, about 10% of cases in North America and 
Western Europe, and ~30-50% of cases in East Asian descent harbour EGFR mutations [254-
257]. Moreover, in both cell culture and transgenic mouse studies, some of the identified 
mutations such as exon 19 deletions, L858R, G719S and ins 770(NPG)-mutated EGFR 
proteins have been proven to be capable of inducing oncogenic transformation, resulting from 
increased EGFR kinase activity and the activation of downstream pro-survival pathways [258-
261]. In tumours, constitutively activated EGFR recruit a variety of key regulatory proteins, 
such as Shc, Grb2 and phospholipase Cγ (PLCγ), and stimulate numerous signalling pathways, 
including PI3K/Akt, mTOR, MAPK, Src kinase, and signal transducers and activators of 
transcription (STATs) [249]. Given its crucial part in the development and evolution of cancer, 
targeting EGFR and the associated signalling network has contributed dramatically to the 
treatment of a range of human cancers [249]. For instance, the first generation of EGFR TKIs, 
such as erlotinib and gefitinib, have been shown to be effective in a subpopulation of patients 
with NSCLC that contains mutations in the kinase domain of EGFR, even if acquired 
resistance occur eventually [262, 263]. Currently, coupled therapy or dual-targeting approach 
is under development to increase drug efficacy and overcome resistance, leading to better 
patient outcomes. 
In 1987, ERBB2 amplification was initially detected in a subset of breast tumours and was a 
significant predictor of both overall survival and time to relapse in patients with breast cancer 
[264]. To date, ERBB2 amplification and overexpression have been found in some other 
cancers, including gastric, ovarian and salivary gland tumours [265-267]. ERBB mutations 
have also been identified in a small proportion of lung cancer and introduction of an ERBB2 
mutant with G776(YVMA) insertion in exon 20 resulted in activating signal transducers, 
phosphorylating EGFR, and inducing survival, invasiveness, and tumourigenicity [268, 269]. 
Moreover, the interaction between ERBB2 and ERBB3 has been recognised as most active 
ERBB signalling dimer and plays a fundamental role in ERBB2-mediated oncogenic 
signalling [67, 68]. In prostate cancer, the ERBB2-ERBB3 dimer might regulate androgen 
receptor protein levels as well as its transcriptional activity in hormone-refractory 
prostate cancer, and might contribute to the proliferation signal in "androgen-independent" 
tumours [270, 271]. Like EGFR, activated ERBB2 allows the recruitment of downstream 
signalling components and the formation of signalling complexes, resulting in aberrant 
activation of multiple crucial signalling pathways including the MAPK and the PI3K-Akt 
pathways in tumours [272]. The subsequent activation of the MAPK pathway increases the 
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transcription of cyclin D1, cyclin D2, Myc and VEGFA, which drive cellular proliferation, 
migration, differentiation and angiogenesis [250, 251]. On the other side, stimulation of the 
PI3K-Akt pathway triggers cellular signalling via GSK3β, NF-κB, p27 and BAD to facilitate 
cell survival, as well as inhibition of apoptosis and cell cycle control [273, 274]. Considering 
its central role in the tumourigenesis of many types of solid tumour, ERBB2 as a target for 
cancer therapy has been well validated and several agents have been developed against 
ERBB2 activation [249, 263, 272, 275]. One of the most known and effective is the 
humanised monoclonal antibody trastuzumab, which has already been approved by the FDA 
as part of standard treatment of ERBB2 amplified breast cancer patients [276]. Through 
interaction with the extracellular juxtamembrane region of ERBB2 (domain IV), Trastuzumab 
inhibits ERBB2 signalling activity, leading to suppression of downstream signalling pathways, 
which consequently cause anti-tumour effects, such as cell cycle arrest and reduction of 
angiogenesis [277-279]. Many new therapies including antibodies, inhibitors, and antibody-
chemotherapy conjugates are under investigation to target against ERBB2 and its regulated 
signalling.  
The examples of EGFR and ERBB2 highlight the significance of uncovering molecular 
mechanisms in the discovery of novel drugs, as well as the importance of collaboration 
between basic research and the oncology clinic. Overall, along with the progress of our 
understanding of the underlying pathogenesis, more effective, improved and personalized 
treatments will be available to patients.   
1.4.2 Cytoplasmic tyrosine kinases (CTKs) 
In the human kinome, 32 CTKs are identified to date and categorised into 10 subfamilies [13, 
27]. In comparison to the sequences of RTKs, CTKs lack extracellular and transmembrane 
spanning regions, thus normally locate in the cytoplasm when inactivated. As shown in 
Figure 11, some members of this family have similar domain organization, including SRC, 
ABL and TEC, share a common core, which is well recognized by N-terminal SH3/SH1 
domain, central SH2 domain and C-terminal kinase domain [280, 281]. SH2 recognizes and 
binds tyrosine phosphorylated sequences in a sequence-specific context and is therefore 
important in relaying cascades of signal transduction, whereas SH3 recognizes and binds to 
sequences typically rich in proline [280, 282]. These regulatory domains are essential for 
protein-protein interactions and coordination of key components of signalling pathways in 
response to extracellular signals. 
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1.4.2.1 Activation of CTKs 
Generally, in unstimulated cells, CTKs such as ABL and SRC stay in an inactive state 
through tight control including intramolecular autoinhibition by various cellular inhibitory 
proteins and lipids in the cytoplasm [283, 284]. In response to stimulus, CTKs are activated 
and subsequent conformational changes occur, which are induced by various intracellular 
signals through disruption of an autoinhibitory state, including oligomerization and 
autophosphorylation upon recruitment to transmembrane receptors, and trans-phosphorylation 
by other kinases [56]. Here are a few examples of the identified mechanisms for activation of 
some CTKs. 
1.4.2.1.1 Activation of c-SRC 
c-SRC was the first identified cellular homologue of a viral oncoprotein, which belongs to the 
SRC family of CTKs [285]. The structural studies revealed that c-SRC consists of several 
important domains: SH4, unique domain, SH3, SH2-SH3 linker, SH2, SH1 (kinase domain) 
and C-terminal negative regulatory region [284]. The SH4 domain located on the N-terminal 
region is a myristoylation sequence crucial for membrane localization [33, 286]. As described 
Figure 11 Cytoplasmic Tyrosine Kinase Families. 
In the human kinome, there are 32 identified CTKs, which contain 10 subfamilies. Here are 
schematic structures presented with the family members. Structural domains, identified by 
structure determination or sequence analysis, are marked according to the key. The kinase domains 
are shown as pink rectangles. Abbreviations: ACK, activated CDC42 kinase 1; CSK, c-SRC 
tyrosine kinase; FAK, focal adhesion kinase; FRK, FYN-related kinase; SYK, spleen tyrosine 
kinase. This figure is adapted from published work from Blume-Jensen and Hunter, 2001. 
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above, the SH3 and SH2 domain binds to proline rich sites and phosphorylated tyrosine sites 
respectively, both of which are important for protein-protein interactions [286, 287]. The SH1 
domain contains the kinase domain and tyrosine residue 419, which can be 
autophosphorylated by active c-SRC [33].  
In its inactive state, tyrosine residue 530 (Tyr530) of the C-terminal of c-SRC is 
phosphorylated and enables the interaction between the C-terminal with the SH2 domain, 
whereas the SH3 domain cooperates with the linker region between the SH2 domain and the 
N-terminal kinase lobe [13, 288]. This allows c-SRC to maintain an isolated conformation 
thus preventing a direct interaction of substrate proteins with the kinase domain. Numerous 
factors can contribute to the activation of c-SRC catalytic activity, such as dephosphorylation 
of phosphorylated Tyr530, SH2 binding and SH3 binding ligands [33]. Dephosphorylation of 
Tyr530 at the C-terminal region triggers its detachment from the SH2 domain, inducing an 
active conformation, which enables substrate protein access to the catalytic kinase site [289]. 
Ligand-activated RTKs allows specific tyrosine autophosphorylation sites to compete for c-
SRC SH2 domains resulting in a dissociation of SH2 from phosphorylated Tyr530 [290]. All 
of these events consequently lead to elimination of inhibitory elements on the kinase domain 
and activation of c-SRC with an open state.  
1.4.2.1.2 Activation of c-ABL 
c-ABL belongs to the ABL family of CTKs and its aberrant activity associated with the 
oncoprotein breakpoint-cluster region (BCR)-ABL contributes to various forms of leukaemia 
in humans [280]. Similar to SRC family, the c-ABL protein contains a conserved kinase 
domain preceded by SH3 and SH2 domains, as well as other unique domains including 
DNA/actin binding domains at the C-terminal and a „Cap‟ region located at the N-terminal 
important for recruiting the protein to membranes through myristoyl and/or palmitoyl groups. 
These structural configurations potentially determine a tight control of autoinhibition in cells 
and a brief description is presented here.  
In inactive state, c-ABL is engaged in the membrane through a covalent N-terminal myristoyl 
group and is inhibited through an intramolecular interaction of the SH3 domain with adjacent 
proline residue, as well as a direct contact of an inhibitory membrane lipid, 
phosphatidylinositol-4,5-bisphosphate (PIP2) to the catalytic domain. These factors together 
repress the kinase activity of c-ABL by maintaining the ATP-binding and catalytic lobes of 
the kinase domain in closed conformation [280, 283]. c-ABL is activated through the 
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phosphorylation of regulatory tyrosine residues, including one in the activation loop and the 
other near the SH3 binding site by related kinases. Upon PDGF stimulus, PDGFRβ is 
dimerized and autophosphorylated, subsequently generating binding sites for c-SRC and 
PLCγ to exert their activity. Activated c-SRC can phosphorylate c-ABL on the regulatory 
tyrosine 412, while PLCγ can hydrolyze and destroy the lipid inhibitor PIP2 [56, 283]. This in 
turn induces conformational changes of c-ABL allowing binding of the substrate and ATP to 
the active site for catalytic reaction.  
1.4.2.1.3 Activation of Jaks 
The Janus tyrosine kinase (Jaks) family has four members (Jak1, Jak2, Jak3 and tyrosine 
kinase 2 (Tyk2). This family is composed of seven Jak homology (JH) domains, named JH1-
JH7 from the carboxyl to amino terminus. Interestingly, JH1 is a typical tyrosine kinase 
domain whereas the neighbouring JH2 region is a pseudokinase domain serving regulatory 
functions of Jaks activity through binding to JH1 [291-293]. The amino terminus of Jaks 
contains an SH2 domain (JH3-JH4) and a Band-4.1, ezrin, radixin, moesin (FERM) homology 
domain (JH6-JH7). The FERM domain plays an important role in modulating interactions 
with transmembrane proteins such as cytokine receptors and is also implicated in positively 
regulating catalytic activity via binding the kinase domain [294-296]. 
Normally, Jaks constitutively interact with cytokine receptors on the cell surface. Upon 
cytokine binding, receptor dimerization occurs, which leads to an activation of Jaks through a 
conformational change in the receptor allowing phosphorylation of the two bound Jaks. 
Activated Jaks can in turn phosphorylate the cytoplasmic domain of the cytokine receptors, 
resulting in recruitment of SH2-domain containing proteins to the receptor complex, such as 
STATs whose activation are widely implicated in many cancers [297-300]. When STATs 
bind the phosphorylated receptor chains, Jaks can subsequently phosphorylate STATs, 
inducing the formation of stable STATs homodimers and heterodimers through interactions 
between SH2 domains and phosphorylated tyrosine residues. Activated STATs can then 
translocate to the nucleus where they activate transcription [297, 301, 302].  
1.4.2.2 CTKs in cancer 
Given their importance in various cellular processes, such as proliferation, apoptosis, 
angiogenesis and immune surveillance, deregulation of the kinase activity of certain CTKs 
has been comprehensively implicated in multiple oncogenic signalling in human malignancies. 
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Here are some examples of CTKs whose aberrant activation by mutations and other genetic 
alterations contribute to carcinogenesis.   
1.4.2.2.1 Jaks 
Jak members are highly associated with hematopoietic malignancies. For example, a gain-of-
function mutation (V617F) in the JH2 domain of Jak2 correlates with myelo-proliferative 
neoplasia [303-306]. Jak1 mutations were also reported in patients with AML and ALL [307, 
308]. In one study, approximate 18% of patients with the T cell precursor ALL were shown to 
have Jak1 mutations, which associates with poor response to therapy and overall prognosis. 
Three gain-of-function mutations identified were implicated in contributing to IL-9 
independent resistance to apoptosis of T cell lymphoma BW5147 cells [307]. In addition, 
Jak3 pathway genes were shown to be elevated in B-lineage ALL and the increased 
expression of these genes correlates with steroid resistance and relapse [309].   
The Jak family has also been suggested to play a role in solid tumour growth. In breast cancer, 
Jaks were shown to interact with SRC tyrosine kinase contributing in constitutive activation 
of STAT3. Inhibition of Jaks by tyrosine kinase selective inhibitors resulted in reduced 
growth and increased programmed cell death in breast cancer cells [310]. In prostate cancer, 
Jaks inhibitor, tyrphostin AG490, can suppress STAT3 activation and inhibit the growth of 
human prostate cancer cells. This indicates that Jaks-STAT3 pathway is crucial in the survival 
and proliferation of prostate cancer cells [311]. Furthermore, erythropoietin was capable of 
activating Jak2-STAT5 signalling leading to metastasis in head and neck squamous cell 
carcinoma [312]. The Jaks-STATs pathway is also involved in lung cancer. Gao et al showed 
that in EGFR constitutively activated human lung adenocarcinoma-derived cells, a pan-Jaks 
inhibitor (P6) significantly reduced STAT3 phosphorylation. Additionally, P6 suppressed 
tumourigenesis of human lung adenocarcinoma cells in vitro and in vivo. Results from this 
study conclude that STAT3 phosphorylation in lung adenocarcinoma is dependent on the IL-
6/gp130/Jaks pathway [313]. 
Numerous reviews on the role of Jaks in cancer have been published recently [314-319]. 
Involvement of Jak kinases in the development of malignancies has resulted in a great number 
of inhibitors currently being evaluated in clinical trials [301, 320, 321]. 
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1.4.2.2.2 c-ABL 
The Philadelphia (Ph) chromosome, a t(9;22)(q34;q11) translocation, was first discovered as 
an abnormal, small chromosome associated with a specific type of leukaemia. This reciprocal 
translocation generates the oncogenic BCR-ABL fusion gene [322]. Subsequently, several 
lines of evidence support BCR-ABL as an oncogene that contributes to CML pathogenesis. In 
cultured cells, introduction of BCR-ABL has been shown to be capable of driving the 
transformation of mouse fibroblast cell lines, haematopoietic cell lines and primary bone-
marrow cells [323, 324]. Similarly, in human CD34
+
 cells, ectopic expression of BCR-ABL 
has demonstrated several features of primary CML progenitors, including increased 
proliferation in primitive progenitor culture, reduced adhesion to fibronectin, and reduced 
chemotaxis to stroma-derived factor-1alpha [325, 326]. In addition to studies in cultured cells, 
several animal models of CML also prove its role in leukaemogenesis. A myelo-proliferative 
disorder (MPD) that resembles CML was shown to be developed when BCR-ABL was 
introduced in mouse bone-marrow cells using retroviral transduction and bone-marrow 
transplantation methods [327-329]. This was confirmed by another mouse model in which a 
murine stem-cell retroviral vector was used to express the BCR-ABL oncogene in 
haematopoietic stem/progenitor cells, and introduction of the transgene in the bone-marrow 
cells of mice induced a human CML-like disease with 100% efficiency [330, 331]. Moreover, 
studies in transgenic mice also showed that inducible expression of BCR-ABL in B-cell 
lymphocytic and megakaryocytic precursors contributed to the development of B-ALL and 
megakaryocytic myelo-proliferative syndrome [332, 333]. 
The kinase domain of ABL as well as other regulatory domains has been shown to be 
important for its capability of tumourigenesis. In vivo studies showed that mice that encode a 
mutant BCR-ABL (a point mutation in the ATP-binding site of ABL), did not develop 
leukaemia, indicating that the kinase activity is required for its function in leukaemogenesis 
[331]. Expression of another mutant ABL with deletion of the SH3 domain, which has 
increased tyrosine kinase activity, can transform both fibroblast and haematopoietic cell lines 
in vitro and induce a CML-like disease in mice [334, 335]. Furthermore, BCR-ABL has been 
implicated to interact with many important proteins, including STAT5, PI3K, PLCγ, Ras 
GTPase activating protein, FAK (also known as PTK2) and FES, which in turn activate 
multiple signalling pathways such as Ras/Raf/MAPK, PI3K/Akt and Jak/STATs and 
potentially contribute to oncogenesis [324]. 
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1.4.2.2.3 Other CTKs in cancer 
The SRC family kinases (SFKs) have been shown to be important for cell proliferation, 
survival, adhesion, invasion and angiogenesis during tumour development [284]. SFKs 
cooperate with many key mediators in multiple signalling pathways to regulate 
tumourigenesis. For example, SFKs interact with RTKs, including EGFR and VEGFR to 
influence cell proliferation and angiogenesis. Moreover, SFKs regulate gene expression 
through transcription factors such as STATs, as well as modulate cell adhesion and migration 
through interaction with integrins, actins, paxillin, and FAK [284]. In breast cancer, SRC 
interacts with ERBB2 to enhance cell growth and SRC activity is necessary for the metastatic 
potential of ERBB2-overexpressing cancer [336]. In lung cancer, it has been reported that 
about 50-80% of patients have elevated expression of SRC protein and/or increased kinase 
activity [337]. In prostate cancer, SRC signalling can stimulate cell growth upon androgen 
treatment, as well as contribute to androgen independent prostate cancer. The addition of SRC 
inhibitor into anti-androgen deprivation therapy for prostate cancer patients may improve 
therapeutic results [338, 339]. In head and neck cancer, expression of dominant active SRC in 
squamous cell carcinoma has shown an increase in growth and invasion in comparison to the 
vector controls [340]. 
FAK plays a critical role in tumour initiation, progression and metastasis. It is a main 
mediator of signal transduction by integrins and is involved in a range of other pathways 
associated with growth factors, G-protein-coupled receptor agonists, cytokines, and other 
inflammatory mediators [341, 342]. In breast cancer, it is well documented that FAK is 
overexpressed in breast cancer patients as well as in cell lines. Moreover, elevated FAK 
expression and activity are frequently associated with poor prognosis and progression to 
metastasis in breast cancer specimens [343-345]. In polyoma middle T oncoprotein (PyMT) 
induced breast cancer model, FAK-deficient PyMT-transformed cells exhibited an arrest of 
growth and a diminished activity of invasion and metastasis, highlighting its involvement in 
Ras- and PI3K-dependent mammary tumour initiation [345]. In addition to its high levels in 
breast cancer, FAK has also been shown to be overexpressed in some other cancer types, 
including brain, cervical, colorectal, gastric, lung, and head and neck, indicating that FAK is a 
common oncogene and a potential therapeutic target in a broad range of cancers [341, 342].  
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1.5 Aims 
Although great efforts have been devoted to study the involvement of KSR1 in certain tumour 
types, its biological functions and associated signalling pathways implicated in breast cancer 
have remained largely undefined. Therefore, in this work, we sought to provide a 
comprehensive picture illustrating its role in breast cancer and our aims were to:  
 identify a KSR1-regulated phospho-proteomic profile in breast cancer cells using a 
stable isotope labelling of amino acids in cell culture (SILAC-based) approach; 
 characterize the functional portrait of the KSR1-regulated proteins identified from 
SILAC using Gene Ontology analysis and reveal new KSR1-associated signalling 
networks;  
 examine the expression of KSR1 in a large breast cancer patient cohort (n>1000) and 
evaluate its clinical association and prognostic significance in breast cancer patients; 
 study the functional effects of KSR1 on breast cancer growth using in vivo and in vitro 
models; 
 gain an insight into the potential mechanisms that contribute to its phenotypic effects 
and propose new intracellular pathways that KSR1 is involved in. 
Although our understanding of TK signalling has developed dramatically over the past 
decades, only approximately half of them are well understood and much more remains to be 
investigated in order to achieve a complete picture of their regulated proteomes. Thus, further 
work in this thesis was addressed at globally decoding tyrosine kinase signalling by combined 
use of RNAi and SILAC quantitative proteomics in breast cancer. The aims were to: 
 determine the expression profile of all 90 TKs in MCF7 cell line using RT-qPCR; 
 silence individually each member of TKs expressed in MCF7 cells using a validated 
RNAi library; 
 identify the TKs-regulated proteomes after siRNA treatment by SILAC-based 
quantitative proteomics; 
 propose a new classification of the TKs family based on the similarity in their 
regulated proteomes; 
 characterize a proteomic signature and a functional portrait for each identified cluster 
by performing various bioinformatic analyses. 
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CHAPTER 2: 
MATERIALS AND METHODS 
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2.1 Materials 
2.1.1 Buffer and solutions 
Table 1. List of buffers and solutions 
Reagent Recipe Storage 
1M Tris-HCl 60.5 g Tris in total of 500ml ddH20 and adjusted to desired 
pH with pure HCl 
RT 
NP-40 50 mM Tris-HCl, pH 8.0; 150 mM NaCl, 10%(v/v) glycerol; 1% NP40; 5 
mM dithiothreitol (DTT); 1 mM EDTA; 1 mM EGTA; 50 μM leupeptin; 
30 μg/ml aprotinin 
4°C 
RIPA Tris-HCl: 50 mM, pH 7.4; NP-40: 1%; Na-deoxycholate: 0.25%; NaCl: 
150 mM; EDTA: 1 mM; PMSF: 1 mM; Aprotinin, leupeptin, pepstatin: 1 
µg/ml each; Na3VO4: 1 mM; NaF: 1 mM 
4°C 
Laemmli buffer 50mM Tris-HCl pH 6.8; 15% glycerol; 0.1% (w/v) bromophenol blue; 4% 
SDS 
-20°C 
5x Loading buffer 0.25M Tris-HCl, pH 6.8; 15% SDS; 50% glycerol; 25% beta-
mercaptoethanol; 0.01% bromophenol blue 
4°C 
10x SDS-PAGE 
Running buffer 
10g SDS; 30.3g Tris, 144.1g glycine dissolved in 1 l of ddH20 RT 
10x Semi Dry 
Transfer buffer 
Tris Base 5.8g; Glycine 2.9g; Methanol 200ml and make up to 1 l with 
ddH20 
RT 
10x TBS 24.23g Trizma HCl; 80.06 g NaCl dissolved in 1l of ddH20 and adjusted 
pH to 7.6 with pure HCl 
RT 
TBS-Tween 100ml of TBS 10x; 900ml ddH20; 1ml Tween® 20 (BDH) RT 
Blocking buffer TBS containing 0.1% (v/v) Tween20 and 5% (w/v) non-fat milk 4°C 
0.4% 
Sulforhodamine B 
(SRB) 
0.4% w/v SRB powder dissolved in 1% acetic acid RT 
40% 
Trichloroacetic 
Acid (TCA) 
40 w/v TCA dissolved in ddH20 4°C 
IF  fixation buffer 4% w/v paraformaldehyde  4°C 
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IF blocking buffer 10% AB-serum in PBS -20°C 
2.1.2 Mammalian cell lines 
Table 2. List of mammalian cell lines 
Cell Type Tissue Morphology Tumourigenicity 
MCF7 Breast Epithelial Human cell line derived from a pleural effusion 
of adenocarcinoma 
MCF7-vector Breast Epithelial MCF7 cell line stably overexpressing pCMV6-
vector plasmid 
MCF7-KSR1 Breast Epithelial MCF7 cell line stably overexpressing pCMV6-
KSR1 plasmid 
MDA-MB-
231 
Breast Mesenchymal Human Metastatic and high invasive cell line 
derived from pleural effusions of ductal 
carcinoma 
MDA-MB-
231-vector 
Breast Mesenchymal MDA231 cell line stably overexpressing 
pCMV6-vector plasmid 
MDA-MB-
231-KSR1 
Breast Mesenchymal MDA231 cell line stably overexpressing 
pCMV6-KSR1 plasmid 
T47D Breast Epithelial Human cell line derived from a pleural effusion 
of an infiltrating ductal carcinoma 
ZR75-1 Breast Epithelial Human cell line derived from metastatic site of 
ductal carcinoma 
SKBR3 Breast Epithelial Human cell line derived from metastatic site of 
adenocarcinoma 
BT474 Breast Epithelial Human cell line derived from a solid, invasive 
ductal carcinoma 
MDA-MB-
453 
Breast Epithelial Human cell line derived from metastatic 
carcinoma 
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Table 3. Normal growth media 
Cell Type Media Additives Storage 
MCF7 
MDA-MB-
231 
T47D 
ZR75-1 
SKBR3 
BT474 
DMEM (Dulbecco‟s 
Modified Eagle‟s Medium) 
(Sigma-Aldrich, Dorset, 
UK) 
2mM Glutamine 
50 units/ml Penicillin 
50μg/ml Streptomycin 
10% FCS 
4°C, used within 
one month 
MCF7-vector 
MCF7-KSR1 
MDA-MB-
231-vector 
MDA-MB-
231-KSR1 
DMEM (Dulbecco‟s 
Modified Eagle‟s Medium) 
(Sigma-Aldrich, Dorset, 
UK) 
2mM Glutamine 
50 units/ml Penicillin 
50μg/ml Streptomycin 
10% FCS  
1000-500μg/ml G-418  
(Roche Diagnostic 
Ltd,  
West Sussex, UK) 
4°C, used within 
one month (G418 
added fresh each 
time) 
 
Table 4. SILAC Media 
Name Media Additives Storage 
DMEM-14 (R0K0) Control SILAC DMEM media 
containing unlabelled arginine 
and lysine amino acids 
10% SILAC dialysed 
foetal bovine serum 
4°C, used 
within one 
month 
DMEM-15 (R10K8) SILAC DMEM media 
containing 13C and 15N 
labelled arginine, and13C and 
15N labelled lysine 
10% SILAC dialysed 
foetal bovine serum 
4°C, used 
within one 
month 
DMEM-16 (R6K4) SILAC DMEM media 
containing 13C labelled 
arginine and 2D labelled 
lysine amino acids 
10% SILAC dialysed 
foetal bovine serum 
4°C, used 
within one 
month 
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Table 5. Transfection media and reagents 
Transfection media Additives Transfection reagents Storage 
Normal growth media 
(NEAT) 
NO HiPerFect Transfection Reagent 
(Qiagen, West Sussex, UK) 
4°C 
Opti-MEM
®
 I Reduced 
Serum Medium(Gibco®) 
NO Lipofectamine
®
 2000 Reagent 
(Invitrogen, Life Technologies 
Ltd, Paisley, UK) 
4°C 
 
2.1.3 Plasmid constructs 
Table 6. List of plasmids and constructs 
Vector Insert 
(Gene) 
Amino Acids ID Source 
pCMV6 
Myc/FLAG 
Empty vector Empty vector PS100
00 
Origene 
pCMV6 
Myc/FLAG 
KSR1 full length RC21
1770  
Origene 
pCMV6 
Myc/FLAG 
KSR1 full length (R502M) N/A Site-directed 
Mutagenesis 
PGL3 p53-R2 (luciferase. reporter) N/A Vikhanskaya et al., 
2007 
PGL3 p53-
GADD45 
(luciferase. reporter) N/A Vikhanskaya et al., 
2007 
PGL3 p53-P21 (luciferase. reporter) N/A Vikhanskaya et al., 
2007 
PGL3 p53-AIP1 (luciferase. reporter) N/A Vikhanskaya et al., 
2007 
PGL3 p53-CYCLIN 
G1 
(luciferase. reporter) N/A Vikhanskaya et al., 
2007 
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PGL3 p53-IGFBP3 (luciferase. reporter) N/A Vikhanskaya et al., 
2007 
pCDNA3.1 Ubiquitin Myc-tag N/A Faronato et al., 2013 
pCDNA3.1 BARD1 FLAG-BARD1 (aa 1-
320) 
N/A Nishikawa et al., 2009 
pCDNA3.1 BARD1 FLAG-BARD1 (full 
length) 
N/A Nishikawa et al., 2009 
pCDNA3.1 BARD1 Myc3-BARD1 (full 
length) 
N/A Nishikawa et al., 2009 
pCDNA3.1 BRCA1 Myc-BRCA1 (aa 1-772) N/A Nishikawa et al., 2009 
pCDNA3.1 BRCA1 FLAG-BRCA1 (aa 1-
772) 
N/A Nishikawa et al., 2009 
pCDNA3.1 BRCA1 Myc3-BRCA1 (full 
length) 
N/A Nishikawa et al., 2009 
pCDNA3.1 HA-NEDD8 Full length 18711 Addgene 
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2.1.4 Antibodies 
Table 7. Primary antibodies 
Name Dilution  Producer 
KSR1 rabbit polyclonal 1:1000 Santa Cruz 
KSR1 rabbit polyclonal 1:1000 Cell Signalling 
Anti-Flag mouse monoclonal 1:1000 Sigma Aldrich 
p53 mouse monoclonal DO-1 1:1000 Santa Cruz 
Acety-p53 rabbit polyclonal 1:500 Cell Signalling 
p-p53 Ser15 rabbit polyclonal 1:500 Cell Signalling 
SIRT1 rabbit polyclonal 1:1000 Cell Signalling 
DBC1 rabbit polyclonal 1:1000 Cell Signalling 
p-DBC1 Thr454 rabbit polyclonal 1:500 Cell Signalling 
β-actin mouse monoclonal 1:20000 Abcam 
BRCA1 rabbit polyclonal 1:1000 Santa Cruz 
BARD1 rabbit polyclonal 1:1000 Bethyl Laboratories 
Ubiquitin mouse monoclonal 1:1000 Cell Signalling 
Anti-Myc mouse monoclonal 1:1000 Sigma Aldrich 
NEDD8 rabbit polyclonal 1:1000 Cell Signalling 
p-MEK1/2 rabbit polyclonal 1:1000 Cell Signalling 
p-ERK1/2 rabbit polyclonal 1:1000 Cell Signalling 
MEK1/2 rabbit polyclonal 1:1000 Cell Signalling 
ERK1/2 rabbit polyclonal 1:1000 Cell Signalling 
p-C-Raf rabbit monoclonal 1:1000 Cell Signalling 
C-Raf rabbit polyclonal 1:1000 Cell Signalling 
p-B-Raf rabbit polyclonal 1:1000 Cell Signalling 
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B-Raf rabbit monoclonal 1:1000 Cell Signalling 
HDAC1 rabbit polyclonal 1:1000 Santa Cruz 
Table 8. Secondary antibodies 
Antibody Dilution  Producer Dilution buffer 
Polyclonal goat anti-rabbit 
IgG/HRP 
1:3000 Dako, Cambridge, UK 5% milk in TBST 
Polyclonal goat anti-mouse 
IgG/HRP 
1:3000 Dako, Cambridge, UK 5% milk in TBST 
Alexa Fluor
®
 555 goat anti-mouse 
IgG 
1:1000 Invitrogen, Paisley, 
UK 
10% AB-serum in PBS 
IRDye
®
 Donkey anti-mouse IgG 1:10000 LI-COR
®
, USA 5% milk in TBST 
IRDye
®
 Donkey anti-rabbit IgG 1:10000 LI-COR
®
, USA 5% milk in TBST 
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2.1.5 Patient characteristics 
The study cohort comprised > 1000 primary operable breast cancer cases from the previously 
validated Nottingham Tenovus Primary Breast Carcinoma Series [174, 346-348]. This well-
characterized resource contains information on patients‟ clinical and pathological data 
including histological tumour type, primary tumour size, lymph node status, histological 
grade and data on other breast cancer relevant biomarkers. All patients participated in this 
study cohort were consented. This study was approved by Nottingham Research Ethics 
Committee 2. 
Table 9. Patient characteristics data  
 Patient characteristics Number (%) 
Tumour Stage   
 1 561 (59.1%) 
 2 297 (31.3%) 
 3 90 (9.5%) 
Grade   
 1 137 (14.4%) 
 2 303 (31.8%) 
 3 510 (53.7%) 
Age   
 <50 317 (33.2%) 
 =>50 635 (66.7%) 
Vascular Invasion   
 Definitive 332 (35.1%) 
 Negative 494 (52.3%) 
 Probable 119 (12.6%) 
Tumour type   
 Invasive Ductal 591 (63.3%) 
 Classical Lobular 44 (4.7%) 
 Tubular Mixed 149 (16.0%) 
 Atypical Medullary 23 (2.5%) 
ER Status   
 Negative 270 (29.1%) 
 Positive 657 (70.9%) 
PgR Status   
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 Negative 402 (44%) 
 Positive 511 (56%) 
cerbB2 Status   
 Negative 794 (85%) 
 Positive 140 (15%) 
Triple Negative Status   
 No 742 (80.4%) 
 Yes 180 (19.5%) 
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2.2 Methods 
2.2.1 Mammalian cell culture 
2.2.1.1 Maintaining and passaging cells   
Cells were usually maintained in 150 cm
2
 flasks with normal growth medium at 37 °C in a 
humidified 5% CO2 incubator. Cells were routinely passaged at a confluence of ~90%. To 
passage cells, medium was first removed with aspirators and washed 2-3 times with room 
temperature PBS. 3 ml of 10% trypsin in EDTA was added into each flask and cells were 
allowed to detach at 37 °C in incubator for 3 min. Medium with FCS was added into flasks to 
neutralize the trypsin and cell clumps were resuspended gently through pipetting. Suspension 
of cells was taken out of flask, and transferred in 15 mL sterile centrifuge tube and 
centrifuged at 1000 rpm for 5 min. Once centrifugation was finished, the supernatant was 
aspirated and cell pellet was resuspended in a certain amount of medium depending on 
requirement. The proper dilution of cells was then reseeded into new flasks and fresh media 
was added. Cell passages used in all experiments were normally between passages 4 and 20 
and mycoplasma was tested routinely.  
2.2.1.2 Cell transfections 
For siRNA transfection, cancer cell lines were seeded into different sizes of dishes (6 cm or 
10 cm) or plates (6-well or 24-well) with appropriate amount of medium depending on 
experiment design. Cells were allowed to attach at 37°C with 5% CO2 for overnight before 
transfection. On next day, the named siRNA (20 nM) was firstly added into neat medium or 
Opti-MEM
® 
without additives and this mix was left at RT for 10 min before proceeding to 
next step. Hiperfect Transfection Reagent (Qiagen) were then put into the previous solution 
and mixed gently. The master mix was incubated at RT for 15 minutes to enable the formation 
of transfection complexes. Subsequently, the complexes were added drop-wise onto the cells, 
and the plates were gently swirled to allow distribution of the transfection complexes evenly. 
The cells with the different transfection complexes were then incubated under normal growth 
conditions for indicated time. Each transfection was performed at least three times and the 
following assays including protein and RNA extractions were implemented. 
For plasmid DNA transfection, cells were plated into the indicated dishes or plates for each 
experiment as aforementioned. On the transfection day, the indicated amount of plasmid DNA 
was added into Opti-MEM
®
 without additives. At the same time, certain volume of 
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Lipofectamine
®
 2000 (ratio 1 ul: 2 ug) was added into same amount of Opti-MEM
®
 without 
additives. Each mix was incubated for 15 min at RM temperature to allow complex formation 
to occur. After incubation, the two complexes were mixed gently and kept at RM temperature 
for another 15 min according to manufacturers‟ protocols. This master mix was then added 
drop-wise onto the cells, and the plates were swirled to allow distribution of the transfection 
complexes evenly. The cells with the different transfection complexes were then incubated 
under normal growth conditions for indicated time. Each transfection was performed at least 
three times for the experiments described in this work. 
2.2.1.3 Cell treatments 
For EGF treatment, MCF7 cells were seeded in 60 mm dishes at a 50% confluence and 
incubated under stripped medium without growth factors. Cells were then transfected with 
indicated plasmid DNA for 24 hours. EGF (Invitrogen, Life Technologies Ltd, Paisley, UK) 
or its vehicle DMSO (for the time point 0) was then added at a final concentration of 10 ng/ml 
for the indicated time points. After each time point, dishes were placed on ice and medium 
was aspirated. Cells were washed three times with cold PBS, scraped and centrifuged for 5 
minutes at 1300 rpm. The supernatant was removed and the cell pellet was processed for 
western blotting assay. 
2.2.1.4 Generation of stable cell lines 
MCF7 and MDA231 cells were used to generate cell lines stably expressing human wild type 
KSR1 (pCMV6-KSR1) and empty vector (pCMV6-vector). These plasmid constructs were 
purchased from Origene (Table 6) and sequences were confirmed before experiments. To start, 
a working concentration of G-418 to guarantee selection and maintenance of the neomycin-
resistant cells by eliminating non-transfected cells was determined as following. A titration 
experiment was designed by treating non-transfected MCF7/MDA231 cells seeded at 
different densities to different doses of G-418 (0, 0.1, 0.3, 0.5, 0.8, 1 mg/ml) for 10 d, and 1 
mg/ml showed to be the minimum amount of G-418 that caused 99% cell death at all densities. 
Next, 1 x 10
6
 cells were seeded in 100 mm dishes in medium in the absence of antibiotics and 
attached overnight. On the following day, plasmids pCMV6-KSR1 or pCMV6-vector were 
transfected into cells using protocol described above. After 48 hours, stably transfected cells 
were treated with normal growth media in the presence of 1 mg/ml of G-418. In 10 days from 
the addiction of the antibiotic, non-transfected cells died and removed. Stably transfected cells 
were plated at a lower density to allow each single cell form a monoclonal colony with G-418. 
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When clones were visualized by eyes, 20 clones for each transfection condition were reseeded 
into 24-well plates: cloning discs were dipped in trypsin-EDTA for 2-3 min, then put on top 
of a single cell colony and incubated for 5 min at 37 ºC to allow cells to detach. Each cloning 
disc carrying monoclonal cells was then transferred to each well of a 24-well plate in presence 
of G-418. Cells derived from monoclonal colonies were cultured by changing medium twice a 
week, and expanded to high confluence before to be transferred to a large scale plate. Finally, 
selected stable cells were acquired and success of transfection was confirmed by RT-qPCR 
and western blotting to check the mRNA and protein expression levels.  
2.2.2 Protein extraction and western blotting 
2.2.2.1 Total protein extraction 
Cells were NP40 lysis buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 10%(v/v) glycerol, 1% 
NP40, 5 mM dithiothreitol (DTT), 1 mM EDTA, 1 mM EGTA, 50 μM leupeptin and 30 
μg/ml aprotinin) was used to extract whole cell lysates. Cell pallets were mixed thoroughly 
with NP40 lysis buffer, and then incubated in ice for 15 min before centrifuging at 15000 rpm 
for 15 min at 4 °C.  
2.2.2.2 Nuclear and cytoplasmic protein extraction 
Nuclear and cytoplasmic extracts were prepared from whole-cell lysis using NE-PER Nuclear 
and Cytoplasmic Extraction Kit (Thermo Scientific). Briefly, cells were harvested with 
trypsin-EDTA and centrifuged at 1000 rpm for 5 minutes to get the pellet. Next, cell pellet 
was washed twice in cold PBS and supernatant was removed. Certain amount of ice-cold 
CER I buffer l depending on the cell pellet volume was added to the cell pellet. Cell lysate in 
the tube was mixed vigorously on the highest setting of vortex for 15 seconds to fully suspend 
the cell pellet and incubated on ice for 10 minutes. Subsequently, ice-cold CER II was added 
to the tube and mixed vigorously on the highest setting of vortex for 10 seconds and incubated 
on ice for 1 minute. Directly, the tube was vortexed for 5 seconds on the highest setting and 
then centrifuged for 5 minutes at maximum speed. After centrifuge, the supernatant 
containing cytoplasmic extract was collected to a clean pre-chilled tube for later use. The 
insoluble (pellet) fraction produced above was resuspended in ice-cold NER. The tube was 
mixed thoroughly on the highest setting for 15 seconds and placed on ice. In every 10 minutes, 
the sample was continued vortexing for 15 seconds for a total of 40 minutes. Immediately, the 
sample was centrifuged at maximum speed (~16,000 × g) in a microcentrifuge for 10 minutes 
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and supernatant containing nuclear extract was transferred to a clean pre-chilled tube for later 
use. 
2.2.2.3 Protein quantification and lysate preparation  
Protein concentration was measured by the bicinchoninic acid (BCA) protein assay (Pierce) or 
Bradford Reagent Kit (Bio-Rad, Berkeley, CA, USA). 1 ul of each protein samples were 
normally added into 1000 ul of Bradford buffer and incubated at room temperature for 5 min. 
Absorbance readings of the prepared samples were then were measured at 595 nm using a 
Beckman DU
®
 530 Life Science UV/Visible spectrophotometer (Harlow Scientific, Arlington, 
MA). After measurement, the concentration of the unknown samples was determined based 
on standard absorbance value. An equal amount of protein in all samples was processed and 
lysates were heated with 5x sodium dodecyl sulfates (SDS) sample buffer at 95 °C for 5 min 
before they were loaded to 10% SDS-PAGE.  
2.2.2.4 SDS-polyacrylamide gel electrophoresis and western blotting 
Different percentages of acrylamide resolving and stacking gels were prepared manually as 
required for indicated proteins. Samples (20 ug) and rainbow markers (Thermo Scientific, 
Leicestershire, UK) were loaded onto the gels. Subsequently, electrophoresis was run at 80V 
for 30 min and changed to 120V for 2 hours in 1x running buffer. Proteins were separated by 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE). 
Samples were then transferred to Hybond ECL super nitrocellulose membranes (GE 
Healthcare). Subsequently the membranes were blocked in TBS containing 0.1% (v/v) 
Tween20 and 5% (w/v) non-fat milk for 1 h. The primary antibodies were probed with 
membranes overnight at 4 °C. The membranes were then washed three times in TBS/Tween 
for 15 min following incubation with HRP-conjugated secondary antibodies (1:3000 dilution) 
for 60 min. The membranes were then washed three times again and were detected with 
Enhanced chemiluminescence (ECL). Films were developed using a Konica SRX-1001A X-
ray developer. Alternatively, membranes were incubated with IRDye Donkey anti-mouse or 
Donkey anti-rabbit secondary antibodies for 60 min and visualized by Odyssey Fc Imaging 
System (LI-COR). 
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2.2.3 RNA extraction and RT-qPCR 
2.2.3.1 RNA extraction from cells 
RNA extraction in this work was performed using RNeasy Mini Kit from Qiagen (Crawley, 
UK). Briefly, cells from 6-well plate were firstly washed three times with PBS, which was 
aspirated straight after wash. 300 µl of RLT buffer was added directly to the cells in the plate 
and mixed well. Lysate in RLT was then transferred into a QIAshredder spin column placed 
in a 2 ml collection tube, which was centrifuged at full speed for 2 min. Subsequently, an 
equal volume of 70% ethanol 300 µl was added to the homogenized lysate, and mixed well by 
pipetting. Next, the mix from previous step was transferred to an RNeasy spin column placed 
in a 2 ml collection tube, which was centrifuged at 10,000 rpm for 15s. The flow-through was 
discarded. 700 µl RW1 buffer was added directly to the RNease spin column and centrifuged 
at 10,000 rpm for 15s to wash the spin column membrane. 500 µl RPE buffer was then added 
to the RNease spin column and centrifuged at 10,000 rpm for 15s to wash the spin column 
membrane. Another 500 µl RPE buffer was added to the RNeasy spin column and centrifuged 
at 10,000 rpm for 2 min to wash the spin column membrane. All the flow-through above was 
abandoned. Lastly, the RNeasy spin column was placed in an autoclaved collection tube and 
30 µl RNase-free water was added to the RNeasy spin column to elute RNA.  
2.2.3.2 cDNA synthesis 
The reverse transcription of total RNA to cDNA was performed using High Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems, Life Technologies Ltd, Paisley, UK). In this 
assay, 1 µg total RNA was used for all the samples acquired. To synthesize single-stranded 
cDNA from total RNA, a master mix containing 2 µl 10x RT buffer, 1 µl dNTP Mix, 2 µl 10x 
RT random primers, 1 µl MultiScribe™  reverse transcriptase and 1 µl RNase inhibitor was 
prepared per sample. Next, 1 µg total RNA with water was added to the master mix up to 20 
µl per reaction. To perform reverse transcription, the reactions were loaded into the thermal 
cycler on the following conditions: step 1 25 °C for 10 min; step 2 37 °C for 120 min; step 3 
85 °C for 5 min; step 4 4 °C ∞. When the reactions were finished, the cDNA samples were 
collected and diluted 1 in 10 with water for the next experiment.  
2.2.3.3 Quantitative real-time PCR 
RT-qPCR assays were performed to study the expression of genes of interest. For each 
reaction 5 µl of cDNA from the previous reverse transcription was used together with 10 µl 
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TaqMan
®
 Universal PCR Master Mix (Applied Biosystems, Life Technologies Ltd, Paisley, 
UK), 1 µl of indicated TaqMan
®
 probe and 4 µl of water.  All the reactions were done in Fast 
Optical 96-well reaction plate (Applied Biosystems) in triplicate. Before putting on the 
machine, the plate was sealed with the Optical Adhesive Cover Starter Kit (Applied 
Biosystems) and centrifuged (2,000 x g) for 30 seconds at 4°C. RT-qPCR analysis was 
performed on a 7900HT Thermocycler (Applied Biosystems) on the program as follows: 
stage 1, 10 min at 95°C; stage 2, 20 s at 95°C and 20 s at 60°C for 40 cycles. Finally, the 
results were recorded and analysed accordingly.  
2.2.4 RNA interference 
For RNA interference experiment, all the certified siRNAs including control siRNA were 
purchased from Qiagen (Crawley, UK) and confirmed silencing efficiency in preliminary 
experiments. To do RNAi transfection, 5×10
5
cells were seeded onto 60 mm dishes for 
overnight to attach. On the transfection day, 20-40 nM of indicated siRNAs or siControl were 
pipetted into neat medium or Opti-MEM® without additives and left at room temperature for 
10 min. After the first incubation, certain amount of HiPerFect Transfection Reagent was 
added straight to the complex and pipetted gently to mix well and kept at room temperature 
for another 15 min to allow them to form a master mix. This complex was then added drop-
wise onto the cells, and the plates were swirled to ensure distribution of the transfection 
complexes evenly. Immediately, the cells were put back to incubators under normal growth 
condition for indicated time. Each transfection was performed at least three times for the 
experiments described in this work. 
For RNAi screen of tyrosine kinases signalling pathways, a certified library of siRNAs 
containing at least a pool of 2 siRNAs against each individual tyrosine kinases has been 
obtained from Qiagen. All siRNAs were initially confirmed knockdown efficiency by RT-
qPCR and western blotting before final screen. In the following experiments, MCF7 cells 
were primarily cultured in SILAC light/heavy medium for at least 7 cell divisions. After that, 
1×10
6
cells were seeded into 100 mm dishes to attach overnight and were then transfected with 
validated siRNAs targeting TKs for 72 hours. On the last day, cells were washed with ice-
cold PBS three times and collected in the pre-chilled tubes. Next, proteins were extracted and 
samples were proceeded to LC-MS/MS analyses for identification and quantification. 
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2.2.5 Plasmids transformation and DNA extraction 
Subcloning Efficiency™ DH5α™ Competent Cells (Invitrogen, UK) were used for plasmids 
transformation. Briefly, 50μl of cells were gently aliquoted into pre-chilled 1.5 ml Eppendorf 
tubes mixing with 100ng of plasmid DNA. Then put on ice for 30 minutes followed by a 45 
seconds heat shock at 42°C and subsequently cooled on ice for 2 minutes. After adding 600μl 
of S.O.C medium (Invitrogen, UK), the transformed cells were incubated at 37°C for 1 hour 
at 200 rpm and were subsequently spread on pre-warmed LB-agar kanamycin or ampicillin 
plates. Plates were incubated upside down overnight at 37°C. QIAGEN Plasmid Maxi Kits 
(QIAGEN, UK) was used to extract plasmid DNA according to the manufacturer‟s protocol. 
The acquired plasmid DNA was then diluted in water for future use.  
2.2.6 Luciferase reporter assay 
8×10
4
/well MCF7 cells were seeded into 24-well plate and transfection was performed using 
FuGENE
®
 HD transfection reagent according to manufacturer‟s instructions (Roche, UK). 
Cells were transfected with different p53 constructs [349], and pCMV6-KSR1 or pCMV6-
vector and together with renilla luciferase reporter vector (pRL-TK). Cell lysates were 
collected after 24 hours transfection and firefly and renilla luciferase activities were measured 
by the Dual-Glo™ Luciferase Assay kit as manufacturer‟s protocols described. Briefly, 50 ul 
of passive buffer was firstly added into each well and incubated at room temperature for 30 
min. After incubation, cell lysis was transferred into white 96-well plate. Immediately, 50 ul 
of Dual-Glo
®
 Luciferase Reagent was added into each well, mixed and left for 10 min at room 
temperature. Once incubation done, the plate was put on a reader to measure the firefly 
luminescence. Next, another 50 ul of Dual-Glo
®
 Stop & Glo
®
 Reagent was added each well, 
mixed and left for 10 min at room temperature. Renilla luminescence was subsequently 
measured in the same plate. The transcriptional activity of various p53 constructs were 
determined by firefly luciferase activity and normalized against renilla luciferase activity 
which was served as control for transfection efficiency. 
2.2.7 Cell proliferation assay 
Sulphorhodamine B (SRB) assay was performed to determine the growth of breast cancer cell 
lines in 96-well plates. After siRNA knockdown of KSR1 at indicated time points, plates were 
collected for the following protocol. Cells were fixed by adding 100 µl/well of ice-cold 40% 
trichloroacetic acid (TCA) to each culture for 1h and incubated in the fridge. Plates were then 
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washed x5 times in running tap water (allow the water to fill wells indirectly). Cells were 
stained with 100 µl of 0.4% (W/V) SRB (Sigma S-9012) in 1% acetic acid for 30mins and 
plates were washed 5 times in 1% acetic acid and left to air dry overnight. On the day of 
reading plates, bound dye was solubilized by adding 100 µl of 10mM tris base to all the wells. 
Then plates were measured at 492 nm on Tecan microplate reader. 
2.2.8 Neddylation assay 
MCF7 cells plated on 15 cm dishes were transfected using FuGENE
®
 HD with 8 µg 
pcDNA3-HA-NEDD8 (Addgene), 8 µg pCMV6-KSR1 or 8 µg pCMV6-Vector constructs as 
indicated. After 24 hours, cells were lysed in Radio-Immunoprecipitation Assay (RIPA) 
buffer (Sigma Aldrich) supplemented with protease inhibitors. Total protein was quantified by 
the BCA assay (Pierce). 2 µg Mouse IgG or p53 (DO-1) was pre-incubated with protein 
agarose beads for 2 hours to form IP matrix complex (ImmunoCruz
™
 IP/WB Optima C 
System, Santa Cruz). 2 mg protein lysate was added into the beads and was incubated on a 
rotator overnight at 4 °C. Beads were washed with RIPA buffer for three times and were 
heated in SDS loading buffer. Neddylated p53 were detected by western blot using p53-
specific DO-1 antibody or NEDD8 antibody (Cell Signalling) as described before [350, 351]. 
2.2.9 Ubiquitination assay 
Cells were transfected with pCMV6-KSR1 or pCMV6-Vector constructs together with Myc-
ubiquitin using FuGENE
®
 HD for 48 hours and treated with MG132 for the last 6 hours [352]. 
Cells were lysed and total protein was quantified as described above. Rabbit IgG or BRCA1 
antibody was pre-incubated with protein agarose beads for 2 hours to form IP matrix complex 
(ImmunoCruz™ IP/WB Optima B System, Santa Cruz). 2 mg protein lysate was added into 
the beads and was incubated on a rotator overnight at 4 °C. Beads were then washed with 
RIPA buffer for three times and were heated in SDS loading buffer. Endogenous 
ubiquitinated BRCA1 was detected using anti-Myc antibody by western blot. 
2.2.10 Soft agar assay 
Agarose in PBS were prepared, autoclaved before use. For each experiment, MCF7-KSR1 or 
MCF7-vector cells after different treatments or transfections were harvested by trypsin, spun 
down and resuspended in warm medium with G418. Cells were counted and seeded in 0.3% 
agar on top of 0.6% agar in six-well plate in triplicates. Every 3 days, full DMEM medium 
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with G418 (500 µg/ml) was replenished on the top layer. After incubation for 2 weeks, 
colonies were counted in at least 3 random fields per well and photographed. 
2.2.11 Three-dimensional overlay culture in Matrigel 
Matrigel (BD Biosciences) was thawed on ice overnight at 4 °C and 70 μl was added into 
each of the wells of the eight-well glass slide chambers (Thermo Scientific), and spread 
evenly in the well to form a 1 mm thick bed. Matrigel was left to solidify at 37 ºC for 15 min. 
Next, on the day of experiment, cells  (5 x 10
3
/well) after different treatments or transfections 
were plated in medium containing 2% Matrigel and allowed to grow in a 5% CO2 humidified 
incubator at 37 ºC for 7 days. The assay medium containing 2% Matrigel was replaced every 
3 days. Axiovert 100 MetaMorph microscope was used to image colonies in Matrigel. 
2.2.12 Single nucleotide polymorphisms and genotyping 
In those patients for whom adequate tissue was available, candidate KSR1 polymorphisms 
were chosen with the assistance of the Ensembl program using two main criteria: first, that the 
polymorphism has some degree of likelihood to alter the function of the gene in a biological 
relevant manner. Intronic or exonic polymorphisms can change gene transcription levels by 
alternative splicing or by affecting binding of a transcription factor. Second, that the 
frequency of the polymorphism is sufficient enough that its impact in clinical outcome would 
be meaningful on a population level (> 10% allele frequency). Genomic DNA was extracted 
from micro-dissected tissue specimens using the QIAamp kit (Qiagen). Two KSR1 
polymorphisms (rs2241906 and rs1075952) were tested using polymerase chain reaction 
restriction fragment length polymorphism (PCR-RFLP) technique. 
2.2.13 Protein immunoprecipitation 
5 x 10
6 
cells were plated on 15 cm dishes to allow attachment overnight. On the next day, 
cells were transfected using Lipofectamine
®
 2000 with certain amount of indicated plasmid 
constructs according to experiment design. After 24 hours, cells were washed three times with 
ice-cold PBS, which was aspirated after last wash. Cells were lysed in IP buffer (50 mM 
HEPES, pH 7.4; 1% Triton X-100; 150 mM NaCl; 2 mM EDTA, pH 8; 10 % Glycerol) 
supplemented with fresh protease and phosphatase inhibitors for 15 min. Directly, cells were 
then scraped and transferred to a pre-chilled tube for centrifuge at 13,000 rpm for 10 min at 4 
˚C. Supernatant was subsequently transferred to a pre-chilled tube. Total protein was 
quantified and a minimum of 2 mg protein was used for each IP. 2-4 µg of indicated 
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antibodies or IgG were normally pre-incubated with protein agarose beads for 4 hours to form 
IP matrix complex (ImmunoCruz™ IP/WB Optima System, Santa Cruz). After incubation, 
the beads containing IP matrix complex were washed three times with IP buffer. 2 mg protein 
lysate was added into the beads and was incubated on a rotator overnight at 4 °C. On the 
following day, beads were washed three times with IP buffer for three times and supernatant 
was removed. Beads were then added with SDS loading buffer and boiled for 10 min and 
centrifuged at 13,000 rmp for 5 min. In the end of step, samples were loaded and western 
blotting for the appropriate proteins was performed.   
2.2.14 Immunofluorescence staining 
5 x 10
5 
MCF7 cells were seeded on glass coverslips in 6 cm dishes to attach. After overnight, 
cells were transfected with either pCMV6-KSR1 or pCMV6-Vector using FuGENE
®
 HD. 
After 24 hours, medium was removed and cells on the coverslips were washed three time with 
ice-cold PBS. Next, cells were fixed in 4% w/v paraformaldehyde at 37 °C for 15 min and 
immediately permeabilized with 0.1% Triton-X for 10 min. Subsequently, cells were 
incubated in immune-fluorescent blocking buffer (10% AB-serum in PBS) for 1h, followed 
by incubation with p53 antibody (DO-1) for 1h at room temperature. Once the incubation was 
done, cells were washed with PBS and coverslips were incubated for 45 min at 37 °C with 
anti-mouse-IgG Alexa Fluor
®
 -555 antibody (Invitrogen). DNA was visualized by DAPI 
staining. Cells were examined on an Axiovert-200 laser scanning inverted microscope (Zeiss) 
as previously described [174].  
2.2.15 Genotyping and the determination of LOH 
We analysed DNA samples - including leucocytes, tumour, and paired circulating cell-free 
DNA (cfDNA) analysed in a - previous study of 65 breast cancer patients [353]. Briefly, DNA 
samples were hybridized on Affymetrix SNP 6.0 arrays following the Genome-Wide Human 
SNP Nsp/Sty 6.0 protocol. Raw data CEL files underwent background correction before 
normalized by quantile normalization. Genotype calls for SNPs were made using Birdseed v2 
(Broad Institute, http://www.broadinstitute.org/mpg/birdsuite/index.html), with loss of 
heterozygosity (LOH) being determined on a paired basis for cfDNA and primary tumour 
(matched to leucocyte DNA) using a max probability of 0.98 and genotype error of 0.02. 
Genomic decay was set to nought. This thresholding allowed for LOH to be called using 
either individual or multiple SNP markers within the genomic interval containing KSR1 (60 
SNP markers span just KSR1). 
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2.2.16 Tumour tissue microarray  
TMAs containing > 1000 primary operable breast cancer cases from the previously validated 
Nottingham Tenovus Primary Breast Carcinoma Series were employed [174, 346-348]. This 
well-characterized resource contains information on patients‟ clinical and pathological data 
including histological tumour type, primary tumour size, lymph node status, histological 
grade and data on other breast cancer relevant biomarkers. These include ERα, PgR, ERBB2, 
BRCA1, Chk1, cytokeratins (CKs; 5/6, 7/8, 18), Ki67 and E-cadherin. The immunoreactivity 
and scoring were defined in this series as previously described [354]. Patients within the good 
prognosis group (Nottingham Prognostic Index (NPI) ≤ 3.4) did not receive adjuvant therapy. 
Hormonal therapy was prescribed to patients with ERα positive tumours and NPI scores > 3.4 
(moderate and poor prognostic groups). Pre-menopausal patients within the moderate and 
poor prognosis groups were candidates for chemotherapy. Conversely, postmenopausal 
patients with moderate or poor NPI and ERα positive were offered hormonal therapy, while 
ERα negative patients received chemotherapy. Data collected included overall survival (OS), 
disease-free survival (DFS). Clinical data were maintained on a prospective basis with a 
median follow-up of 124 months (range 1 to 233).  
2.2.17 Immunohistochemistry 
Anti-KSR1 rabbit polyclonal antibody (Santa Cruz, Heidelberg, Germany) was optimized to a 
working concentration of 2μg on full-face excisional tissue sections. Subsequently, breast 
cancer TMA (n = 945) cases comprising 4 μm thick formalin fixed paraffin embedded tissue 
cores were immuno-stained with anti-KSR1 on the Leica BOND-MAX automated system 
using manufacturer‟s instructions. Hit-induced epitope retrieval was performed in citrate 
buffer (ER1) for 5 mins. Detection was achieved using the Polymer Detection kit (Leica 
Microsystems Inc., USA). Determination of the optimal cut-offs were performed using X-tile 
bioinformatics software (Yale University, USA). Cytoplasmic staining was scored based on 
intensity ranging from 0 to +2; 0 = null, +1 = intermediate and +2 = high level of staining 
intensity. Scoring for each tissue core on the TMAs was performed by two independent 
investigators. High resolution digital imaging (NanoZomer, Hamamatsu Photonics, Welwyn 
Garden City, UK) at 20x magnification with a web-based interface (Distiller, SlidePath Ltd., 
Dublin, Ireland) was used. All cases were scored without knowledge of the clinic-pathologic 
or outcome data. 
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2.2.18 in vivo tumourigenicity assay in breast cancer xenografts in nude 
mice 
Female 7-week-old, nu/nu-BALB/c athymic nude mice were acclimated in the animal house 
one week before experimentation. Before cells injection, a 0.72mg 17-β Estradiol 60-day 
release pellet was implanted subcutaneously (Innovative Research of America) into each 
mouse. MCF7-vector or MCF7-KSR1 cells were harvested by trypsin and spun down at 1000 
rpm for 5 min. Subsequently, 5×10
6
 cells were resuspended in the total volume of 100μL PBS 
supplemented with 1 mg/ml of G-418 solution. Nude mice were anaesthetized with 4% 
isofluorane and their body temperature was maintained stable by laying them on a thermal 
pad. Cells were then injected subcutaneously into the flank of the animals by groups (n=9, per 
group). Tumour growth was analysed by caliper measurements every three days and 
calculated using the formula 1/2 length (mm) x width (mm)
2
. After the mice were sacrificed, 
primary tumours were excised and formalin fixed. Samples were paraffin embedded, cut at 3 
μm and IHC stained for histological evaluation of target proteins expression. This study was 
conducted under the UK Home Office Project License. 
2.2.19 Proteome analysis (SILAC) 
2.2.19.1 SILAC cell culture  
SILAC dialysed calf serum and custom DMEM mediums containing either unlabelled 
12C6,14N4-arginine (Arg) and 12C6-lysine (Lys) (R0K0 -„light‟) or labelled 13C6-Arg and 
2D-Lys (R6K4 -„medium‟), or labelled 13C6,15N4-Arg and 13C6-Lys (R10K8 -„heavy‟) 
were purchased from Dundee cell products (Dundee, UK).  MCF7 cells were grown in these 
custom DMEM mediums along with 10% dialysed FCS and 1% of antibiotics (Penicillin and 
Streptomycin). All the cells that were grown for at least seven to eight passages to allow 
stable labelling were used for this experiment. 
2.2.19.2 Protein digestion and peptide fractionation 
Equal amounts of protein from unlabelled and labelled samples were combined prior to 
protein digestion. Briefly, samples were reduced in 10 mM DTT and alkylated in 50 mM 
Iodoacetamide prior to boiling in loading buffer, and then separated by one-dimensional SDS-
PAGE (4-12% Bis-Tris Novex mini-gel, Invitrogen) and visualized by colloidal Coomassie 
staining (Novex, Invitrogen). The entire protein gel lanes were excised and cut into 10 slices 
each. Every gel slice was subjected to in-gel digestion with trypsin overnight at 37 
0
C. The 
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resulting tryptic peptides were extracted by formic acid (1%) and acetonitile, lyophilized in a 
speedvac and resuspended in 1% formic acid. 
2.2.19.3 Protein digestion and phosphopeptide enrichment 
FASP Procedure was performed as previously described [355]. 500 ul FASP 1 (8 M urea, 20 
mM DDT in 100 mM Tris/HCL pH 8.5) was added to ~2 mg protein lysate to dilute SDS 
concentration and transferred to a Vivacon 500, 30k MWCO HY filter (Sartorius Stedim 
Biotech, VN01H22). The sample was buffer exchanged using FASP1 several times by 
spinning the tube at 7000g to remove detergents. The protein lysate was concentrated by 
centrifugation and diluted in FASP 2 (100 mM Tris/HCl pH 8.5) ready for trypsin digestion. 
The sample was reduced using 50mM fresh IAA in FASP 2 in the dark for 30 min. Lysates 
were spun down to remove excess IAA and buffer exchanged into FASP 3 (100mM TEAB 
(triethyl ammonium bicarbonate)). Trypsin was dissolved in FASP 3 to give a 1:200 enzyme 
to protein ratio and added in a volume of at least 100 μl for 4-6 hours. This was repeated with 
fresh trypsin for a further overnight incubation. Lysates were spun down and washed with 
0.5M NaCl and 150 μl 10% TFA added to reduce the pH. A standard desalting procedure was 
used [356]. 
Hydrophilic Interaction Chromatography (HILIC) fractionation: A TSKgel Amide-80 
separation column with a TSKgel Amide guard column was used for HILIC separation of 
FASP peptides. Buffer A: 80 % ACN, 0.1 % Formic Acid & Buffer B: 0.1 % Formic Acid 
was used for the gradient at a flow rate of 0.6 mj/min. The sample was separated into 45 
fractions, collected 2mins/vial and dried using a speed vac.  
TiO2 Enrichment was performed as previously described [356]. TiO2 beads were washed & 
re-suspended in Buffer B at 50 μg/μL and added to tubes to give 1 mg per tube. The sample 
was re-suspended in loading buffer, added to beads & incubated at RT for 20 min. After 
washes using buffers A & B samples were eluted using aliquots of 0.5% NH4OH. Elutions 
were pooled & 10 μl of 20 % FA added to adjust the pH. Samples were dried and re-
suspended in 1% FA. 
2.2.19.4 Mass spectrometry methods 
Trypsin-digested peptides were separated using an Ultimate 3000 RSLC (Thermo Scientific) 
nanoflow LC system. On average 0.5 µg was loaded with a constant flow of 5 µl/min onto an 
Acclaim PepMap100 nanoViper C18 trap column (100 µm inner-diameter, 2 cm; Themro 
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Scientific). After trap enrichment, peptides were eluted onto an Acclaim PepMap RSLC 
nanoViper, C18 column (75 µm, 15 cm; Thermo Scientific) with a linear gradient of 2-40% 
solvent B (80% acetonitrile with 0.08% formic acid) over 65 min with a constant flow of 300 
nl/min. The HPLC system was coupled to a linear ion trap Orbitrap hybrid mass spectrometer 
(LTQ-Orbitrap Velos, Thermo Scientific) via a nano electrospray ion source (Thermo 
Scientific). The spray voltage was set to 1.2 kV, and the temperature of the heated capillary 
was set to 250 °C. Full-scan MS survey spectra (m/z 335-1800) in profile mode were acquired 
in the Orbitrap with a resolution of 60,000 after accumulation of 1,000,000 ions. The fifteen 
most intense peptide ions from the preview scan in the Orbitrap were fragmented by collision-
induced dissociation (normalized collision energy, 35%; activation Q, 0.250; and activation 
time, 10 ms) in the LTQ after the accumulation of 10,000 ions. Maximal filling times were 
1,000 ms for the full scans and 150 ms for the MS/MS scans. Precursor ion charge state 
screening was enabled, and all unassigned charge states as well as singly charged species 
were rejected. The lock mass option was enabled for survey scans to improve mass accuracy. 
Data were acquired using the Xcalibur software. 
2.2.19.5 Proteome quantification 
The raw mass spectrometric data files obtained for each experiment were collated into a 
single quantitated data set using MaxQuant [357] and the Andromeda search engine software 
[358]. Enzyme specificity was set to that of trypsin, allowing for cleavage N-terminal to 
proline residues and between aspartic acid and proline residues. Other parameters used were: 
(i) variable modifications, methionine oxidation, protein N-acetylation, gln  pyro-glu; (ii) 
fixed modifications, cysteine carbamidomethylation; (iii) database: target-decoy human 
MaxQuant (ipi.HUMAN.v3.68); (iv) heavy labels: R6K4 and R10K8; (v) MS/MS tolerance: 
FTMS- 10ppm , ITMS- 0.6 Da; (vi) maximum peptide length, 6; (vii) maximum missed 
cleavages, 2; (viii) maximum of labelled amino acids, 3; and (ix) false discovery rate, 1%. 
Peptide ratios were calculated for each arginine- and/or lysine-containing peptide as the peak 
area of labelled arginine/lysine divided by the peak area of non-labelled arginine/lysine for 
each single-scan mass spectrum. Peptide ratios for all arginine- and lysine-containing peptides 
sequenced for each protein were averaged. Data are normalised using 1/median ratio value for 
each identified protein group per labelled sample. 
104 
 
2.2.19.6 Bioinformatic analysis 
All the bioinformatic analysis was completed with R. Specifically, the hierarchical clustering 
of SILAC proteomics data upon silencing TKs was performed based on calculated distances 
by R's hclust function [359]. The complete linkage method which aims to find similar clusters 
based on overall cluster measure was used. For the correlation heatmap, we calculated and 
plotted pairwise distances between tyrosine kinases according to their protein quantification 
signatures. The distance metric was conducted using the centred Pearson correlation [360]. To 
visualize the TKs-modulated proteomics, the heatmap of quantified values showing the 
overall pattern of regulation was presented. Individual protein was plotted in either red for 
down regulated proteins, or white for non-differential and non-identified, or blue for up-
regulated proteins (log2 fold change of 0.7 as the cut-off for down regulation and 1.3 as the 
threshold value for up-regulation). The hyper-geometric test was used to identify gene terms 
that are enriched in the de-regulated genes for each cluster. For each identified cluster, GO 
analysis was performed in the three domains: biological process (BP) cellular component (CC) 
and molecular function (MF) [361, 362].  
2.2.20 Statistical analysis 
Statistical analysis for TMAs was performed using SPSS 16.0 statistical software (SPSS Inc., 
Chicago, IL, USA). Analysis of categorical variables was performed with the appropriate 
statistical test. Survival curves were analysed using the Kaplan-Meier method with 
significance determined by the Log rank test; multivariate analysis was performed by Cox 
hazards regression analyses. DFS was defined as the period from the date of initial diagnosis 
to the date of the first documented relapse or death, and OS was defined as the time from the 
initial diagnosis to death. DFS time was censored at the date of last follow-up if patients were 
still relapse-free and alive, and OS was censored at the time when patients were alive. A 
forward stepwise Cox regression model was conducted to select baseline patient demographic 
and tumour characteristics to be included in the multivariate analyses of 2 KSR1 
polymorphisms and clinical outcome. Chi-square tests were used to examine the associations 
between tumour characteristics and KSR1 polymorphisms. Tests were 2-sided at a 0.05 
significance level. 
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3.1 KSR1 regulates p53 transcriptional activity through deleted in 
breast cancer 1 (DBC1) modulation 
3.1.1 Phospho-proteomic analysis of KSR1-regulated proteins using SILAC 
To elucidate the KSR1-related signalling pathways in breast cancer, a quantitative proteomic 
analysis (SILAC-based) was performed to obtain a profile of KSR1-regulated phospho-
proteins. 
3.1.1.1 Strategy of studying KSR1-regulated phospho-proteome in breast cancer 
In this work, we used MCF7 cells to study the KSR1-regulated phospho-proteome in breast 
cancer. MCF7 cells were first cultured and passaged in either R0K0 „light‟ medium, 
containing unlabelled 
12
C6,
14
N4-arginine (Arg) and 
12
C6-lysine (Lys) amino acids, or in 
R10K8 „heavy‟ medium, containing labelled 13C6 
15
N4-Arg and 
13
C6 
15
N2-Lys for at least 7 
cell divisions to allow labels to incorporate. Following, labelled cells were transfected with 
either the pCMV6 vector construct (R0K0, control) or with a pCMV6-KSR1 plasmid (R10K8) 
that encodes for the full length KSR1. After 24h, cells were washed with ice-cold PBS and 
proteins were extracted, mixed 1:1, separated on SDS-PAGE, trypsin-digested and 
fractionated. The samples were then analysed and identified through specific peptides or 
phospho-peptides by LC-MS/MS using MaxQuant software [357]. A SILAC-based workflow 
is presented in Figure 12.  
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Figure 12 Strategy of studying KSR1-regulated phospho-proteomics in breast cancer. 
MCF7 cells were cultured and passaged in either R0K0 „light‟ medium or in R10K8 „heavy‟ 
medium for at least 7 cell divisions. Labelled cells were then transfected with either the pCMV6 
vector construct (R0K0, control) or with a pCMV6-KSR1 plasmid (R10K8) encoding the full 
length KSR1. After 24h, proteins were extracted, mixed 1:1, separated on SDS-PAGE, trypsin-
digested, fractionated and analysed by LC-MS/MS using MaxQuant software. 
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3.1.1.2 Profile of KSR1-modulated phospho-proteomics in MCF7 
In the KSR1-regulated proteome analysis, a total of 2504 proteins were identified by SILAC 
and 2032 of them were quantified (false discovery rate <1%). Moreover, 1409 
phosphopeptides from 891 phospho-proteins were identified by SILAC and 1165 
phosphopeptides from to 812 phospho-proteins were quantified. After normalisation, the 
phosphorylation vs total protein level ratios between control and KSR1-overexpressed 
samples were determined accordingly. From our analysis, phosphorylation changes of 379 
potential sites corresponding to 240 proteins were observed, as in some cases more than one 
potential phosphorylation sites have been identified for one protein. Amongst these modulated 
sites, 341 phosphoserine (pSer), 37 phosphothreonine (pThr), and 1 phosphotyrosine (pTyr) 
sites were reported. 
Interestingly, only 3 out of the 379 identified phospho-sites were induced more than 50% 
while most of them (233 out of 379) were actually decreased (<50%) upon KSR1-
overexpression in MCF7 cells. A scatter plot representing the value from total and 
phosphorylated proteins was generated to demonstrate the log2 normalised „total proteins‟ 
versus the log2 „phosphorylated proteins‟ ratios (Figure 13).  
 
 
 
 
 
 
 
 
 
 
 
 
 
109 
 
 
 
Figure 13 Scatter plot of KSR1-regulated phospho-proteome in MCF7. 
Log2 ratios (fold changes) of phosphorylated and total protein levels between KSR1 
overexpression and control samples are quantified and presented here. As shown in blue, phospho-
DBC1 is significantly decreased upon KSR1 overexpression.  
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3.1.2 Gene ontology analysis of KSR1 regulated phospho-proteins in breast 
cancer 
Gene Ontology (GO) analysis was implemented using the „Panther‟ tool [363] to classify the 
KSR1-regulated phospho-proteome based on i) biological process, ii) molecular function, and 
iii) cellular component (Figure 14). Significant enrichments were identified for GO molecular 
functions terms related to binding (GO: 0005488), catalytic activity (GO: 0003824), structural 
molecule activity (GO: 0005198), as well as transcription regulator (GO: 0003824) and 
enzyme regulator (GO: 0030234) activities. While identifying biological processes modulated 
in this phospho-proteomics analysis, cell cycle (GO: 0007049) and communication (GO: 
0007154) along with metabolic (GO: 0008152), cellular (GO: 009987) and transport (GO: 
0006810) processes were significantly represented. Finally, in relation to the localisation of 
the identified KSR1-regulated phospho-proteins, a similar distribution between 
membrane/cytoplasmic and nuclear cell components were observed. To the best of our 
knowledge, this is the first ontology analysis of KSR1 regulated phospho-protein profile in 
breast cancer, which will provide new insights for others to study its functions in signalling 
pathways other than the canonical Ras-Raf-MAPKs cascades.  
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Figure 14 Gene Ontology (GO) classification of the KSR1-regulated phospho-proteome in 
MCF7 cells. 
GO analysis was performed by the „Panther‟ tool based on biological function (A), molecular 
process (B) and cellular component (C).  
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3.1.3 Phospho-proteomics analysis shows a decrease of phospho-DBC1 after 
KSR1 overexpression 
The identified KSR1-regulated phospho-proteome provided us a number of interesting targets 
that might play a role in breast cancer. To further utilize the data we acquired from the SILAC 
analysis, we demonstrated that some of these phospho-proteins have been previously reported 
to be important in the development of breast cancer. For instance, androgen-induced 
proliferation inhibitor (APRIN), a protein phosphorylated by ATM and ATR kinases, has 
been documented as a BRCA2-interacting protein essential for genome integrity and a 
predictor of clinical outcome in response to chemotherapy in breast cancer [364, 365]. Rho 
GTPase activating protein 35 (ARHGAP35) has been shown to be important in RhoA 
inactivation, Ras activation and promotion of breast cancer growth and migration upon its 
phosphorylation by breast tumour kinase (Brk) [366]. Phospho-Hsp27 was correlated with 
HER-2/neu status and lymph node positivity in breast cancer, and was also connected to 
cancer invasiveness and drug resistance [367, 368]. Histone deacetylase 1 (HDAC1) /Sin3A 
complex phosphorylation has been correlated to ERα expression and hormonal therapy 
resistance in breast cancer cells [369]. These links suggest an important role of KSR1 and its 
regulated phospho-proteome in breast cancer.  
Interestingly, phospho-DBC1 was one of the most significantly KSR1-regulated 
phosphorylated proteins (Figure 13). DBC1 has been shown previously to play an important 
role in p53 activation via SIRT1 and its phosphorylation is essential in this process [370, 371]. 
Considering the importance of p53 in breast cancer, we then studied the potential association 
between KSR1 and p53 activity through DBC1. 
3.1.4 KSR1 regulates p53 transcriptional activity 
Firstly, we sought to investigate the effects of KSR1 on p53 transcriptional activity. To do so, 
we performed luciferase reporter assays using various p53-dependent gene promoter 
constructs (including p53-R2, p53-AIP1, p53-IGFBP3 and p53-CYCLIN G1). MCF7 cells 
were transfected with either pCMV6 or pCMV6-KSR1 plasmids together with different p53-
dependent promoter constructs. After 24 hours, cells were treated with either DMSO or 
etoposide, which can induce p53 activity. Interestingly, luciferase assays showed that the 
activity of all four different p53-regulated genes was significantly repressed upon KSR1 
overexpression, indicating an inhibitory role of KSR1 on p53 activation (basal levels and after 
etoposide treatment; Figure 15A). On the other hand, KSR1 silencing led to a clear increase 
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in the activity of p53-dependent promoter genes (Figure 15B). These results support a 
potential involvement of KSR1 in regulating p53 transcriptional activity.  
 
 
 
  
Figure 15 Effect of KSR1 on p53 transcriptional activity in the presence or absence of 
etoposide by luciferase assays. 
A. MCF7 cells were transiently co-transfected with either pCMV6 (vector) or pCMV6-KSR1 
plasmids in the presence of four individual p53-dependent promoter constructs expressing firefly 
luciferase genes (p53-R2, p53-AIP1, p53-CYCLIN G1, and p53-IGFBP3) following DMSO or 
etoposide (40μM) treatment for 3h. B. MCF7 cells were transfected with control siRNA (siCT) or 
siKSR1 for 48 hours, followed by transfection of three p53-dependent promoter constructs 
expressing firefly luciferase genes (p53-R2, p53-AIP1, and p53-CYCLIN G1) for additional 24 
hours. DMSO or etoposide (40μM) were subsequently added. Firefly/ Renilla luciferase activity 
was measured and renilla luciferase activity was used to normalize transfection efficiency. The 
normalized luciferase activity of empty vector is set as 1. Results shown are the average of at least 
three independent experiments and error bars represent SD. (*P < 0.05, ** P <0.01). 
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3.1.5 KSR1 does not affect p53 mRNA, protein, subcellular localisation and 
neddylation levels 
To further examine the potential mechanism resulting in the effects of KSR1 overexpression 
on p53 transcriptional activity, we first checked whether KSR1 affects the gene (mRNA) and 
protein expressions of p53. RT-qPCR and western blotting analyses reported no significant 
changes in the p53 mRNA and protein levels respectively after KSR1 transient 
overexpression in MCF7 cells (Figures 16A and 16B). Similarly, no change in p53 protein 
levels was observed in MCF7 stably overexpressing KSR1 cells comparing with MCF7 
parental cells (Figure 16B).  
As it is known that nuclear localisation of p53 is essential for its transcriptional activity, 
immunofluorescence staining of p53 was therefore performed to observe its potential 
translocation alteration upon KSR1 overexpression. As shown in Figure 17, 
immunofluorescence revealed that there was no cytoplasmic/nuclear translocation of p53 
upon KSR1 transient overexpression. To further confirm our results, a subcellular protein 
fractionation assay was performed showing that p53 did not translocate from the cytoplasm to 
the nucleus after overexpression of KSR1 (Figure 18A).  
Moreover, it has been well studied that neddylation of p53 can inhibit its transcriptional 
activity [350, 351]. We performed a neddylation assay on p53. To do so, MCF7 cells were co-
transfected with HA-NEDD8 and pCMV6 vector or pCMV6-KSR1 plasmids as indicated. 
After 24 hours, cells were harvested and protein was extracted. p53 was then 
immunoprecipitated using a p53 specific antibody and the neddylated-p53 was detected by 
immunoblotting using anti-NEDD8 and anti-p53 antibodies. However, results from the 
neddylation assay showed no significant changes following KSR1 overexpression ruling out 
neddylation as the cause and suggesting other alternative mechanisms might be responsible 
for the observed decrease in p53 activity (Figure 18B). 
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Figure 17 Immunofluorescence staining of p53 after KSR1 overexpression. 
MCF7 cells were transfected with either pCMV6 vector or pCMV6-KSR1 plasmids for 24 hours. 
p53 was then detected with an anti-p53 antibody and the nucleus was stained with DAPI. 
Representative pictures of three independent experiments are shown. 
Figure 16 Effect of KSR1 overexpression on p53 mRNA and total protein levels. 
MCF7 cells were transiently transfected with pCMV6 or pCMV6-KSR1 plasmids for 24 hours. 
Subsequently, relative mRNA levels of TP53 and p53 total protein were measured by qRT-PCR 
(A) and western blotting (B), respectively. Gene expression level from cells transfected with 
pCMV6 vector was set as 1. Results shown are the average of at least three independent 
experiments. Similarly, in MCF7 stably overexpressing KSR1 cells, p53 total protein was 
evaluated by western blotting (B). Blots shown are representatives of at least three independent 
experiments.  
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Figure 18 Effect of KSR1 overexpression on p53 subcellular localisation and neddylation. 
A. Subcellular fractionation assays were performed after 24 hours transfection with either pCMV6 
vector or pCMV6-KSR1 plasmids in MCF7. Tubulin and HDAC1 expression served as positive 
control for cytoplasmic and nuclear proteins respectively. Blots shown are representatives of at 
least three independent experiments. B. Neddylation assay on p53 after KSR1 overexpression. 
MCF7 cells were co-transfected with HA-NEDD8 and pCMV6 vector or pCMV6-KSR1 plasmids 
as indicated. p53 was immunoprecipitated using a p53 specific antibody (DO-1) and the 
neddylated-p53 was detected by immunoblotting using anti-NEDD8 and anti-p53 specific 
antibodies. Blots shown are representatives of at least three independent experiments. 
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3.1.6 KSR1 decreases p53 acetylation by reducing phosphorylation of DBC1 
Post-translational modifications of p53 such as phosphorylation and acetylation are important 
for p53 activity in response to genotoxic stress [372, 373]. We therefore decided to investigate 
whether KSR1 has any effects on p53 post-translational modifications. We examined the 
effects of KSR1 on phospho-p53 and acetylated-p53. MCF7 cells were transfected with 
pCMV6-vector or pCMV6-KSR1 plasmids for 24 hours and then treated with either DMSO 
or etoposide, to induce genotoxic stress. As shown in Figure 19A, the phosphorylation levels 
of p53 (Ser15) did not change upon KSR1 overexpression in the presence or absence of 
etoposide. However, the level of acetylated-p53 was reduced after KSR1 overexpression upon 
etoposide treatment (Figure 19A).  
It is already well established that SIRT1 is a NAD-dependent p53 deacetylase that regulates 
p53 activation [373-375]. Additionally, DBC1 can interact with and negatively regulate 
SIRT1 lead to an increase in p53 acetylation [370, 371]. Taking this potential link into 
consideration, we sought to study the effects of KSR1 on these two proteins.  
Our western blotting results showed that KSR1 up-regulation did not affect the total protein 
levels of either SIRT1 or DBC1 Figure 19A. Based on the SILAC data showing the effects of 
KSR1 on the phosphorylation of DBC1 and the known relation between DBC1 and SIRT1, 
we checked the effect of KSR1 on DBC1 phosphorylation in vitro. Western blotting 
demonstrated that KSR1 overexpression resulted in a decrease of phospho-DBC1 (Thr454) in 
both basal and etoposide-induced conditions (Figure 19A). On the other hand, KSR1 
silencing caused an increase in acetylation of p53 upon etoposide treatment (Figure 19B). 
Moreover, knockdown of KSR1 did not change the total proteins of SIRT1 and DBC1, but 
increased DBC1 phosphorylation at Thr454 (Figure 19B). These in vitro data further confirm 
our SILAC results and also suggest a new role of KSR1 in regulating p53 acetylation through 
phospho-DBC1 and SIRT1, providing an explanation for its effect on p53 transcriptional 
activation.  
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Figure 19 Effect of KSR1 on DBC1 phosphorylation. 
A. Effects on p53 acetylation and phosphorylation of DBC1 after KSR1 overexpression followed 
by etoposide treatment. MCF7 cells were transiently transfected with pCMV6 vector or pCMV6-
KSR1 plasmids for 24 hours. Subsequently, cells were treated with various concentration of 
etoposide (20, 40, 80 µM, 3h). Total SIRT1, total DBC1, p53 phosphorylation, p53 acetylation and 
DBC1 phosphorylation were assessed by western blotting with specific antibodies as indicated. B. 
Effects on p53 acetylation and phosphorylation of DBC1 after KSR1 silencing followed by a 
titration of etoposide treatment. MCF7 cells were transfected with control siRNA (siCT) or siKSR1 
for 72 hours followed by etoposide treatment (20, 40, 80 µM, 3h). Total SIRT1, total DBC1, p53 
acetylation and DBC1 phosphorylation were assessed by western blotting with specific antibodies 
as indicated. 
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3.1.7 The effects of KSR1 on p53 acetylation is dependent on DBC1 and 
requires its intact kinase domain  
To further validate that the effect of KSR1 on p53 acetylation is dependent on DBC1, we 
examined the effects of KSR1 on acetylated p53 after DBC1 silencing upon etoposide 
treatment in MCF7 cells. As shown in Figure 20A, western blotting results demonstrated that 
acetylated p53 was consistently elevated after KSR1 was depleted, whereas the effects of 
KSR1 silencing on p53 acetylation disappeared after silencing DBC1 upon etoposide 
treatment. This suggests that KSR1 regulation of p53 acetylation requires DBC1, as depletion 
of DBC1 weakens the effect of KSR1 on acetylated p53. 
Next, we examined whether the effect of KSR1 on DBC1 requires its catalytic domain. To do 
so, we generated a KSR1 mutant (KSR1/R502M) that comprises a key amino acid mutation 
(arginine to methionine) within its kinase domain resulting in impaired catalytic activity [179]. 
As shown in Figure 20B, wild type KSR1 consistently caused a decrease of phosphorylated 
DBC1, whereas mutant KSR1/R502M demonstrated no effect on pDBC1 levels compared to 
the control. This data indicates that an intact catalytic domain of KSR1 is indispensable for 
regulating DBC1 phosphorylation. 
Finally, it has been reported that genotoxic stress induces DBC1 phosphorylation, which 
creates binding sites for SIRT1 and strengthens the interaction between SIRT1 and DBC1 
[376, 377], which consequently weakens the deacetylase activity of SIRT1 on p53. Based on 
this, we then hypothesized that KSR1 could affect the SIRT1-DBC1 interaction induced by 
genotoxic stress. As shown in Figure 20C, co-immunoprecipitation revealed that the 
interaction between SIRT1 and DBC1 was decreased after KSR1 overexpression upon 
etoposide treatment in MCF7. This supports our hypothesis and also suggests that the reduced 
interaction between SIRT1 and DBC1 by KSR1 overexpression potentially enables SIRT1 to 
bind with p53 and promote deacetylase activity of SIRT1 on p53 acetylation. 
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Figure 20 Mechanism of KSR1-regulated p53 acetylation. 
A. Effect of KSR1 on p53 acetylation is mediated through DBC1. MCF7 cells were treated with 
control siRNA (siCT) or siKSR1 in concordant with siCT or siDBC1 for 72 hours followed by 
etoposide treatment (40 µM, 3h). Acetylated p53, DBC1 and KSR1 protein levels were assessed by 
western blotting with specific antibodies as indicated. B. Effect of KSR1 on DBC1 
phosphorylation is dependent on its intact kinase domain. MCF7 cells were transiently transfected 
with vector, wild type KSR1 or mutant KSR1 (R502M) plasmids for 24 hours followed by 
etoposide treatment (40 µM, 3h). DBC1 phosphorylation was measured by western blotting with 
specific antibody. C. Interaction of DBC1 and SIRT1 after KSR1 overexpression with etoposide 
treatment by immunoprecipitation. MCF7 cells were transiently transfected with pCMV6 vector or 
pCMV6-KSR1 plasmids for 24 hours. Subsequently, cells were treated with etoposide (40µM, 3h). 
The interactions between SIRT1 and DBC1 were detected by immunoprecipitation (IP) of SIRT1 
or DBC1 followed by immunoblotting with DBC1 and SIRT1 antibodies respectively. Blots shown 
are representatives of at least three independent experiments.  
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3.1.8 KSR1 is important for breast cancer proliferation 
We next studied whether KSR1 has any effects on breast cancer growth in vitro. Cell 
proliferation assay (SRB assay) was implemented to examine its effect on four different breast 
cancer cell lines. As shown in Figure 21, KSR1 silencing markedly inhibited cell growth in 
all four breast cancer cell lines including MCF7, ZR75-1, SKBR3 and MDA231 after six days 
in comparison to control siRNA. This result demonstrates that KSR1 is important for breast 
cancer proliferation in vitro. 
 
 
  Figure 21 Effect of KSR1 silencing on breast cancer cell proliferation in vitro. 
SRB assay was performed to examine its effects on cell proliferation. Briefly, MCF7, ZR75-1, 
SKBR3 and MDA231 cells were transfected with 20 nM of either siKSR1 or „non-targeting‟ 
siRNA (Control siRNA) or vehicle (Hiperfect) for a time course to 6 days. At the end of 
experiment, absorbance at 492nm was measured and analysed. Error bars represent SD of 3 
experiements each in quintuplicates (*P< 0.05, compared with control siRNA at day 6 (Student‟s t 
test)). 
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3.1.9 Disscussion 
KSR1 was initially recognized as a novel protein kinase evolutionarily conserved in 
Drosophila and Caenorhabditis elegans acting between Ras and Raf in the Ras-Raf-MAPKs 
signalling pathway [107-109]. Owing to a mutation in the lysine residue in the catalytic 
domain important for the kinase activity, mammalian KSR1, however, has been widely 
denoted as a pseudokinase [43]. The scaffolding function of KSR1 was then revealed shortly 
after. Murine KSR1 (mKSR1) was shown to be able to interact with activated Ras to enhance 
the activity of MAPK kinases resulting in a stimulation of Xenopus oocyte maturation and 
cellular transformation [111]. Meanwhile, KSR1‟s role as an active kinase was also described. 
One group observed that upon TNFα and ceramide activation, KSR1 autophosphorylation was 
increased and KSR1 was capable of phosphorylating and activating Raf-1 [114]. Therefore, 
increasing evidence suggests that KSR1 can function as an active kinase as well as a scaffold 
protein [137, 146]. Additionally, KSR1 has been previously indicated as an oncogene in Ras-
dependent cancers, such as pancreatic and lung carcinomas [127, 166]. Its biological functions 
and associated signalling pathways implicated in breast cancer have remained largely 
undefined. 
In this work, a global comparative proteomic analysis using SILAC was performed to reveal 
the modulated phospho-proteome by KSR1 in MCF7 breast cancer cells. A number of new 
KSR1-regulated proteins as well as KSR1-involved signalling networks were identified, apart 
from the classical Ras-Raf-MAPKs pathway. Interestingly, our phospho-proteomic analysis 
showed that the majority (233 out of 379) of the identified phospho-sites were actually 
decreased upon KSR1 overexpression comparing to a small number of increased 
phosphorylation (3 out of the 379). This potentially suggests that KSR1 might function 
primarily as a scaffold protein not a kinase at least in this context. Alternatively, some 
negative feedback loops might exist in this system. However, none of the previous identified 
proteins or phospho-proteins including MEK and ERK in the canonical Ras-Raf-MAPKs 
pathways have been reported in our study. The possible explanation could be that the Ras-
mutations are very rare in breast cancer [378]. Moreover, phospho-profiling of the major 
members of the Ras-Raf-MAPKs cascades after KSR1 overexpression/silencing had no 
significant effects on the phosphorylation levels of the main components in the Ras-Raf-
MAPKs signalling pathway (results shown in section 3.2.3).  
Furthermore, the KSR1-modulated phospho-proteins identified in this study provided us with 
a comprehensive picture of KSR1-invloved signalling networks. Bioinformatic analysis 
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demonstrated the involvement of KSR1 in multiple biological processes and its capability of 
modulating many molecular functions, including cell cycle, metabolism and apoptosis. 
Importantly, some of the identified phospho-proteins have been indicated to play an essential 
role in the tumourigenesis and development of breast cancer. For instance, APRIN, a protein 
phosphorylated by ATM and ATR, was shown as a BRCA2-interacting protein important for 
genome integrity and correlated with chemotherapy in breast cancer [364, 365]. Moreover, 
ARHGAP35 phosphorylation was reported to play a part in breast cancer proliferation and 
migration [366]. Phospho-Hsp27 was related to invasiveness and drug resistance in breast 
cancer [367, 368]. Most interestingly, the KSR1-regulated phospho-proteomic analysis has 
established phospho-DBC1, which is a potential link to the modulation of p53 transcriptional 
activity by KSR1 in this work.  
DBC1 was previously identified as a major player involved in regulating p53 acetylation [370, 
371], which is crucial for activation of p53 transcriptional activity [373]. Thus, our work 
further studied the effect of KSR1 on p53 transcriptional activity, as well as the potential 
mechanism on KSR1-related regulation of p53 transcriptional activity, including through p53 
acetylation. Luciferase assays using several different p53-dependent gene promoter constructs 
displayed that p53 transcriptional activity was inhibited after KSR1 overexpression in the 
absence or presence of etoposide, whereas the opposite results were detected upon 
knockdown of KSR1, indicating a regulatory role of KSR1 in p53 activity. Mechanistic 
studies revealed that overexpression of KSR1 did not affect p53 mRNA and total protein 
levels, or p53 subcellular locolization, phosphorylation and neddylation, which are all 
potentially important in the regulation of p53 activity.  
Interestingly, p53 acetylation was reduced after KSR1 overexpression, whereas knockdown of 
KSR1 caused an increase in p53 acetylation in the absence or presence of etoposide, 
indicating an involvement of KSR1 in regulating p53 acetylation. It has already been known 
that DBC1 can directly interact with and negatively regulate SIRT1, a NAD-dependent p53 
deacetylase, leading to elevated p53 acetylation [370, 371]. In addition, upon genotoxic stress, 
phospho-DBC1 is able to produce binding sites and increase the interaction between SIRT1 
and DBC1 complex, which successively abolishes the deacetylase activity of SIRT1 on p53 
[376, 377]. Consistently, we revealed that KSR1 overexpression reduces the phosphorylation 
levels of DBC1 in the non-stressed context as well as in the presence of etoposide. On the 
other hand, KSR1 silencing increases levels of phosphorylated DBC1. These results provide 
us with an explanation of the observed effects of KSR1 on p53 acetylation and activity 
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suggesting that the action of KSR1 on p53 activation is through DBC1. Finally, co-
immunoprecipitation results demonstrated that overexpression of KSR1 mitigates the SIRT1-
DBC1 interaction, which therefore enables SIRT1 to bind more with p53 triggering a 
reduction of p53 acetylation. Our data presented is in agreement with previous reports and 
together with our SILAC analyses allows KSR1 to incorporate into an established signalling 
network with DBC1 and SIRT1 in modulating p53 activity. 
However, more work remains needed to illuminate the mechanism of KSR1 on regulating 
DBC1 phosphorylation. The recent work from Zannini et al. demonstrated that ATM/ATR is 
competent to directly phosphorylate DBC1 on Thr454 upon DNA damage. Subsequently, 
phosphorylated DBC1 interacted with SIRT1 and suppressed its activity, leading to the 
dissociation of the SIRT1-p53 complex and eventually an increase in p53 acetylation [377]. 
Additionally, another group showed that protein kinase A and AMP-activated protein kinase 
can initiate the separation of SIRT1 from its endogenous inhibitor DBC1, hence regulating 
downstream effects [379]. Therefore, alternative mechanisms including whether the action of 
KSR1 on DBC1 phosphorylation is through ATM/ATR kinases await further exploration.  
Taken together, the first SILAC analyses of phospho-proteome modulated by KSR1 highlight 
its contribution in numerous biological and molecular processes as well as cellular signalling 
pathways in breast cancer. The characterization of novel KSR1-regulated proteins will 
provide new insights into KSR1-modulated networks involved in breast cancer. In the present 
study, a model is proposed to define the function of KSR1 in the known DBC1-SIRT1-p53 
network (Figure 22). When KSR1 is at basal levels in cancer cells, phosphorylated DBC1 
directly binds and acts together with SIRT1 and inhibits the deacetylase activity of SIRT1, 
which results in an increase of p53 activation initiating gene transcription. On the other hand, 
in KSR1-transduced cells, DBC1 phosphorylation is reduced, which destabilises the direct 
interaction between DBC1 and SIRT1. This in turn enables SIRT1 to diminish p53‟s 
acetylated state, which consequently impedes transcriptional activity of p53. Our study sheds 
new light on the function of KSR1 in p53 regulation and reveals an interesting mechanism for 
its contribution in breast cancer development. 
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Figure 22 Schematic model illustrating the role of KSR1 on p53 transcriptional activity in 
breast cancer cells. 
i) In cancer cells with basal level of KSR1 phosphorylated DBC1 directly interacts with SIRT1 and 
reduces its deacetylase activity resulting in p53 activation and gene expression initiation. ii) In 
KSR1-transduced cells, KSR1 suppresses DBC1 phosphorylation, which undermines the direct 
interaction between DBC1 and SIRT1. This in turns allows SIRT to decrease p53 acetylation state, 
thus inhibiting p53 transcriptional activity. 
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3.2 KSR1 regulates BRCA1 degradation and inhibits tumour 
growth 
3.2.1 KSR1 is an independent predictor of overall survival in breast cancer  
3.2.1.1 KSR1 expression in breast cancer patients 
To determine the clinical significance of KSR1 in breast cancer patients, we employed TMAs 
containing > 1000 primary operable breast cancer cases from the previously validated 
Nottingham Tenovus Primary Breast Carcinoma Series [174, 346-348]. This well-
characterized cohort encloses detailed information on patients‟ clinical and pathological data 
and immunoreactivity and scoring were characterised in this series as previously described 
[354]. Cytoplasmic KSR1 abundance in breast cancer tissues was determined by 
immunohistochemistry (Figure 23).  
 
 
 
  
Figure 23 KSR1 expression in breast cancer tissues by IHC. 
Immunohistochemistry staining (IHC) of paraffin embedded breast cancer tissues for KSR1 
expression. Representative images of staining intensities: i) negative, ii) 1+ and iii) 2+. Images 
were adopted from the high resolution digital imaging (NanoZomer,Hamamatsu Photonics, 
Welwyn Garden City, UK) with a web-based interface (Distiller, Slide-Path Ltd., Dublin, Ireland) 
Magnification, x 100. 
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3.2.1.2 Clinical significance of KSR1 expression in the European cohort 
KSR1 staining was scored based on intensity ranging from 0 to +2; 0 = null, +1 = 
intermediate and +2 = high level of staining intensity, which was performed by two 
independent investigators. Kaplan-Meier survival curves showed that high KSR1 levels were 
significantly associated with longer overall survival (P = 0.012; Figure 24A) and an increased 
disease free survival (P = 0.014; Figure 24B) in > 20 years follow-up. KSR1 expression was 
not significantly associated with an improved response to endocrine therapy (n= 272, P = 
0.064; Figure 24C) and adjuvant chemotherapy (n= 155, P = 0.096; Figure 24D), although 
results indicated a trend of high KSR1 expression towards improved response to endocrine 
adjuvant chemotherapy.  
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Figure 24 Clinical significance of KSR1 in breast cancer. 
A. Kaplan-Meier survival curves for KSR1 expression levels with overall survival (High = 278, 
Low = 527; P = 0.012) and B. disease free survival (High = 325, Low = 620; P = 0.012) in a 240 
months follow-up. C. Kaplan-Meier overall survival curves for KSR1 expression levels with 
response to endocrine therapy (High = 101, Low = 171; P = 0.064) and, D. to chemotherapy (High 
= 58, Low = 97; P = 0.096) in a 240 months follow-up. 
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Multivariate Cox-proportional hazards analysis revealed KSR1 as an independent prognostic 
factor (Table 10). Furthermore, KSR1 expression was also examined in the available paired 
adjacent normal breast (NB) and invasive breast carcinoma (BC) tissues from the same 
patients by western blotting. Consistently, KSR1 abundance is decreased in invasive BC 
compared to NB (Figure 25). We also identified two intronic KSR1 polymorphisms 
(rs2241906 and rs1075952) but they were not correlated with either disease free or overall 
survival (Figure 26).  
 
 
    
    
  
  OS DFS 
    
 
    
  
  
Variable 
Hazard 
ratio 
95% 
CI 
P 
value 
Hazard 
ratio 
95% CI P value 
Stage
a
 1.846 
1.562-
2.180 
<0.00
1 
  1.893   
1.585-
2.260 
  <0.001 
Grade
b
 1.755 
1.435-
2.146 
<0.00
1 
  2.222   
1.747-
2.825 
  <0.001 
Size>1.5 
cm
c
 
1.825 
1.246-
2.674 
0.002   2.026   
1.310-
3.134 
0.002 
KSR1 
status 
1.543 
1.189-
2.001 
0.001   1.541   
1.166-
2.037 
0.002 
a Fitted as linear term, i.e., Increase in risk for change in lymph node stage of 
one unit  
b Fitted as linear term, i.e., Increase in risk for change in grade of one unit  
  c Compared with tumour size ≤1.5cm 
       Table 10. Cox-proportional hazards analysis for predictors (model including KSR1 
expression) of OS and DFS. 
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Figure 25 KSR1 expression in the paired adjacent normal breast and invasive breast cancer 
tissues. 
Pairs of tissues from six patients were collected and western blotting was performed to examine the 
KSR1 expression using specific anti-KSR antibody. Representative images from three independent 
experiments are shown here. 
Figure 26 Correlations of KSR1 polymorphisms with overall survival and disease free 
survival in breast cancer patients. 
Kaplan-Meier curves demonstrate the association between two KSR1 polymorphisms: A. 
rs2241906 and overall survival (P = 0.3841) and B. disease-free survival (P = 0.2481). C. 
rs1075952 and overall survival (P = 0.4710) and D. disease-free survival (P = 0.3529). 
131 
 
3.2.1.4 Correlations between KSR1 expression and tumour biomarkers in European 
breast cancer patients 
To investigate patients‟ characteristics, tumour biomarkers and their correlations with KSR1 
expression in European breast cancer patients, we utilised a well-characterized resource in this 
cohort [174]. It contains information on patients‟ clinical and pathological data including 
histological tumour type, primary tumour size, lymph node status, histological grade and data 
on other breast cancer relevant biomarkers. These include ERα, PgR, ERBB2, BRCA1, Chk1, 
cytokeratins (CKs; 5/6, 7/8, 18), Ki67 and E-cadherin. 
Our results showed that there were no significant associations of KSR1 with standard breast 
cancer histopathologic biomarkers including tumour stage, grade and size (Table 11); KSR1 
levels were also not associated with the expression of hormone receptors ERα and PgR, or 
ERBB2). However, high KSR1 was associated with high BRCA1 (P = 0.002), BARD1 (P < 
0.001) and Chk1 (P < 0.001) expression (Table 11). 
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  KSR1 expression P value 
Variable/biomarker Weak (%) Strong (%)   
Tumour Stage    
1 370(59.7) 191(58.2) 0.787 
2 194(31.3) 103(31.4)  
3 56(9.0) 34(10.4)  
Grade    
1 95(15.3) 42(12.8) 0.544 
2 199(32.0) 104(31.7)  
3 328(52.7) 182(55.5)  
Tumour Size    
<1.5cm 141(22.7) 71(21.6) 0.719 
=>1.5cm 481(77.3) 257(78.4)  
Age    
<50 197(31.6) 120(36.6) 0.119 
=>50 427(68.4) 208(63.4)  
Vascular Invasion    
Definitive 217(34.9) 115(35.6) 0.973 
Negative 326(52.4) 168(52.0)  
Probable 79(12.7) 40(12.4)  
Tumour type    
Invasive Ductal 376(61.3) 215(67.0) 0.18 
Other 237(38.7) 106(33.1)  
ER Status    
Negative 167(27.5) 103(32.2) 0.149 
Positive 440(72.5) 217(67.7)  
PgR Status    
Negative 258(43.1) 144(45.9) 0.42 
Positive 341(56.9) 170(54.1)  
ERBB2 Status    
Negative 521(85.4) 273(84.3) 0.639 
Positive 89(14.6) 51(15.7)  
Triple Negative Status    
Non-Triple 493(81.9) 249(77.8) 0.137 
Triple Negative  109(18.1) 71(22.2)  
Cytokeratin 5/6    
Negative 504(83.3) 260(81.8) 0.555 
Positive 101(16.7) 58(18.2)  
Cytokeratin 14    
Negative 522(86.4) 273(86.7) 0.919 
Positive 82(13.6) 42(13.3)  
BRCA1       
0 100(20.0) 40(15.2) 0.002 
1 222(44.4) 96(36.4)   
2 178(35.6) 128(48.5)   
BARD1    
Negative 502(80.3) 227(69.6) <0.001 
Positive 123(19.7) 99(30.4)  
Chk1       
Negative 460(90.4) 210(77.8) <0.001 
Positive 49(9.6) 60(22.2)   
Ki67    
0 175(42.0) 79(36.1) 0.149 
1 242(58.0) 140(63.9)  
Table 11. Patients‟ characteristics and tumour biomarkers and correlations with KSR1 expression in 
European breast cancer patients 
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3.2.1.5 Oncomine  analysis of KSR1 gene expression between normal breast tissues 
versus breast carcinoma. 
Oncomine anlaysis has been widely utilised to characterise gene expression using large 
microarray datasets in cancers [375]. Our searches for KSR1 gene expression based on 11 
datasets revealed four [380-383] with a significant p value (P < 0.05) and gene ranks in the 
top 18% amongst all differentially expressed genes. In all of these cases, KSR1 was 
consistently decreased in invasive cancers compared to normal breast tissue (Figures 27A-D). 
Moreover, in the dataset of Finak et al., which contained the largest sample number among 
these datasets, a similar pattern of BRCA1 and BARD1 expressions decreasing in invasive 
carcinoma was also observed, further supporting the correlation between KSR1 with BRCA1 
and BARD1 (Figure 27E and 27F). 
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Figure 27 Oncomine data-mining analysis of KSR1 expression in different datasets. 
KSR1 expression was decreased in invasive ductal breast cancers compared to normal breast tissue 
in Finak et al (A), Karnoub et al (B), Ma et al (C) and Richardson et al (D). In Finak et al dataset, a 
similar pattern of reduced BRCA1 (E) and BARD1 (F) mRNA levels was also observed in breast 
carcinoma in comparison to normal breast tissues. 
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3.2.1.6 Kaplan Meier Plotter analysis supports the good prognostic outcome of KSR1 
Using public available microarray data from n=2878 breast cancer patients, we further 
validated the correlations between KSR1 expression and clinical outcome. The positive 
prognostic effect of KSR1 expression was supported by Kaplan Meier Plotter analysis 
(www.kmplot.com) [384], which showed that high KSR1 abundance correlates with a better 
disease free survival using microarray data from n=2878 breast cancer patients (Figure 28).  
 
 
  
Figure 28 Kaplan Meier Plotter analysis of KSR1 expression in breast cancer. 
Kaplan-Meier survival plots demonstrating the good prognostic effect of KSR1 overexpression 
correlates with a longer disease free survival in breast cancer patients gene samples (n=2878, 
P=0.0001). 
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3.2.2 The KSR1 gene interval shows loss of heterozygosity (LOH) in 
primary breast tumour DNA 
The Oncomine analysis revealed that KSR1 gene expression is reduced in multiple breast 
cancer datasets which suggested that this gene may be silenced during breast cancer 
progression. Therefore, we examined SNP and copy number in the KSR1 gene interval in 
paired tumour and plasma of patients with breast cancer (n=65) who were on follow-up [353], 
and identified LOH at KSR1 in 35% of the primary tumour DNA samples. Moreover, in 10% 
of these patients matched LOH was also detectable in paired circulating cell-free DNA 
(cfDNA) samples taken at an average of 6 and 9 years after surgery and treatment respectively. 
In the rest of these patients, there was heterogeneity of LOH in cfDNA (Figure 29). We also 
examined concomitant LOH in BRCA1 and KSR1 in an independent cohort of 28 patient 
samples and found the following: 1). Concomitant LOH in 32% (9/28); 2). KSR1 LOH only in 
21% (6/28); 3). BRCA1 LOH only in 4% (1/28); 4). LOH in neither genes in 43% (12/28). 
Thus, KSR1 loss can occur independently of loss of BRCA1. 
 
 
Figure 29 Loss of heterozygosity (LOH) reported in KSR1 and surrounding genes in primary 
breast tumour and circulating cfDNA. 
LOH was derived on a paired basis (matched to normal leucocyte DNA). In individual patients, 
common LOH was reported in: A. primary tumour DNA and matched 6- and 9-year cfDNA 
samples; B. primary tumour DNA and just 9-year cfDNA sample; and C. just the 6- and 9-year 
cfDNA samples. T, primary tumour DNA; P1, 6-year cfDNA sample; P2, 9-year cfDNA sample. 
Genomic positions of SNP markers from the chip are represented by vertical bars. 
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3.2.3 KSR1 is not a positive regulator of the canonical Ras-Raf-MAPKs 
pathway in breast cancer 
3.2.3.1 KSR1 is ubiquitously expressed in breast cancer cell lines 
To define the role of KSR1 in vitro, we examined its mRNA and protein expression levels in 
a panel of breast cancer cell lines and MCF10A non-tumourigenic human mammary gland 
cell. As shown in Figure 30A, KSR1 gene is expressed in all the breast cell lines we have 
tested, although its expression varies individually. This variability in expression pattern was 
also observed in its protein expression levels (Figure 30B). Additionally, in certain cell lines 
such as BT474 and MDA453, the mRNA and protein expression levels are not well correlated, 
a potential indicator of post-transcriptional regulation.  
 
 
  
Figure 30 Expressions of KSR1 mRNA and protein in mammary epithelial cell MCF10A and 
24 breast cancer cell lines. 
A. KSR1 mRNA levels were measured by RT-qPCR. KSR1 expression in MCF10A is set as 1 and 
all other 24 cell lines are normalized relative to MCF10A mRNA levels. Error bars represent SD of 
3 experiments, each in triplicate. B. KSR1 protein expressions were detected by western blotting 
using anti-KSR1 antibody. Representative blot of KSR1 expression is shown. Experiments were 
repeated at least three times. 
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3.2.3.2 KSR1 is not a positive regulator of the canonical Ras-Raf-MAPKs pathway in 
breast cancer 
The clinical significance of KSR1 in breast cancer suggests a tumour suppressive role, which 
contradicts its documented oncogenic function in other cancer types. Moreover, KSR1 has 
been well established as a positive regulator of the Ras-Raf-MAPKs pathway playing an 
oncogenic role in Ras-transformed cancers such as pancreatic, lung and skin cancer [43]. We 
sought to study its effects on the main players in Ras-Raf-MAPKs cascades, including BRaf, 
CRaf, MEK1/2 and ERK1/2.  
First of all, we overexpressed KSR1 in a breast cancer cell line MCF7 in the presence of 
serum. As shown in Figure 31A, our western blotting results showed that total and phospho-
protein levels of BRaf, CRaf, MEK1/2 and ERK1/2 remained unaltered after KSR1 
overexpression. We further confirmed this observation in another two breast cancer cells 
including T47D and ZR75-1 (Figure 31B and 31C). We then went on to check the effects of 
knockdown KSR1 in this context. Similarly, no significant changes in total and phospho-
protein levels of BRaf, CRaf, MEK1/2 and ERK1/2 were observed upon KSR1 silencing in 
these cell lines (Figure 31).  
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Figure 31 Effect of KSR1 on activation of canonical Ras-Raf-MAPKs pathway in breast 
cancer. 
For KSR1 overexpression, breast cancer cell lines including MCF7 (A), T47D (B) and ZR75-1 (C) 
were transiently transfected with either pCMV6-KSR1 or pCMV6-vector for 24 hours in full 
medium. For KSR1 silencing, cells were transfected with either control siRNA (siCT) or siKSR1 
for 72 hours. Subsequently, the protein expression levels of KSR1, Ras, pBRaf, total BRaf, pCRaf, 
total CRaf, pMEK1/2, total MEK1/2, pERK1/2 and total ERK1/2 were assessed by western 
blotting using specific antibodies as indicated. Representative blots are shown here. Experiments 
were repeated at least three times. 
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To further address whether KSR1 has an effect on Ras-Raf-MAPKs signalling under stimulus 
conditions, MCF7 cells were treated with EGF at various time points (0, 3, 5, 10 mins) after 
KSR1 overexpression. The western blotting results showed that no significant changes were 
observed in pERK1/2 protein levels upon KSR1 overexpression, confirming that KSR1 is not 
a positive regulator after EGF-stimulus (Figure 32). 
 
  
Figure 32 Effect of KSR1 on activation of ERK upon EGF treatment.   
MCF7 cells were stripped for 72 hours before transfected with lipofectamine 2000 (vehicle), 
pCMV6-vector or pCMV6-KSR1. After 24 hours of transfection, cells were treated with EGF (10 
ng/ml) and collected at the indicated time points (0, 3, 5 and 10 mins). The protein levels of Flag-
KSR1, pERK1/2 and Tubulin were determined by western blotting by specific antibodies as 
indicated. Representative blots are shown here. Experiments were repeated at least three times. 
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3.2.4 KSR1 overexpression inhibits tumour formation and growth in vitro 
and in vivo 
Given the fact that Ras-mutations are rare in breast cancer, our data so far suggest that the 
biological functions of KSR1 are different to and independent of the canonical Ras-Raf-
MAPKs signalling in this setting. We next assessed whether KSR1 has a tumour suppressive 
effect on breast cancer formation in vitro and in vivo as suggested by its clinical correlations. 
3.2.4.1 Generation of KSR1 stably overexpressing breast cancer cell lines 
In order to study the role of KSR1 in breast cancer growth and colony formation, we 
generated a breast cancer cell line stably overexpressing KSR1 (MCF7-KSR1) through G418 
selection as described in methods. Single clones were selected and KSR1 overexpression was 
confirmed by western blotting (Figure 33A).  
3.2.4.2 KSR1 overexpression inhibits tumour formation in vitro 
Firstly, 3D Matrigel-overlay assay allowing integration of the extracellular matrix signalling 
components was performed to study the tumourigenic effect of KSR1 using the selected 
clones from MCF7 cells as described above. Overexpression of KSR1 significantly reduced 
the size of the large and loose aggregates compared to the parental MCF7 cells (Figure 33B). 
 
 
 
 
Figure 33 Validation of MCF7 stably overexpressing KSR1 cell lines and its effect on 
tumourigenesis in 3D matrigel assay. 
A. MCF7-KSR1 and MCF7-vector stable cells were generated by transfection of either pCMV6-
KSR1 or pCMV6-vector into MCF7 cells and single clones were selected in the presence of G418 
(1 mg/ml). KSR1 overexpression was confirmed by western blotting. Representative blots are 
shown here. B. 3D matrigel assay was performed as described above using different MCF7-KSR1 
clones and representative images from three independent experiments are shown here. 
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We next performed a soft agar assay to observe the tumour colony formation upon KSR 
overexpression. MCF7-KSR1 cells stably overexpressing KSR1 were seeded in medium with 
soft agar and cultured for 14 days. At the end of experiment, cell colonies were imaged, 
counted and colony sizes were measured. As shown in Figure 34A, MCF7-KSR1 
cells derived much fewer and smaller colonies compared to MCF7-vector cells. Subsequent 
analysis also confirmed this finding (Figure 34B, P < 0.001).  
 
 
 
 
 
 
Figure 34 Effect of KSR1 on colony formation in soft agar assay. 
A. MCF7-vector or MCF7-KSR1 cells were incubated for 14 days in soft agar. Optical sections of 
representative colonies are shown. Scale bar, 50 µm. B. Colonies from soft agar assays were 
counted in 5 random fields per well. Diameters of colonies were measured and grouped as (≤75 
µm, 75-100 µm and 100 µm). Bar chart shows data of three independent experiments, mean ± SD 
(*P < 0.001, by Student's t-test). 
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To further prove this finding in other breast cancer cells, we generated another breast cancer 
cell line stably overexpressing KSR1 (MDA231-KSR1) and exerted the same 3D Matrigel-
overlay assay. Similar results were obtained showing that KSR1 overexpression cells formed 
smaller size acini compared to parental MDA231 cells (Figure 35).  
 
 
 
 
 
3.2.4.3 KSR1 overexpression inhibits tumour growth in vivo 
We next examined the action of KSR1 overexpression on tumour growth in breast cancer 
xenograft mouse model in vivo. To do so, we subcutaneously injected MCF7 stably 
overexpressing cells MCF7-KSR1 or MCF7-parental cells into BALB/c nude mice. The 
tumour volumes of breast cancer xenografts overexpressing KSR1 were markedly reduced 
compared with the control group (Figure 36A and 36B). Immunohistochemistry analysis of 
mouse tumour tissues showed that the Ki67 proliferation index was strongly decreased in 
MCF7-KSR1 mice with higher KSR1 expression, lending further support to our hypothesis 
(Figure 36C). Collectively, our in vitro and in vivo results demonstrate the anti-proliferative 
effect of KSR1 in breast cancer, supporting our clinical results. 
 
 
 
Figure 35 Effect of KSR1 on tumourigenesis in MDA231 cells by 3D matrigel assay. 
3D matrigel assay was performed as above using stably overexpressing KSR1 (MDA231-KSR1) 
and MDA231-vector. Representative images from three independent experiments are shown here. 
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Figure 36 Effect of KSR1 overexpression on tumour growth in vivo. 
A. Breast cancer xenograft model in BALB/c nude mice. 5×106 MCF7-vector or MCF7-KSR1 
cells were injected subcutaneously in the flanks of nude mice (n = 9). Tumour volume was 
measured every 3 days using callipers. Growth curves shown are mean tumour ± SD. B. 
Representative set of xenografts derived from MCF7-vector or MCF7-KSR1 cells are shown. C. 
Representative IHC analyses for KSR1 and Ki67 on paraffin-embedded section of xenografts 
derived from MCF7-parental or MCF7-KSR1 cells. 
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3.2.5 KSR1 stabilizes BRCA1 by reducing BRCA1 ubiquitination and 
inhibits tumour growth through BRCA1 
Based on the positive correlation between KSR1 and BRCA1 expressions in the clinical 
samples and the tumour growth inhibitory role of KSR1, we then examined the effect of 
KSR1 on BRCA1 protein and whether its tumour suppressive action is BRCA1-dependent. 
3.2.5.1 KSR1 affects the protein abundance of BRCA1 but not the mRNA levels 
We first studied the effect of KSR1 on BRCA1 mRNA expression. As shown in Figure 37A, 
overexpression of KSR1 in MCF7 cells had no effect on BRCA1 mRNA levels after 24 hours 
transient transfection. However, our western blotting showed that KSR1 overexpression 
increased BRCA1 protein abundance after 24 and 48 hours of transfection (Figure 37B). We 
then checked whether KSR1 has the same effect in other breast cancer cell lines. MDA231 
and ZR75-1 cells were transfected with pCMV6-vector or pCMV6-KSR1 for 24 hours. 
Consistently, similar results showed that BRCA1 protein expression was elevated after KSR1 
up-regulation in both MDA231 and ZR75-1 cells (Figure 37C). 
We then went on to check the effect of KSR1 silencing on BRCA1 protein expression. Firstly, 
MCF7 cells were transfected with sicontrol (siCT) or siKSR1 for 72 hours. Western blotting 
was subsequently performed to measure the protein abundance of BRCA1. As shown in 
Figure 37D, KSR1 silencing resulted in a decrease of BRCA1 protein. Likewise, consistent 
results were observed in other two breast cancer cell lines, MDA231 and ZR75-1, which 
showed that BRCA1 protein was down-regulated upon knockdown of KSR1 (Figure 37E). 
These data support that KSR1 affects the protein abundance of BRCA1 but not its mRNA 
levels.  
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Figure 37 Effect of KSR1 on BRCA1 mRNA/protein levels. 
A. MCF7 cells were transfected with either pCMV6 vector or pCMV6-KSR1 plasmids for 24 
hours. RNA was extracted and RT-qPCR was performed to measure BRCA1 gene expression. B. 
MCF7 cells were transfected with either pCMV6 vector or pCMV6-KSR1 plasmids for 24 or 48 
hours. The protein expression levels of BRCA1 were assessed by western blotting using indicated 
antibodies. C. MDA231 or ZR75-1 cells were transiently transfected with either pCMV6 or 
pCMV6-KSR1 plasmids for 24 hours. The protein expression levels of BRCA1 were assessed by 
western blotting. D. For knock-down of KSR1, MCF7 cells were transfected with either control 
siRNA (siCT) or siKSR1 for 72 hours. BRCA1 abundance was assessed by western blotting. E. 
MDA231 or ZR75-1 cells were transfected with either control siRNA (siCT) or siKSR1 for 72 
hours. BRCA1 abundance was assessed by western blotting. Representative blots are shown here. 
Experiments were repeated at least three times. 
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3.2.5.2 KSR1 stabilizes BRCA1 through reducing BRCA1 ubiquitination 
Based on our results above showing that KSR1 affects the protein expression of BRCA1, we 
next decided to examine whether KSR1 is involved in BRCA1 degradation. MCF7 cells were 
transfected with either pCMV6 vector or pCMV6-KSR1 plasmids for 24 hours followed by 
treatment with different proteasome inhibitors MG115 or MG132 (10 µM, 6h), which can 
impede BRCA1 degradation through its ubiquitination. Subsequently, BRCA1 protein 
expression was measured by western blotting. Our results showed that the effect of KSR1 
overexpression on BRCA1 protein levels was compromised in the presence of MG115 and 
MG132, as the fold change of BRCA1 abundance in the absence of proteasome inhibitors was 
2.4 and subsequently declined to 1.5 (MG132) or 1.6 (MG115) (Figure 38). This indicated 
that KSR1 might affect BRCA1 stability partly by regulating BRCA1 degradation and 
ubiquitination, although an alternative mechanism other than protection from ubiquitin-
mediated degradation is possible. 
 
 
 
 
 
Therefore, we sought to investigate the effect of KSR1 overexpression on BRCA1 
ubiquitination. As shown in Figure 39A, a ubiquitination assay revealed that ubiquitinated 
BRCA1 was reduced upon overexpression of KSR1 in MCF7 cells. In order to show whether 
this happens in other breast cancer cells, we performed the same ubiquitination assay in 
MDA231 cells where similar result was also observed (Figure 39B). In summary, our data 
Figure 38 Effect of KSR1 overexpression on BRCA1 protein levels in the presence of 
proteasome inhibitors. 
MCF7 cells were transiently transfected with pCMV6 vector or pCMV6-KSR1 plasmids for 24 
hours, followed by treatment with MG115 or MG132 (10 µM, 6h). BRCA1 protein levels were 
then assessed by western blotting with specific antibodies as indicated. Representative blots are 
shown here. Experiments were repeated at least three times. 
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demonstrates that KSR1 appears to stabilize BRCA1 through reducing ubiquitination of 
BRCA1. 
 
 
 
 
 
 
3.2.5.3 The inhibitory effect of KSR1 on tumour growth is through BRCA1 
Based on the fact that BRCA1 is a well-established tumour suppressor in breast cancer and 
the described link herein between KSR1 and BRCA1, we suspected that KSR1 acts as an 
inhibitory factor through BRCA1 in this setting. Therefore, we examined whether the tumour 
suppressive action of KSR1 is dependent on BRCA1. In vitro 3D Matrigel and soft agar 
assays were performed to examine tumour formation after different combinations of KSR1 
and BRCA1 expression levels.  
As shown in Figure 40A (upper panel) and Figure 40C, 3D Matrigel assay showed that 
comparing with MCF7-vector cells, MCF7-KSR1 cells formed much smaller size acini (lane 
1 vs 3), which is consistent to our previous finding. Furthermore, the tumour inhibitory effect 
Figure 39 Effect of KSR1 on BRCA1 ubiquitination. 
A. MCF7 or B. MDA231 cells were transfected with either pCMV6 vector or pCMV6-KSR1 
plasmids together with Myc-Ubiquitin as indicated for 48 hours and followed by treatment with 
MG132 for 6 hours. Subsequently, protein samples were extracted and immunoprecipitation was 
then performed with IgG or specific anti-BRCA1 antibody. Western blotting was implemented to 
measure the Myc-tagged ubiquitinated BRCA1 using anti-Myc antibody. Representative blots are 
shown here. Experiments were repeated at least three times. 
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of KSR1 was abolished when BRCA1 protein was silenced, as 3D Matrigel demonstrated that 
the colonies recuperated in this setting (lane 3 vs 4). Similarly, in the soft agar assay (Figure 
40B, lower panel; Figure 40D), our results revealed that the size of colonies derived from 
MCF7-KSR1 cells was significantly smaller than the counterparts formed by MCF7-vector 
cells. Moreover, when BRCA1 protein was deleted, the colonies generated by MCF7-KSR1 
cells were recovered (lane 3 vs 4). These results strongly support our hypothesis that the 
inhibitory effect of KSR1 on breast tumour growth is through BRCA1.   
 
 
  
Figure 40 BRCA1 is required for the tumour suppressive effect of KSR1. 
A. 3-D Matrigel overlay assay (upper panel). MCF7-vector or MCF7-KSR1 stable cells were 
transfected with either siCT or siBRCA1 for 72 hours and then embedded in Matrigel and cultured 
for 6 or 7 days in 10% FCS DMEM supplemented with 2% Matrigel. Phase contrast images of 
representative acini structures were taken in the end of the experiment. Scale bar, 50 µm. B. Soft 
agar growth assay (lower panel). After 72 hours transfection with either siCT or siBRCA1, MCF7-
parental or MCF7-KSR1 cells were incubated for 14 days in soft agar. Optical sections of 
representative colonies are shown. Scale bar, 50 µm. C. Acini or D. Colonies (~30 per condition) 
were measure by Axiovert 100 MetaMorph as described before and normalized to MCF7-vector 
siCT group. Bar chart shows data of three independent experiments, mean ± SD (**P < 0.01 and 
***P < 0.01; P value determined by Student's t-test). 
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3.2.6 KSR1 regulates BRCA1 stability via elevated BARD1 abundance and 
increased BRCA1-BARD1 interaction 
3.2.6.1 KSR1 affects the protein abundance of BARD1 not its mRNA level 
To further explore the mechanism through which KSR1 regulates BRCA1 expression, the 
positive association between KSR1 and BARD1 provided a potential link in the present study. 
It is already known that BRCA1 forms a heterodimeric complex with BARD1 that promotes 
stabilization by reducing its ubiquitination [385, 386]. We therefore studied the effect of 
KSR1 on BARD1 mRNA and protein expression levels. We first studied the effect of KSR1 
on BARD1 mRNA expression. Our RT-qPCR results showed that KSR1 overexpression does 
not affect the mRNA level of BARD1 (Figure 41A). Interestingly, western blotting revealed 
that up-regulation of KSR1 increases BARD1 protein levels in MCF7 (Figure 41B). 
Following, we wanted to confirm whether KSR1 has the similar effect on BARD1 expression 
in other breast cancer cell lines. Therefore, MDA231 and ZR75-1 cells were transfected with 
pCMV6-vector or pCMV6-KSR1 for 24 hours and western blotting was performed to 
determine the protein expression levels of BARD1. As anticipated, consistent results were 
observed from MDA231 and ZR75-1 cells showing that BARD1 protein expression was 
increased after KSR1 up-regulation (Figure 41C).  
We next decided to examine the effect of KSR1 knockdown on BARD1 protein expression. 
As shown in Figure 41D, BARD1 protein expression was down-regulated upon KSR1 
silencing in MCF7 cells. As expected in MDA231 and ZR75-1 cells, same results by western 
blotting showed that BARD1 abundance was also decreased after KSR1 silencing (Figure 
41E). These data support that KSR1 affects the protein abundance of BARD1 not mRNA 
level.  
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3.2.6.2 The effect of KSR1 on BRCA1 expression is partly through BARD1 
To investigate whether the effect of KSR1 on BRCA1 regulation is mediated through BARD1, 
we decided to silence BARD1 following overexpression of KSR1 to examine the total 
BRCA1 protein levels. To do so, MCF7 cells were transfected with control siRNA (siCT) or 
siBARD1 for 48 hours followed by KSR1 transient transfection with pCMV6 vector or 
pCMV6-KSR1 plasmids for 24 hours. As previously reported, silencing of BARD1 resulted 
in a decrease of BRCA1 expression (Figure 42A, lane 1 vs 3). Moreover, KSR1 
overexpression after BARD1 deletion did not restore the up-regulated BRCA1 levels in 
MCF7 (Figure 42A, lane 2 vs 4), indicating a requirement of BARD1 in the regulation of 
BRCA1 by KSR1. However, an alternative mechanism of BRCA1 up-regulation by KSR1 
Figure 41 Effect of KSR1 on BARD1 mRNA/protein levels. 
A. MCF7 cells were transfected with either pCMV6 vector or pCMV6-KSR1 plasmids for 24 
hours. RNA was extracted and RT-qPCR was performed to measure BARD1 gene expression. B. 
MCF7 cells were transfected with either pCMV6 vector or pCMV6-KSR1 plasmids for 24 hours. 
The protein expression levels of BARD1 were assessed by western blotting using indicated 
antibodies. C. MDA231 or ZR75-1 cells were transiently transfected with either pCMV6 vector or 
pCMV6-KSR1 plasmids for 24 hours. The protein expression levels of BARD1 were assessed by 
western blotting. D. For knock-down of KSR1, MCF7 cells were transfected with either control 
siRNA (siCT) or siKSR1 for 72 hours. BARD1 abundance was assessed by western blotting. E. 
MDA231 or ZR75-1 cells were transfected with either control siRNA (siCT) or siKSR1 for 72 
hours. BARD1 abundance was assessed by western blotting. Representative blots are shown here. 
Experiments were repeated at least three times. 
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other than through BARD1, such as a potential cooperative action of KSR1 and BARD1 or 
another unidentified protein involved, cannot be ruled out, as BRCA1 expression was still 
elevated albeit much less in the BARD1-knockdown cells (Figure 42A, lane 3 vs 4). We then 
went on to check whether this is a more general effect of KSR1 in other breast cancer cell 
lines. As above, ZR75-1 and MDA231 cells were used to confirm the effects of KSR1 on 
BRCA1 regulation is through BARD1. The same protocols were performed to measure the 
BRCA1 protein levels after KSR1 overexpression in BARD1 silenced cells. Consistently, the 
above observation was confirmed in ZR75-1 and MDA231 cells as well (Figure 42B and 
39C). 
 
 
 
  
Figure 42 Effect of KSR1 overexpression on BRCA1 protein levels after BARD1 silencing. 
A. MCF7 cells were transfected with control siRNA (siCT) or siBARD1 for 48 hours followed by 
KSR1 transient transfection with pCMV6 vector or pCMV6-KSR1 plasmids for 24 hours. The total 
levels of BRCA1 and BARD1 were assessed by western blotting using indicated antibodies. B. 
ZR75-1 cells or C. MDA231 cells were transfected with control siRNA (siCT) or siBARD1 for 48 
hours followed by KSR1 transient transfection with pCMV6 vector or pCMV6-KSR1 plasmids for 
24 hours. The expressions of BRCA1 and BARD1 were measured by western blotting. 
Representative blots are shown here. Experiments were repeated at least three times. 
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3.2.6.3 The interaction between BRCA1 and BARD1 is increased upon KSR1 
overexpression 
We then speculated as to whether KSR1 could directly interact with BRCA1 or BARD1. To 
determine a direct interaction between KSR1 with BRCA1 or BARD1, anti-KSR1 
immunocomplexes were precipitated to examine its capability of co-precipitating endogenous 
BRCA1 or BARD1 in MCF7 cells. Western blotting of the immunocomplexes with anti-
BRCA1 antibody showed that KSR1 did not co-precipitate with BRCA1. However, western 
blotting of the immunocomplexes with anti-BARD1 antibody showed that KSR1 co-
precipitated with endogenous BRAD1 (Figure 43A). On the other hand, western blotting 
analysis of anti-BARD1 immunocomplexes showed that BARD1 was capable of co-
precipitating with KSR1, as well as BRCA1, which has already been demonstrated previously 
(Figure 43B). These results suggest that KSR1 interacts with BARD1 but not with BRCA1. 
Next, we sought to explore the effect of KSR1 on BRCA1-BARD1 complex formation. Anti-
BRCA1 immunocomplexes were precipitated to evaluate the interaction between BRCA1 and 
BARD1. Western blotting revealed that the interaction between BRCA1 and BARD1 was 
increased after KSR1 overexpression (Figure 43C). We could therefore conclude that KSR1 
increases BARD1 abundance resulting in elevated BRCA1 and enhanced steady state level of 
the BRCA1-BARD1 dimer. 
 
 
 
  
Figure 43 Effect of KSR1 on BRCA1 and BARD1 interaction. 
A. Cell lysates from MCF7 were immunoprecipitated (IP) with an anti-KSR1 antibody. 
Subsequently, western blotting was performed to examine the interaction between KSR1 with 
BRCA1 and BARD1 with specific antibodies indicated. B. Cell lysates from MCF7 were 
immunoprecipitated (IP) with an anti-BARD1 antibody and western blotting was exerted to 
confirm the interaction between KSR1 and BARD1 with the indicated antibodies. C. Effects of 
KSR1 overexpression on the interaction between BRCA1 and BARD1. MCF7 cells were 
transiently transfected with pCMV6 vector or pCMV6-KSR1 plasmids for 24 hours. The 
interactions between BRCA1 and BARD1 were detected by immunoprecipitation (IP) of BRCA1 
followed by western blotting with an anti-BARD1 antibody. Representative blots are shown here. 
Experiments were repeated at least three times. 
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3.2.6.4 BARD1-BRCA1 nuclear abundance is increased upon KSR1 overexpression 
We then examined whether KSR1 can increase BARD1-BRCA1 nuclear abundance, which is 
linked to BRCA1 activation and essential for the tumour suppressive function of BRCA1. To 
do so, we performed cell fractionation assays. MCF7 cells were transfected with either 
pCMV6 vector or pCMV6-KSR1 plasmids for 24 hours. Subsequently, cytoplasmic and 
nuclear proteins were isolated following manufacturer‟s protocol. Our results showed that 
KSR1 overexpression resulted in an increase of nuclear accumulation of both BARD1 and 
BRCA1 (Figure 44), which can consequently result in an enhancement of BRCA1 activity. 
 
 
 
 
 
 
  
Figure 44 Effect of KSR1 on subcellular localization of BRCA1 and BARD1. 
MCF7 cells were transiently transfected with pCMV6 vector or pCMV6-KSR1 plasmids for 24 
hours. Protein fractions from the nucleus and cytoplasm were extracted as described in Materials 
and Methods. HDAC1 and β-actin expressions served as positive normalising control for nuclear 
and cytoplasmic proteins respectively. All blots shown are representatives of at least three 
independent experiments. 
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3.2.7 Discussion 
Scaffolding proteins play an essential role in the assembly of multiprotein complexes that 
initiate signal transduction in various intracellular compartments; correct complex 
organization determines key cellular activities including cell proliferation, differentiation and 
apoptosis [387, 388]. KSR1 was originally identified more than 15 years ago as a novel 
protein kinase implicated in the Ras-Raf pathway; defects in KSR1 inhibit activated Ras, 
without affecting the pathways induced by activated Raf [107-109]. Interestingly, it appears 
that the expression levels of KSR1 can determine its function. Specifically, low levels of 
KSR1 enhance Ras-induced activity, whereas high KSR1 expression can suppress the Ras 
pathway [127]. Emerging evidence suggests that KSR1 possesses dual activity as active 
kinase phosphorylating Raf-1 and MEK1 [144-146] and as a scaffold protein that can also 
form dimers with Raf modulating its activity [137, 139]. Taken into consideration of its role 
in Ras-Raf-MAPKs signalling, most work have focused on the contribution of KSR1 in Ras-
dependent tumours, including skin [162], pancreatic [166] and lung carcinomas [167]. Its 
clinical significance and biologic functions have not been comprehensively studied in breast 
cancer.  
Here, we establish a role of KSR1 as an independent prognostic biomarker in breast cancer. 
High KSR1 expression correlates with a better overall and disease free survival in a large 
patient cohort (n=1000) with 20 years follow-up. In addition, a trend approaching statistical 
significance associating KSR1 expression with response to endocrine and chemotherapy 
treatments was observed perhaps suggesting a predictive role, which requires further 
validation. This observation, however, is supported by a previous report, in which Kim et al 
showed that KSR1 overexpression in MCF7 cells increased CDDP sensitivity and apoptosis 
[168]. Our present study is the first in-depth report to demonstrate a protective role for KSR1 
in cancer, as thus far it has been linked to tumour induction in pancreatic and lung cancer 
[166], indicative of contrasting and tissue specific mechanisms of function in different 
biologic contexts. In addition, we also showed that KSR1 positively correlates with BRCA1 
and BARD1 expression in breast cancer tissues in this cohort. In agreement with our clinical 
observations, Oncomine analysis revealed that KSR1 gene expression is reduced in four 
different breast cancer datasets, while as expected it is up-regulated in lung and colorectal 
cancers probably due to abnormally activated/mutated Ras signalling pathways. However, 
disparities still exist in different breast cancer datasets, as we recently reported that KSR1 
mRNA expression is increased in breast carcinoma in one TCGA dataset contradicting to our 
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findings in this work [389]. One possible reason is that it is difficult to compare between 
datasets owing to sometimes small sample sizes as well as the heterogeneity of samples. 
Another important aspect is that a correlation between KSR1 with BARD1 and BRCA1 was 
identified in the Finak‟s dataset in this study, but not in the previous TCGA dataset. This 
suggests that the tumour suppressive role of KSR1 might require a cooperative action of 
BARD1 and BRCA1 as we suggest herein. Moreover, a large microarray data set analysis 
(n=2878) further supported the good prognostic effect of KSR1 overexpression. 
We also identified a high frequency of LOH (35%) at the KSR1 gene interval in primary 
tumour DNA samples analysed as part of a previous study [353] suggesting a tumour 
suppressor role for KSR1 in some breast cancers. Additionally, we found LOH at KSR1 in 10% 
of matched cfDNA samples taken an average of 6 and 9 years after surgery and treatment 
respectively. In some cases, we also identified LOH that was unique potentially suggesting 
the emergence of new tumour clone harbouring a loss of KSR1. This finding also suggests that 
KSR1 loss can occur independently of loss of BRCA1, highlighting its value in cancer 
screening. 
We then explored whether the action of KSR1 is through its involvement in the canonical 
Ras-Raf-MAPKs pathway in breast cancer. In doing so, we examined a phospho-profile on 
the main members of this pathway upon overexpression/silencing KSR1 in several breast 
cancer cell lines. KSR1 has no significant effects on pBRaf, pCRaf, pMEK1/2 and pERK1/2 
in both full serum condition and EGF-induced treatment. This finding suggests that the 
function of KSR1 in breast cancer might not be connected to this pathway, also supported by 
the fact that Ras mutation is very rare in breast cancer.  
Using cells stably overexpressing KSR1, we examined the biological role of KSR1 in vitro 
and in vivo. The physiologically relevant 3D-Matrigel overlay assay, which integrates 
signals from the extracellular matrix was performed, and showed a decrease in the number 
and size of tumour acini formed by KSR1 overexpressing MCF7 cells. To further address the 
effect of KSR1 on the tumourigenic potential of breast cancer cells, we performed a soft agar 
assay, where KSR1-MCF7 cells colony formation was significantly compromised. Moreover, 
results from mice xenografts revealed that KSR1 up-regulation markedly inhibits tumour 
growth, supporting a tumour suppressive role of KSR1 in breast cancer. These results add 
complexity to the role of KSR1 in breast tumourigenesis, as another study of ours recently 
showed that KSR1 knockdown inhibits the proliferation of breast cancer cell lines including 
MCF7 (result section 3.1.8) [389]. The discrepancies might be due to the scaffolding function 
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of KSR1 itself, as while at basal levels scaffold concentration enhances signal transmission, a 
further increase or decrease beyond an optimal level can inhibit or even reverse the original 
effect [390]. Consistently, this fact is also strongly supported by other studies that 
demonstrated that either high or low KSR1 expression exhibits inhibitory effects resulting in 
regulation of the proliferative potential of cells [120, 122, 126, 127]. 
The correlation between KSR1 and BRCA1 in breast cancer tissues underscores the potential 
role of KSR1 in tumour suppression. Our in vitro results showing increased BRCA1 levels 
after KSR1 overexpression are in accordance with the clinical findings. Our results revealed 
that KSR1 increases BRCA1 protein through reducing its ubiquitination. Of note, this study 
showed that the tumour suppressive action of KSR1 is BRCA1 dependent as the oncogenic 
ability of breast cancer cells overexpressing KSR1 recovered when BRCA1 is depleted. The 
positive association between KSR1 and BARD1 from clinical samples also indicated a link in 
the potential KSR1-BRCA1-BARD1 complexes. Mechanistically, we also determined that 
KSR1 does not affect the mRNA levels of BARD1 but increases BARD1 protein, which has 
been previously reported to form a heterodimer with BRCA1 thereby stabilising it by 
reducing its ubiquitination [386]. Moreover, the BRCA1-BARD1 interaction is elevated upon 
KSR1 overexpression, resulting in BRCA1-BARD1 translocation to the nucleus, which is 
essential for tumour inhibition in breast cancer, as previously described [391].  
The effect of KSR1 on BRCA1 is modulated partly by BARD1, as KSR1 overexpression 
increases BRCA1 less strongly if BARD1 is silenced, indicating a need of BARD1 in the 
regulation of BRCA1 by KSR1. However, alternative mechanisms of BRCA1 up-regulation 
by KSR1 other than through BARD1, such as a potential cooperative action of KSR1 and 
BARD1, cannot be ruled out, as BRCA1 expression was still elevated albeit to a lesser degree 
in the BARD1-knockdown cells. Our recent work showing that KSR1 inhibits 
phosphorylation of DBC1, which was previously identified as a transcriptional repressor for 
BRCA1, suggests an alternative mechanism controlling the effect of KSR1 on BRCA1 [389, 
392]. Interestingly, in this same study, we reported that KSR1 negatively regulates p53 
activity through modulation of DBC1 (result section 3.1) [389]. Given that DBC1 is a well-
studied positive regulator of p53 as well as a repressor for BRCA1, it potentially links KSR1 
into a network involving p53 and BRCA1, which merits further investigation. Up to now, we 
have already shown that KSR1 decreases p53 activity, whereas it increases BRCA1 
expression. A rational explanation to the discrepancies between the previous study and the 
current one regarding the tumour suppressive function of KSR1 in carcinogenesis might be 
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that BRCA1 can compensate for loss of p53, as it has been previously shown [393]. Therefore, 
this allows KSR1 to employ its inhibitory effects through BRCA1 up-regulation. However, 
further investigation is needed to address the underlying mechanisms. In addition, we have 
shown that KSR1 interacts directly with BARD1 but not BRCA1. Whether KSR1 regulates 
BARD1 through phosphorylation or other alternative functions also requires exploration. 
Taken together, we present that patients with breast cancer with high KSR1 showed better 
disease free- and overall survival. Moreover, KSR1 interacts with BARD1 and regulates 
BRCA1 ubiquitination through elevated BARD1 expression and increased BRCA1-BARD1 
interaction. This in turn allows the nuclear import of BRCA1-BARD1 complex leading to 
increased BRCA1 activity, and lends mechanistic support to the tumour suppressive function 
of KSR1 in breast cancer (Figure 45). 
 
 
 
  
Figure 45 Proposed model of BRCA1 regulation by KSR1. 
KSR1 acts as a scaffold protein that interacts with BARD1, which is capable of forming a 
heterodimer with BRCA1 and stabilising each other. KSR1 regulates BRCA1 degradation, partly 
through elevated BARD1 expression and increased BRCA1-BARD1 interaction. This in turn 
results in increased translocation of BRCA1 to the nucleus where it functions as a tumour 
suppressive protein through regulating cell cycle arrest and apoptosis. 
159 
 
3.3 Global mapping of TKs signalling by combined use of RNAi 
and quantitative proteomics  
3.3.1 Strategy for identification of TKs signalling by combined use of 
quantitative proteomics and RNAi 
The purpose in this study was to perform a global TKs-signalling mapping by using a high 
throughput RNAi screen combined with SILAC-based quantitative proteomics in breast 
cancer cells. In doing so, we were hoping to identify an in-depth proteomic signature for each 
TK investigated herein. Our approach employed to achieve this aim is shown in Figure 46.  
Briefly, step 1 was to determine the expression profile of all 90 TKs using RT-qPCR and then 
set a minimum expression threshold to allow candidates to proceed to the next step. In step 2, 
a certified RNAi library composed of 2 siRNAs against TKs was used to silence each member 
of the TKs identified from the previous stage. Two follow-up validation assays by RT-qPCR 
and western blotting were performed to confirm the knockdown efficiency. In step 3, MCF7 
cells were primarily cultured in SILAC either R0K0 „light‟ medium, containing unlabelled 
12
C6,
14
N4-arginine (Arg) and 
12
C6-lysine (Lys) amino acids, or R6K4 „medium‟, R10K8 
„heavy‟ medium, containing labelled 13C6,
15
N4-Arg and 
13
C6-Lys for at least 7 cell divisions 
and were then transfected with validated siRNAs targeting the 65 TKs that are expressed in 
MCF7 cells (CT value <34.5). Subsequently, protein samples were taken and LC-MS/MS 
protein identification and quantification analyses were exerted. Finally, bioinformatic analysis 
was performed to evaluate changes in signalling dynamics and eventually propose a new 
classification for the TKs family based on similarities in their regulated proteomes.     
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Figure 46 Strategy for identification of TKs signalling by combined use of quantitative 
proteomics and RNAi. 
The expression profile of all 90 TKs was examined using RT-qPCR in MCF7 cells. A certified 
RNAi library composed of 2 siRNAs against TKs was used to silence each member of the TKs 
identified from the previous stage. SILAC proteomic analysis was then performed after silencing 
each verified tyrosine kinase in MCF7 cells. Bioinformatic analyses were subsequently used to 
reclassify the family of TKs.  
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3.3.2 Expression profile of TKs family in MCF7 breast cancer cells 
First of all, we decided to examine the expression profile of all members of TKs family in 
MCF7 breast cancer cells. To do so, a quantitative RT-qPCR analysis was performed to 
determine the endogenous expression levels of all 90 TKs including 58 Receptor Tyrosine 
Kinases (RTKs) and 32 Cytoplasmic Tyrosine Kinases (CTKs) (Figure 47). We set as cut-off 
a threshold cycle (CT) value of <34.5, above which the data has a high chance of resulting 
from cross contamination or amplification of fluorescent artifacts (using GAPDH as 
endogenous control housekeeping gene with a CT value of ~17). Based on this analysis, 66 
TKs validated are expressed at variable levels with CT values ranging from 21.5 to 34.5 
(Figure 48).  
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Figure 47 Expression profile of TKs family in MCF7 breast cancer cells. 
A quantitative RT-qPCR analysis was performed to determine the endogenous expression levels of 
all 90 TKs in MCF7. CT values of all 90 TKs are presented here.  A cut-off threshold cycle (CT) 
value was set as 34.5, above which the data can be interpreted as results of cross contamination or 
amplification of fluorescent artifacts. RT-qPCR assay was done two times in four replicates each 
time.  
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3.3.3 A high-throughput RNAi screen of TKs family in MCF7 breast cancer 
cells 
We continued to silence each individual TK expressed in MCF7 cells, using a siRNA library 
composed of 2 siRNAs/targeted gene. MCF7 cells were transfected for 72h, followed by RT-
qPCR to verify the knockdown efficiency of the siRNAs. 65 out of 66 TKs were successfully 
silenced with a decrease of ≥70% at the mRNA levels (Figure 49). We also validated the 
siRNA silencing efficacy by performing western blotting analysis on several of the TKs 
(Figure 50). 
 
 
Figure 48 Expression levels of targeted TKs in this study. 
66 validated TKs are expressed at variable levels with a CT value ranging from 21.5 to 34.5, all of 
which were targeted using siRNA for the next proteomic analysis.  
Figure 49 Validation of siRNAs targeting TKs using RT-qPCR. 
MCF7 cells were transfected with an siRNA library composed of 2 siRNAs/targeted gene against 
65 TKs for 72 hours. RT-qPCR was then performed to verify the knockdown efficiency of the 
siRNAs. Fold changes of mRNA levels comparing to siControl (blue) are presented here. 
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3.3.4 Identification of TKs regulated proteomes in MCF7 
Considering the documented role and involvement of TKs in cancer signalling [13] and the 
fact that till now there has been a focus on only a few of them, we performed a quantitative 
proteomic analysis of the breast cancer tyrosine kinome after silencing each one of them to 
elucidate the TKs-regulated protein networks. 
To do so, we used the SILAC approach which uses metabolic labelling into cellular 
proteomes during normal biological processes, introducing natural “light”, “medium” or 
“heavy” labelled amino acids into synthesized proteins. When light and heavy cell 
populations are mixed and digested to peptides, proteins are identified by liquid 
chromatography tandem MS (LC-MS/MS). This thus enables direct and accurate comparison 
of changes in protein abundance while concurrently allowing for the identification of 
modulated proteome upon silencing each tyrosine kinase in the heavy SILAC state [394].  
Specifically, MCF7 cells were grown for 7 cell divisions in either R0K0 „light‟ medium, 
containing unlabelled 
12
C6,
14
N4-arginine (Arg) and 
12
C6-lysine (Lys) amino acids, or R6K4 
„medium‟, R10K8 „heavy‟ medium, containing labelled 13C6,
15
N4-Arg and 
13
C6-Lys. 
Following, R0K0, R6K4 and R10K8 labelled cells were transfected with either control siRNA 
or a pool of 2 validated siRNAs targeting two individual TKs out of 65 for 72 hours, 
respectively. Total protein lysates were prepared, mixed 1:1:1, digested, fractionated, 
subjected to LC-MS/MS and analysed using MaxQuant [357]. From ~ 27,000 nonredundant 
peptide sequences, a SILAC-based proteome comprising more than 2,000 distinguishable and 
unambiguously identified proteins with a minimum of two peptides (minimal peptide length 7 
aa) was assembled in this study. 
Figure 50 Validation of siRNAs targeting TKs using western blotting. 
MCF7 cells were transfected with siRNAs for 72 hours. Western blotting was then performed to 
verify the knockdown efficiency of the siRNAs on 7 randomly chosed TKs. All blots shown are 
representatives of at least three independent experiments. 
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In all SILAC proteomics analyses after silencing 65 individual TKs, approximately 2,000 
proteins were identified in each dataset with either 1 peptide or a minimum of 2 peptides, both 
with a false discovery rate (FDR) of 1%. Out of these proteins, more than 1,500 were 
quantified and their distribution according to fold changes was determined. The log2 ratios 
distribution shows a constant incorporation of the label and the excellent quantitative 
precision of the experiment. A representative summary of key features of one SILAC analysis 
after silencing ABL2 and its log2 ratios distribution is shown here (Table 12 and Figure 51). 
 
High Confidence Quantitative Proteome: Size and Features siABL2/siControl 
Proteins (with unique peptides > 0 + nonunique >1) 1907 
Proteins (unique > 1, ratio counts >2) 1607 
Identified nonredundant peptides 26914 
Quantifiable peptide ratios 26881 
False positive rate (FPR) peptides 1% 
False positive rate (FPR) proteins 1% 
Minimal peptide length (aa) 7 
Up-regulated (Ratio significance B <0.05)  81 
Down-regulated (Ratio significance B < 0.05)  103 
Table 12. Key features from the SILAC analyse of siABL2/siControl. 
 
 
 
 
 
Figure 51 Log2 ratios distribution of siABL2 vs siControl from SILAC quantitative 
proteomics. 
Log2 normalized H/L ratios (siABL2/siControl) distribution with a standard deviation of 0.2294. 
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3.3.5 Global proteomic portrait of TKs signalling  
3.3.5.1 Proteomic alteration after knockdown of TKs 
A SILAC ratio representing the fold change of protein abundance after individually silencing 
65 TKs was compared and normalized to control group (siControl). After normalization, 
values of fold changes are all above 0, with value 1 showing that the expression levels of the 
specific proteins are not altered after TKs silencing. To acquire a portrait of the TKs-regulated 
proteome, the overall pattern of regulation is shown in the heatmap of quantified values. To 
improve resolution and concentrate the plot in the most significantly enriched region, 
approximately 1000 identified proteins were presented. For each knockdown (rows), the 
quantified values are plotted in red for down-regulated, white for no-change and non-
identified and blue for up-regulated proteins (Figure 52).  
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3.3.5.2 Identification of 10 distinctive clusters of TKs 
We then calculated and plotted pairwise distances based on the quantifications of TKs-
regulated proteomic signatures using centred Pearson correlation. In the correlation heatmap 
showing the distance metric between all kinases in our study, the smaller distances are 
displayed in purple corresponding to similar signatures, whereas the longer distances are in 
green (Figure 53). Based on the calculated distances, we performed hierarchical clustering of 
65 TKs using R's hclust function. The complete linkage method that aims to find similar 
clusters based on overall cluster measure was used. Ten distinctive clusters were obtained and 
Figure 52 Heatmap of quantified proteins after silencing TKs. 
The overall pattern of regulation is shown in the heatmap of quantified values. After normalized to 
siControl, values of fold changes are all above 0, with value 1 showing that the expression levels of 
the specific protein are not altered after silencing TKs. For each knockout (rows) the quantified 
value for an identified protein is plotted in red for down regulated proteins (below 1), white for 
non-differential and non-identified and blue for up-regulated proteins (above 1). The row labels 
indicate the knock out experiment and the colours correspond to the clusters described below. 
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the complete dendrogram is shown with the labels coloured for these clusters (Figure 54). 
The number of TKs in the clusters is plotted against the clusters and the colour coding of the 
clusters is used throughout to identify the analysis relevant to the corresponding clusters 
(Figure 55). 
We thus characterized 10 novel clusters according to the similarity of each TKs-regulated 
proteome. Cluster 1 contains 8 members: ABL1, AXL, EPHA2, EPHA4, LMTK2, MST1R, 
NTRK1, RYK; Cluster 2 is the biggest family with 15 members, including ABL2, BTK, 
CSF1R, CSK, DDR1, EPHA3, EPHA6, EPHA7, EPHB2, EPHB6, ERBB3, FES, FGFR1, 
FLT3, FYN; Cluster 3 comprises 3 members, which are EGFR, EPHA1, NTRK3; Cluster 4 
has 6 members, namely EPHB1, EPHB4, FGFR2, FLT1, FRK, INSR; Cluster 5 is the 
smallest family with only 2 members: EPHB3, ERBB2; Cluster 6 consists of 6 members, 
including ERBB4, LMTK3, MATK, ROR2, TYRO3, ZAP70; Cluster 7 contains 7 TKs, 
which are HCK, IGF1R, MERTK, MET, PDGFRB, PTK6, SRC; Cluster 8 comprises JAK1, 
LCK, PTK2; Cluster 9 is the second largest group with 12 TKs, consisting of JAK2, KDR, 
NTRK2, PTK2B, PTK7, RET, ROR1, SYK, TEC, TNK1, TYK2, YES1; Cluster 10 has 3 
members, which are LYN, STYK1, TNK2. 
 
 
 
 
 
Figure 53 Correlation heatmap of the distance metric between all TKs in this study. 
Pairwise distances were calculated and plotted according to the quantifications of TKs-regulated 
proteomic signatures using centred Pearson correlation. In the correlation heatmap showing the 
distance metric between all kinases in our study, the smaller distances are displayed in purple, 
whereas the longer distances are in green.  
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Figure 54 Hierarchical clustering of the 65 TKs expressed in MCF7. 
Hierarchical clustering of the 65 TKs was performed using R's hclust function. The complete 
linkage method which aims to identify similar clusters based on overall cluster measure was used. 
10 distinctive clusters were obtained and the complete dendrogram is shown with the labels 
coloured for these clusters. 
Figure 55 Number of TKs in each identified cluster. 
Number of TKs in the chosen clusters is plotted against the clusters. The colour coding of the 
clusters is used throughout to identify the analysis relevant to the corresponding clusters. 
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3.3.5.3 Characterization of a proteomic signature and functional portrait for each 
cluster 
We next investigated the TKs-regulated proteomic changes within each classified cluster in 
more detail to delineate the proteomic signature of each cluster. Using normalized fold 
changes of each protein quantified, we identified proteins significantly affected after 
knockdown of TKs in each cluster. Specifically, we used 0.7 as the cut-off for down 
regulation and 1.3 as the threshold value for up-regulation. All the subsequent analyses were 
conducted based on these cut-off values. To characterize the top hits within each cluster, we 
firstly filtered the proteins by requiring that they should be identified in at least 30% of the 
TKs in the cluster. We then selected up-regulated proteins that have a mean cluster value of 
more than 1.3 and down-regulated proteins with a mean value of less than 0.7. Counts of the 
most significantly regulated proteins in each cluster are shown in Figure 56. It appears that 
more proteins were up-regulated than down-regulated, which is an interesting discovery 
requiring further study (A full list of proteins significantly regulated in each cluster is not 
presented here due to its large size and limited space).  
 
 
 
 
Figure 56 Number of proteins significantly up or down-regulated in each identified cluster. 
For each cluster, we firstly filtered the proteins by requiring that they should be identified in 30% 
of the experiments in the cluster. We then selected the up-regulated proteins that have a mean 
cluster value of more than 1.3 (Red). Similarly, down-regulated proteins have a mean value of less 
than 0.7 (Blue). x-axis shows 10 different clusters and y-axis indicates the counts.  
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In the proteomic profiles of all 10 classified clusters, there is a unique signature of proteins 
and associated pathways regulated by the TKs/cluster, although a few proteins were 
recognized in more than one cluster. To gain insight on the biological processes distinctively 
modulated by each cluster, we identified the top GO categories to which the differential 
proteins in each cluster belong. We ran the GO analysis on cellular components (CC), 
biological processes (BP) and molecular function (MF). Overall, the identified proteins are 
scattered in a variety of cellular components, including extracellular matrix, cell membrane, 
cytoplasm, nuclei, synapse and other organelles. They are involved in a wide range of cellular 
activities such as immune system process, reproduction, metabolic process, growth, cell 
communication, development, cell cycle, transcription and cell adhesion, whose deregulation 
can contribute to oncogenesis (Figure 57).  
 
 
 
 
Figure 57  Functional portrait of protein-related biological processes in each cluster. 
A functional profile of top GO biological processes that the up- and downregulated proteins belong 
to is presented. x-axis shows the percentage of hits in each cluster that belong to a GO biological 
process term. The colour coding and the number for each cluster are indicated as above. 
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The GO analysis of molecular functions demonstrated a large percentage of proteins with 
binding, catalytic, structural and enzyme regulatory activities within each cluster (Figure 58). 
This supports the established role of TKs as important modulators in signal transduction via 
functional and physical protein-protein interactions. We thus sought to integrate the GO 
analyses with the STRING database to delineate the enrichment of functional protein-protein 
interaction networks in each cluster. First we identified GO terms that were overrepresented 
in the differential proteins of each cluster. We then depicted the STRING network for the 
differential proteins within an overrepresented GO term. Colour-coded networks were 
generated to distinguish up- (green) or down-regulation (red) of proteins. As expected, 
Figure 58  Functional portrait of protein-related molecular functions in each cluster. 
A functional profile of top GO molecular functions that the up- and downregulated proteins belong 
to is presented.  x-axis shows the percentage of hits in each cluster that belong to a GO molecular 
function term. The colour coding and the number for each cluster are indicated as above. 
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comprehensively integrated sub-networks emerged in a functional linked manner. The sub-
networks from each cluster uncovered an exclusive feature of functional connections 
contributed by the regulated proteomes and also highlighted the complexities in TKs-
modulated cellular signalling.  
Representatives of the most enriched functional networks within each cluster are displayed 
(Figure 59): in cluster 1, spliceosome assembly and anion transport; in cluster 2, RNA 
processing and catabolic process; in cluster 3, immune response; in cluster 4, metabolic 
process; vehicle-mediated transportation, endocytosis; in cluster 5, regulation of apoptotic 
signalling pathway and catabolic process; in cluster 6, cell adhesion; cellular component; cell 
cycle; in cluster 7, small molecule metabolic process, cellular component organization; in 
cluster 8, DNA replication initiation; organelle organization; in cluster 9, DNA-dependent 
transcription; cellular response to stress; in cluster 10, response to reactive oxygen species; 
cellular amino acid metabolic process. However, similarity is also present across some 
clusters, suggesting the fact that TKs in different clusters can regulate the same pathways and 
compensate for each other. For example, metabolic process is overrepresented in both cluster 
4 and 7, as these two clusters are indeed very close in distance in our dendrogram of 
hierarchical clustering (Figure 54). 
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Instead of structural homology, our classification highlights the similarity in biological 
function and signalling network shared among TKs in different clusters. Significantly, this 
clustering verifies current knowledge of the recognized functions of TKs, and also indicates 
the potential involvement of TKs in undocumented biological processes, which merits further 
investigation. One good example is manifested in cluster 8, which comprises JAK1, LCK, and 
PTK2. In this study, the bioinformatics analysis revealed a key characteristic of cluster 8 that 
is its contribution to DNA replication initiation and elongation during cell cycle through 
regulating mini-chromosome maintenance (MCM) proteins (MCM2-7) (Figure 59), whose 
deregulation is associated with genomic instability and cancer [395-398]. Our SILAC 
proteomic data showed that, upon silencing the three kinases in cluster 8, protein levels of all 
MCM members were decreased, which would subsequently lead to an inhibition in 
Figure 59 Representatives of defined functional networks in each classified TK cluster. 
The functional networks were generated using GO analysis combined with the STRING platform. 
Proteins in green are up-regulated, whereas red indicates down-regulation. Arrows show the 
interactions between connected proteins. Representative defined functional networks associated 
with their clusters are shown here. The colour coding and the number for each cluster are indicated 
as above. 
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uncontrolled DNA replication in cancer. Ultimately, silencing TKs can block sustained 
replicative immortality of tumour cells. This finding is consistent with the current perceptions 
of TKs, that they are oncogenic and good therapeutic targets in cancer. In addition to the role 
in DNA replication, several lines of evidence from previous literature have hinted at a 
putative network involving JAK1, LCK and PTK2 together with MCMs in regulating 
transcription. Specifically, MCM5 protein, as well as other members of the MCM family, has 
been shown to be essential for transcriptional activation mediated by STATs [399, 400], 
whose activity can be regulated by JAK1, PTK2 and LCK. Above all, the signalling network 
related to MCMs and STATs, which is coordinated by JAK1, PTK2 and LCK, can modulate 
DNA replication and transcription, as well as other processes including proliferation, 
apoptosis, migration and cell cycle [302].  
Collectively, we performed for the first time a global unbiased analysis of the TKs-regulated 
proteomes in breast cancer. Our study identified 10 new distinctive clusters and characterized 
a unique proteomic signature and functional portrait in each cluster. The biological relevance 
of our proteomic study in decoding the TKs-regulated proteomes supports the essential role of 
TKs in regulating all aspects of cellular activities, underlining TKs as good therapeutic targets 
in cancer. Further exploration of the data will surely improve our understanding of signalling 
in TKs and might identify potential targets for tumour treatments.   
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3.3.6 Discussion 
TKs play an essential role in regulating various intracellular signal-transduction pathways 
involving almost every aspect of cell activity, including proliferation, survival, differentiation, 
apoptosis, metabolism, angiogenesis, immune surveillance and motility [13]. Perturbation of 
TK signalling affects their kinase activities, which contributes to various human diseases, 
including multiple malignancies [13, 56]. Given their importance in cellular processes and 
their involvement in tumourigenesis, enormous efforts have been devoted to illustrate their 
structural characteristics, biological implications and associated signalling pathways. 
However, most of the early studies have focused on elucidating the function of individual 
member within the TK family in cancer. Less than half of the 90 TKs described so far have 
been thoroughly studied and in these cases a global functional analysis and understanding of 
their regulated-proteome is still lacking [197]. Therefore, a complete proteomic portrait and 
mapping of the TK signalling pathways could produce novel insights and a more complete 
functional picture albeit accompanied by certain technically challenges [401]. With the recent 
progress in global comparative quantitative proteomic analysis, a large-scale, robust and 
confident identification of biochemical networks implicated in cancer has become feasible 
[402]. 
SILAC represents one of the most popular quantitative methods that have been extensively 
employed in proteomic research [403]. Pioneering studies on genome-wide interaction in the 
yeast proteome demonstrated that protein-protein interactions can determine eukaryotic 
cellular machines [404, 405]. Functional mapping of protein interactions in the ERBB family 
also emphasized an important role of protein-protein interaction in contributing to the 
oncogenic potential of tyrosine kinases [406]. Global phosphoproteome analysis was applied 
to identify and quantify the dynamics in signalling networks upon EGF stimulus delineating 
an integrative picture of cellular regulation [407]. In addition, loss-of-function studies using 
genome-wide RNAi screens have been successfully developed to identify molecular targets as 
well as key regulators in biological processes in cancer [408-410].  
Here, we describe a global mapping of TKs-regulated proteome and their associated 
signalling using a high throughput RNAi screen combined with SILAC-based quantitative 
proteomics in breast cancer cells MCF7. First, the expression profile of all 90 known TKs was 
determined by RT-qPCR in MCF7 cells. Our results showed that 66 TKs with CT values 
ranging from 21.5 to 34.5 are present. A RNAi library targeting against 65 out of 66 identified 
TKs was verified to produce good knockdown efficiency by RT-qPCR and western blotting. 
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Subsequently, a quantitative proteomic analysis using SILAC was performed after silencing 
65 TKs individually in MCF7 to identify the TKs-regulated proteomes and to quantify their 
expression changes, thus elucidating their involvement in multiple signalling networks. 
Our SILAC proteomic analyses showed that around 2,000 proteins were identified in each 
dataset after silencing each of 65 TKs. Among these proteins, more than 1,500 were 
quantified and the distribution of their log2 ratios showed a constant incorporation of the label 
and an excellent quantitative precision. Silencing of individual TKs, despite their high 
homology in their kinase domains and phylogenetic relationship, results in a diverse 
proteomic landscape. However, some of the protein changes observed might be due to off-
target siRNA effects (Figure 52). This could be tested by separately analysing two (or more) 
siRNAs for some of the more interesting TKs. The massive amount of data allowed us to 
carry out further bioinformatics analysis to gain a broad picture of the TKs-modulated 
proteomes. A heatmap of quantified protein expression levels was generated to visualize the 
overall regulation pattern of the altered proteomic architecture upon silencing all 65 TKs. 
From the acquired heatmap, similarities in modulated proteomes after knockdown of TKs 
could be observed. We therefore calculated correlation distances based on the quantifications 
of TKs-regulated proteomic signatures and performed hierarchical clustering of 65 TKs 
accordingly. As a result, a new classification of TKs, which contains 10 distinctive clusters, 
was established. This new grouping based on similarity in regulated proteomes differs with 
the canonical classification of TKs in the human kinome, although in certain cases some TKs 
are categorized into the same group by the two clustering, such as EPHA2 and EPHA4, 
EPHB1 and EPHB4. The number of TKs in each of the 10 clusters varies, with 15 in the 
largest group and only 2 in the smallest one. This variance might indicate that some TKs in 
the bigger families tend to function together in regulating related signalling pathways, but 
other TKs in the smaller groups are likely to act alone with less connection to fellow TKs.  
We further explored the proteomic changes within each cluster more thoroughly and 
identified the most up- and down-regulated proteins in each group. Our analysis uncovered 
numerous significantly modulated proteins, among which more proteins were actually 
overexpressed than down-regulated. The mechanisms of these indirect downstream effects 
require further investigation. Importantly, from the detailed proteomic profiles of the 10 
classified clusters, a distinctive signature of regulated proteins in each group was perceived. 
To fully characterize the modulated proteomes and to gain insights on the biological 
functional portrait belonging to each cluster, GO categories enriched in each group were 
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compared between the clusters. In general, the identified proteins appear widely distributed 
across different cellular compartments, including the extracellular matrix, cell membrane, 
cytoplasm, nuclei, synapse and other organelles. Moreover, our analysis showed that these 
proteins are implicated in numerous biological processes, including immune system process, 
reproduction, metabolic process, cell growth, developmental process, cell cycle, transcription 
and cell adhesion, many of whose aberrant regulation can lead to tumourigenesis. 
Our results also verified the fundamental role of TKs as crucial players in cellular signalling 
relay through functional and physical interactions with their substrates, supported by the GO 
analysis revealing a prominent fraction of proteins with binding, catalytic, structural and 
enzyme regulatory activities within each cluster. Further combined analyses using GO 
biological processes together with the STRING database demonstrated a clear picture of 
comprehensively integrated functional protein-protein interaction networks assembled by the 
TKs-regulated proteomes. Unique features were uncovered for each cluster and are presented 
by defined TKs-regulated functional networks, for example immune response predominating 
in cluster 3, metabolic process in cluster 4, regulation of apoptosis in cluster 5 and DNA 
replication in cluster 8. Conversely, some clusters are featured by their involvement in similar 
biological processes as shown by the overrepresentation of metabolic processes in cluster 4 
and 7, pointing to the presence of functional similarity in certain clusters. This further 
supports the notion that TKs in different clusters can contribute to the activation of the same 
pathways and compensate for each other through cross-talk between cellular signalling.  
In strong support of the acquired TKs-regulated proteomic data, our classification underscores 
the similarity in biological function shared by TKs and signalling network coordinated by 
TKs within each unique cluster. Meanwhile, our clustering confirms the known role of TKs in 
cell activities and implies the participation of TKs in undocumented biological processes that 
await further investigation. For example, in cluster 8, functional analysis of the proteomes 
modulated by JAK1, LCK and PTK2 establishes the extensive regulation of processes related 
to DNA replication through governing MCM proteins (MCM2-7). MCM2-7 has been shown 
to play an important role in DNA replication initiation and elongation during cell cycle and 
perturbation of MCM proteins can result in genomic instability and cancer [395-398]. In our 
study, silencing of kinases in cluster 8 caused reduced protein levels of all MCM proteins. 
This might result in an inhibition of sustained replicative immortality of tumour cells, which 
supports current opinions that TKs are tumourigenic and can represent therapeutic targets in 
cancer. Furthermore, previous studies have documented that the MCM members are central 
179 
 
for transcriptional activation mediated by STATs [399, 400], which are downstream effectors 
of JAK1, PTK2 and LCK. A potential signalling network involving JAK1, LCK and PTK2 
with MCMs is therefore indicated to play a role in regulating transcription. So far, we 
highlight a functional protein-protein interaction coordinated by JAK1, LCK and PTK2, 
which is implicated in modulation of multiple cellular processes in oncogenesis.  
However, to fully interpret the massive amount of data from SILAC proteomics, further in 
vitro and in vivo studies are needed to investigate the most enriched functional networks in 
each cluster, particularly those associated to cancer development. Moreover, it would be of 
interest to characterize the TKs-regulated phospho-proteomic profile using a similar strategy 
by SILAC and RNAi screen as phosphorylating substrates is one of the most important 
activities executed by TKs. Notably, global proteomic analysis that can complement genomic 
studies can help us study cellular regulation such as protein interaction information, and can 
uncover novel mechanisms contributing to tumour progression. Indeed, one recent study has 
quantified phospho-proteomic changes in skin cancer development using in vivo SILAC 
revealing a deregulated PAK4-PKC/SRC network during mouse skin carcinogenesis [411]. 
Another group has presented the protein interaction landscape of the human CMGC kinase 
family discovering a set of protein interactions genetically linked to various human diseases, 
including cancer [412]. Surely, our research will benefit greatly from the global-scale 
proteomics integrated with functional analysis carried out by other groups in future. 
In summary, the experimental approach through combined used of SILAC and RNAi screen 
in this study shows high accuracies for the proteomics quantification and important 
advantages for interpretation of the results. The global comparative proteomic analysis 
identifies a unique classification of TKs, which is purely based on the similarity in their 
regulated proteomes, presenting a different angle to understand TKs. Our results provide new 
insights to the current understanding of TKs families, and particularly highlight the 
resemblance in biological processes shared among various members from different groups. 
This key characteristic strongly supports the fact that TKs can compensate for each other to 
maintain functional activity upon disruption and can contribute to the same downstream 
signalling in tumour initiation and development. Importantly, it offers an explanation to the 
observed resistance to the TKs-targeted inhibitors considering the plasticity and reciprocity 
between TKs. Our study clearly emphasizes a rationale for the development of a combination 
of multi-targeted TKs as antitumour drugs. Furthermore, we uncover various biochemical 
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networks that will help us further understand and elucidate the cross-talk between cellular 
signalling pathways implicated in breast cancer. 
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CHAPTER 4: 
DISCUSSION 
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4.1 The role of KSR1 in breast cancer  
KSR1, initially described as a novel protein kinase in the Ras-Raf pathway [107-109], is an 
essential scaffolding protein that co-ordinates the assembly of the MAPK complex, consisting 
of MEK and ERK [144, 145, 413]. Mammalian KSR1 has been extensively referred to as a 
pseudokinase, due to the fact that it lacks a key catalytic residue in its kinase domain [43]. 
However, a great body of evidence suggests that KSR1 functions as an active kinase as well 
as a scaffold protein. 
Given the role of KSR1 in the Ras-Raf-MAPKs cascade, intensive efforts have focused on 
Ras-dependent cancers. For instance, recent studies reported that KSR1 regulates the 
proliferative and oncogenic potential of cells and inhibition of KSR1 abrogates Ras-dependent 
pancreatic cancer [127, 166]. Similarly, KSR1 is required for tumour formation in a skin 
cancer mouse model [162]. Previous studies indicated that KSR1 is important in breast cancer 
metastasis and depletion of KSR1 reduced tumour formation in Ras-dependent mammary 
tissue in mice [125, 151]. As Ras mutations are rare in breast cancer, the involvement of 
KSR1 may not depend on the canonical Ras-Raf-MAPKs pathway [378]. Moreover, its 
biologic function in this setting needs further exploration, as do its major partner proteins and 
pathways including those connected to p53 and BRCA1, which are implicated here. 
4.1.1 KSR1 in p53 regulation 
The p53 tumour suppressor is a well-established central player in cell growth, cell cycle arrest, 
apoptosis and cellular response to genotoxic stress [414, 415]. Its transcriptional activity is 
highly regulated by post-transcriptional modifications including acetylation [372, 373]. 
Previous data has demonstrated that DBC1 directly interacts and negatively regulates the 
deacetylase SIRT1 resulting in an increase of p53 acetylation [370, 371]. Furthermore, 
phosphorylation of DBC1 is necessary for its interaction with SIRT1 while phosphorylated 
DBC1 inhibits the activity of SIRT1 in response to DNA damage [376, 377].  
4.1.1.1 Summary of findings 
In the present study, we reveal a KSR1-regulated phospho-proteome profile in breast cancer 
cells using a comparable quantitative proteomic approach, SILAC. Numerous new KSR1-
regulated proteins and its associated pathways were identified outlining a comprehensive 
picture of KSR1-invloved signalling networks. Bioinformatic analysis indicated a role of 
KSR1 in various biological processes, including cell cycle, metabolism and apoptosis. A 
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handful of the characterized phospho-proteins, such as APRIN [364, 365], ARHGAP35 [366],  
Hsp27 [367, 368], have been shown to play an important role in breast cancer initiation, 
development and migration. Most interestingly, the KSR1-regulated phospho-proteomic 
analysis has identified phospho-DBC1, which is a connection of KSR1 to the modulation of 
p53 transcriptional activity. 
Subsequently, we investigated the effect of KSR1 on p53 transcriptional activity, as well as 
the potential mechanism on KSR1-related regulation of p53 transcriptional activity, including 
through p53 acetylation, which is indispensable for p53 activity. Using different p53-
dependent gene promoter constructs, luciferase assays demonstrated that p53 transcriptional 
activity is inhibited after KSR1 overexpression and is increased upon depletion of KSR1. We 
then revealed that KSR1 overexpression results in a reduction of p53 acetylation and 
knockdown of KSR1 causes an increase in p53 acetylation. Mechanistic studies showed that 
KSR1 overexpression reduces the phosphorylation levels of DBC1 and silencing increases 
phosphorylated DBC1. Moreover, Co-IP results demonstrated that overexpression of KSR1 
diminishes the SIRT1-DBC1 interaction, which allows SIRT1 to interact with p53, thus 
reducing p53 acetylation. These findings highlight the action of KSR1 on p53 activation is 
through DBC1. 
4.1.1.2 Future direction 
As we have shown that KSR1 might regulate p53 activity through phosphorylation of DBC1, 
future work will focus on addressing the mechanism of KSR1 on regulating DBC1 
phosphorylation. To do so, it would be necessary to study: 
 whether KSR1 can directly interact with DBC1, therefore somehow inhibiting the 
phosphorylation of DBC1 by associated kinases;  
 whether the action of KSR1 on DBC1 phosphorylation is through ATM/ATR kinases, 
as one group recently has demonstrated that ATM/ATR is competent to directly 
phosphorylate DBC1 on Thr454 upon DNA damage, inducing the detachment of the 
SIRT1-p53 complex and ultimately an increase in p53 acetylation [377];  
 another alternative mechanism through PKA and AMP-activated protein kinase, since 
it has been revealed that these kinases can trigger the separation of SIRT1 from its 
endogenous inhibitor DBC1, hence affecting downstream effects [379];  
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4.1.1.3 Conclusion 
In conclusion, we present the first SILAC analyse of KSR1-modulated phospho-proteome 
establishing its involvement in multiple important cellular processes in breast cancer. 
Furthermore, we identify a role of KSR1 in the regulation of p53 transactional activity by 
reducing p53 acetylation via the modulation of DBC1-SIRT1 interaction. 
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4.1.2 KSR1 in BRCA1 regulation 
BRCA1 tumour suppressor gene mutations contribute to a proportion of hereditary breast and 
ovarian cancers [416]. BRCA1 forms a heterodimer with BARD1 protein, which was 
discovered in a yeast two-hybrid screen as a binding partner of BRCA1 [391]. Subsequent 
work revealed that BARD1 interacts with and stabilises BRCA1 by inhibiting its 
ubiquitination [385, 386]. This heterodimer has ubiquitin ligase activity and regulates 
numerous cellular functions including DNA repair, apoptosis, cell cycle progression and gene 
transcription, essentially contributing to genomic stability and tumour suppression [417].  
4.1.2.1 Summary of findings 
In this work, using tumour tissue microarrays in a large patient cohort (n>1000) with 20 years 
follow-up, we determined that breast cancer patients with high KSR1 displayed better disease 
free- and overall survival, results also supported by Oncomine analyses, microarray data 
(n=2878) and genomic data from paired tumour and cfDNA samples revealing loss of 
heterozygosity. KSR1 expression is associated with high BRCA1, high BARD1 and Chk1 
levels in breast cancer specimen. In paired normal/breast cancer tissues, higher KSR1 was 
detected in normal tissues, whereas KSR1 is ubiquitously expressed in a panel of breast 
cancer cell lines. Phospho-profiling of major components of the canonical Ras-Raf-MAPKs 
pathway, including Raf, MEK and ERK, showed no significant changes after KSR1 
overexpression or silencing. 
Furthermore, breast cancer cells overexpressing KSR1 formed fewer and smaller size colonies 
compared to the parental ones. Likewise, the growth of xenograft tumours overexpressing 
KSR1 was significantly slower than the control group. Mechanistically, it appears that the 
tumour suppressive action of KSR1 is BRCA1-dependent shown by in vitro 3D-matrigel and 
soft-agar assays. Consistent with the positive correlation between KSR1 and BRCA1 in 
clinical samples, our in vitro results showed KSR1 overexpression increases BRCA1 protein 
levels through decreasing BRCA1 ubiquitination. Additionally, based on the fact that BARD1 
has been previously reported to form a heterodimer with BRCA1 thereby stabilising it by 
reducing its ubiquitination [386], we then assessed the effect of KSR1 on BARD1 and 
whether the action of KSR1 on BRCA1 is through BARD1. We revealed that KSR1 has no 
effect on the mRNA levels of BARD1 but up-regulates BARD1 protein abundance, and the 
BRCA1-BARD1 interaction is increased upon KSR1 overexpression. Importantly, the effect 
of KSR1 on BRCA1 is partly through BARD1, as KSR1 overexpression increases BRCA1 
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less strongly when BARD1 is depleted. These findings integrate KSR1 into a complicated 
signalling network involving BRCA1-BARD1 complex in breast cancer. 
4.1.2.2 Future direction 
In light of the results presented in this work, numerous issues remain to be addressed to fully 
understand the role of KSR1 in regulating BRCA1 and the associated tumour suppressive 
effect.  
We have established that high KSR1 expression correlates with better overall and disease free 
survival in European patients. Thus, whether the associations between KSR1 expression and 
clinical outcomes are the same in Asian patients merits further exploration. It would be 
necessary to determine this in other cohorts, such as a Singapore cohort from our 
collaborators [348].  
We have also shown that the effect of KSR1 on BRCA1 is partially mediated via BARD1. 
Therefore, other alternative mechanisms regarding KSR1‟s effect on BRCA1 need to be 
investigated. Moreover, our results have demonstrated that KSR1 increases protein levels of 
BARD1 and directly interacts with BARD1. However, the detailed mechanism underlying the 
action of KSR1 on BARD1 is still not clear. It would be essential to assess: 
 whether KSR1 has any effect on the cell cycle proteins CDK2 and cyclin E1, as it has 
been shown that overexpression of CDK2 and cyclin E1 can reduce the abundance of 
BRCA1 and BARD1, and enhance their export to the cytoplasm [418]; 
 the mechanism of how KSR1 regulates BARD1 protein expression. Furthermore, as 
phosphorylation of BARD1 is critical for the function of BRCA1/BARD1 complex 
[419], the effect of KSR1 on BARD1 phosphorylation is worthwhile examining. 
In addition, our work has reported a positive correlation between KSR1 and Chk1 in patient 
tissues. As previously shown that BRCA1 regulates Chk1, Wee1 and 14-3-3  proteins to 
control the G2/M checkpoint [420], it would be interesting to study whether KSR1 contributes 
to cell cycle control through BRCA1 and Chk1. 
Finally, we have revealed that KSR1 decreases p53 activity, and at the same time it increases 
BRCA1 expression. Based on the literature, it seems that BRCA1 can compensate for loss of 
p53 [393]. It would be necessary to explore:  
 the effect of KSR1 on BRCA1 transcriptional activity by a luciferase assay using 
BRCA1-dependent gene constructs; 
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 whether KSR1 cooperates with DBC1 to affect BRCA1 activity and the BRCA1-p53 
signalling, given that DBC1 is a well-studied positive regulator of p53 as well as a 
repressor for BRCA1 [389, 392]. 
4.1.2.3 Conclusion 
Collectively, our study shows that KSR1 may be a valuable prognostic marker in breast 
cancer. The mechanistic findings demonstrate that KSR1 regulates breast cancer development 
through the BRCA1-BARD1 complex, and consequently affects the in vitro and in vivo 
oncogenic potential of breast cancer cells, highlighting a new role of KSR1 in tumourigenesis. 
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4.2 Proteomic analysis of TKs signalling in breast cancer 
TKs are important regulators in multiple intracellular pathways related to most aspects of cell 
activities, including proliferation, survival, differentiation, apoptosis, metabolism and motility 
[13]. Deregulation of TK signalling leads to alteration of their kinase activity, which 
contributes to the development and progression of human diseases, particularly cancer [13, 
56]. Considering their pivotal role in cellular signalling and essential involvement in 
oncogenesis, extensive studies on addressing the structural characteristics and biological 
functions have focused on certain members of the TK family, such as the EGFR subgroup. 
Additionally, in some cases, TKs haven become an important group of drug targets and 
therapies against TKs have improved the clinical outcome of patients in the past decades [56, 
218].  However, up to now, still approximately half of the 90 TKs are poorly investigated and 
a global functional analysis to elucidate their regulated-proteome and related signalling 
processes is very much needed [197]. A global mapping of the TKs-regulated proteomes with 
an integrated functional exploration will shed new light on our understanding of this 
important family in the human kinome. 
4.2.1 Summary of findings 
In this work, we established an approach using a high throughput RNAi screen combined with 
SILAC-based quantitative proteomics to decode the TKs-regulated proteome and their 
associated signalling in MCF7 breast cancer cells. We first determined the expression profile 
of all 90 TKs by RT-qPCR and our results revealed that 66 TKs are expressed in MCF7. 
Among the 66 identified TKs, we were able to successfully silence 65 of them verified by RT-
qPCR showing a decrease of at least 70% at mRNA levels. A good silencing efficacy was 
also confirmed by western blotting on several of these TKs. Next, a SILAC-based quantitative 
proteomic analysis to accurately identify the TKs-regulated proteomes and to quantify their 
expression alterations was carried out upon silencing 65 TKs individually in MCF7. Our 
SILAC proteomic analyses identified 2,000 proteins modulated and quantified 1,500 out of 
them after each individual silencing of the 65 TKs. Intriguingly, in spite of structural 
homology, silencing of each TKs results in diverse proteomic landscapes and the massive data 
acquired from SILAC-based analysis enabled further bioinformatics exploration to obtain a 
fuller picture of TKs-modulated proteomes and their associated functional networks.  
We then produced a heatmap of quantified protein expression levels to visualize the overall 
regulation pattern of altered proteomic portrait upon silencing all 65 TKs. As presented in the 
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heatmap, similarity was observed in the altered expression levels of the proteomes leading to 
hierarchical clustering of the 65 TKs. Subsequently, we characterized a new classification of 
TKs arising from the calculated correlation distances, which represent the similarity in 
regulated proteomes. A total of 10 distinctive clusters were established and the analysis 
revealed that the number of TKs within each cluster varies, with 15 in the largest group and 2 
in the smallest one. Although our clustering method is completely different from the way used 
for the well-established TKs classification, which is based on sequence relatedness of 
catalytic domains, some TKs are grouped into a same cluster by the two classifications, such 
as EPHA2 and EPHA4, EPHB1 and EPHB4. This supports a degree of consistency between 
the two approaches of clustering TKs, but also indicates that some TKs probably should not 
be classified together in the first place, considering the marked differences in regulated 
proteomes and their associated biological function. 
Further analysis identified the most up- and down-regulated proteins in the 10 classified 
clusters, which showed a distinctive signature of regulated proteins in each group. In-depth 
GO analysis was performed to elucidate the biological functional portrait related to each 
cluster. Consistent to what has already known about TKs-modulated molecules, our results 
demonstrated that the proteins regulated by TKs are distributed into a variety of cellular 
compartments, including the extracellular matrix, cell membrane, cytoplasm, nucleus, synapse 
and other organelles. Moreover, these proteins are important in a wide range of biological 
processes, including immune system process, reproduction, metabolic process, cell growth, 
developmental process, cell cycle and cell adhesion, whose perturbation can contribute to 
cancer initiation and development. We also discovered a major population of proteins with 
binding, catalytic, structural and enzyme regulatory activities in each cluster highlighting the 
influential contribution of TKs in coordinating signal transduction through phosphorylation 
and direct interaction. We then integrated GO analysis with the STRING database to evaluate 
the functional networks assembled by the TKs-regulated proteomes. Distinctive features 
displayed by specific functional networks were uncovered in each cluster. Interestingly, in 
some cases, same biological processes were shown to be enriched in different clusters, such as 
metabolic processes in cluster 4 and 7, possibly indicating a functional compensation through 
cross-talk by TKs from different clusters. Finally, our classification highlights the similarity 
in TKs-regulated biological function and their associated signalling network within each 
cluster, and supports their recognized role in a wide range of cellular processes, while hinting 
at their participation in undetermined signalling pathways that require further exploration. 
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4.2.2 Future direction 
In this study, the SILAC-based proteomics has accurately identified and quantified a 
substantial part of the proteome upon silencing 65 TKs in breast cancer. Following 
bioinformatics analysis has identified 10 unique clusters and illustrated multiple defined 
functional networks within each cluster. Up to now, all the initial analyses have been 
completed, and future work will aim to:  
 validate altered expression levels of specific candidates, such as the MCM proteins in 
cluster 8;  
 investigate the oncogenic potential of the identified TKs-regulated signalling network 
in breast cancer, including the JAK1, LCK and PTK2 associated-MCMs cascade; 
 determine the clinical significance of the established clusters in breast cancer patients 
using online free-access database such as KM Plotter and Oncomine platform. 
4.2.3 Conclusion 
In conclusion, we performed a global unbiased SILAC-based proteomic analysis to identify 
the TKs-regulated proteomes in breast cancer. More than a thousand proteins were detected 
and quantified, showing diverse landscapes of modulated proteins upon silencing 65 
individual TKs. Based on the similarity in their proteomic changes, we presented 10 new 
distinctive clusters from the 65 TKs and ultimately characterized a unique proteomic 
signature and functional portrait in each cluster. Our defined functional analysis of the TKs-
regulated proteomes supports a fundamental involvement of TKs in every aspect of key 
biological processes. Our established database in this study is a useful resource for the initial 
inspection of the function of your TK of interest and its associated signalling networks. 
Furthermore, it provides researchers with many potential targets that make up cellular 
processes of known importance in breast cancer. 
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Drug targetsKinases play a critical role in regulating many cellular functions including development, differentiation and
proliferation. To date, over 518 proteins with kinase activity, comprising ~2–3% of total cellular proteins,
have been identiﬁed from within the human kinome. Interestingly, approximately 10% of kinases are
categorised as pseudokinases since they lack one or more conserved catalytic residues within their kinase
domain and were originally thought to have no enzymatic activity. Recently, there has been strong evidence
to suggest that some pseudokinsases can not only function as scaffold proteins, but may also possess kinase
activity leading to modulation of cell signalling pathways. Altered activity of these pseudokinases can result
in impaired cellular function, particularly in malignancies. In this review we are discussing recent evidence
that apart from a scaffolding role, pseudokinases also orchestrate cellular processes as active kinases per se
in signalling pathways of malignant cells.
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The human kinome accounts for approximately 2% of all genes
[1,2] and protein kinases are essential for regulating many cellular
functions in both the physiological and pathological context. Kinases
have conserved residues necessary for their catalytic activity, by
transferring phosphate groups from adenosine-5′-triphosphate
(ATP) to speciﬁc serine, threonine or tyrosine residue in target
proteins. Phosphorylation leads to activation or inhibition,
depending on the target substrate, usually resulting in downstream
effects involving other proteins. However nearly 10% of known
kinases lack one or more of these residues and are classiﬁed as
pseudokinases therefore becoming catalytically inactive or lacking
necessary binding domains. Pseudokinases are randomly distributed
on the phylogenetic tree of kinases suggesting that they may have
evolved from diverse active kinases. The initial belief that
pseudokinases are vestigial remnants of active kinases that primarily
act as scaffold proteins is changing. Some of them demonstrate
kinase activity while others play critical roles as activators of their
speciﬁc targets. Aberrant regulation of pseudokinases is implicated
in the cause and development of a variety of diseases. In this review,
we identify which pseudokinases have been associated with cancer
and discuss recent important advances in uncovering their potential
roles as therapeutic targets.2. Pseudokinases: evolutionary counterparts of protein kinases?
The term “pseudokinase” originated from the concept that these
protein kinases lack one or more conserved residues that are crucial
for enzymatic activities compared to classic protein kinases suchFig. 1. Multiple sequence alignment of pseudokinases comparing the three conserved mot
enzymatic activity. Highlighted in black are the indicated missing motifs for each pseudokias protein kinase A (PKA), and therefore they are not be able to phos-
phorylate different substrates. Based on sequence analysis, Manning
and colleagues [1] showed that approximately 50 protein kinases in
the human kinome are classiﬁed as pseudokinases, which require
the intact three motifs: i) VAIK (Val–Ala–Ile–Lys), ii) HRD (His–Arg–
Asp) and iii) DFG (Asp–Phe–Gly) for ATP and peptide binding
(Fig. 1) (reviewed by Boudeau and Alessi, Zeqiraj and Aalten [3–5]).
Interestingly, it appears that these pseudokinases are widely located
in every branch in the phylogenetic tree, which implies from evolu-
tionary perspective that they might function similarly to active pro-
tein kinases. Recent structural investigations have provided further
evidence to support this hypothesis. For example, the WNK kinase
lacking the key lysine (K) residue in the VAIK motif, within the cata-
lytic subdomain II was shown that it can function actively by using
another neighbouring lysine in the β strand 2 domain [6,7]. Ca2+/
calmodulin-dependent serine protein kinase (CASK) is another good
example where despite the absence of key enzymatic residues in
the DFG motif, which is indispensable for Mg2+ binding, it can still
implement itself in a constitutively active conformation, capable of
autophosphorylation and for phosphorylating speciﬁc substrate such
as the synaptic protein neurexin-1. Unlike other kinases that require
Mg2+ for their function, CASK works independently of Mg2+, which
surprisingly inhibits its catalytic activity [8,9]. The elucidation of the
crystal structure of the receptor tyrosine protein kinase HER3
(erbB3) challenged the concept that it was an inactive pseudokinase,
since it was lacking the intact conserved motif HRD, which is required
for phosphorylation. In fact, in order to promote phosphate transfer,
HER3 can adopt itself in an active conformation through a unique
mechanism by its kinase-defective domain [10,11].
No matter what functions these pseudokinases perform either as
scaffold proteins, allosteric regulators or active kinases, emergingifs (VAIK, HRD and DFG), located within the catalytic domain, which are essential for
nase.
Table 1
Catalytic activity and functions of pseudokinases involved in cancer.
Pseudokinases Kinase
family
Activity Substrates Function Types of cancer References
CASK CAMK Yes Neurexin-1 Not known Oesophageal, acute lymphobastic
leukaemia, squamous cell carcinomas
[91–93]
CCK4 TK Not known N/A Promotes tumour proliferation
and invasion
Colon, melanoma and AML [208,209,211,213]
EphB6 TK Not known N/A Suppresses tumour invasion
and metastasis
Neuroblastoma, non-small cell lung,
melanoma and breast
[225–232] and reviewed
in [233]
EphA10 TK Not known N/A Potentially promotes tumour
metastasis
Prostate and breast [234,235] and reviewed
in [233]
HER3 TK Yes N/A Promotes tumour proliferation,
invasion and metastasis
Breast, non-small cell lung, melanoma,
ovarian and colorectal
[53,54,68,69,73,76,77,79,80]
and reviewed in [67]
ILK TKL Controversial β1 Integrin, AKT,
MLC, GSK3β and
others
Promotes/suppresses tumour
proliferation, invasion and
migration
Prostate, colon, gastric, ovarian,
melanoma, breast and rhabdomyosarcoma
Reviewed in [95,96,99,119,236]
KSR1 TKL Controversial Raf, MEK, ERK Promote tumour proliferation Breast, pancreatic and non-small cell lung [31–34]
STRAD α STE Not known N/A Indirect tumour suppressor
activity
Breast, colon, pancreatic, stomach, ovary [157–159]
Trb1 CAMK Not known N/A Induces leukemogenesis AML [167–170]
Trb2 CAMK Not known N/A Induces leukemogenesis and
promotes tumour proliferation
AML, melanoma, non-small cell lung [167,171,172,175,176]
Trb3 CAMK Not known N/A Promotes tumour proliferation,
invasion and migration
Colon, oesophageal, breast and lung [177–179]
TRRAP Atypical
protein
kinase
Not known N/A Involved in tumorigenesis and cell
proliferation
Breast, malignant melanoma, glioblastoma
multiforme, pancreatic
[199,201,202,206,207]
VRK3 CK1 Not known N/A Not known Colon [224]
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entiation, apoptosis and metastasis (Table 1).
3. Pseudokinases with activity
3.1. KSR1
Kinase suppressor of ras1 (KSR1) was ﬁrst identiﬁed more than
15 years ago as a novel protein kinase functioning either downstream
of Ras or on a parallel pathway to Raf in Drosophila and Caenorhabditis
elegans by genetic screenings, showing that defects in KSR1 inhibited
activated Ras, but did not affect the pathways induced by activated
Raf [12,13]. KSR1 was demonstrated to be able to translocate from
the cytoplasm to the plasma membrane to form a complex involving
Raf-1, MEK1 and 14-3-3 in the presence of activated Ras. In turn, this
led to the activation of Raf-1 without requiring kinase activity of
KSR1, which indicated the central role as a modulator in the
mitogen-activated protein (MAP) kinase pathway [14–16]. KSR1
contains ﬁve conserved areas named CA1–CA5. CA1 is located in the
N-terminus and is unique to KSR1; CA2 is a proline-rich domain
with unidentiﬁed functions; CA3 is a cysteine-rich sequence
mediating membrane recruitment of KSR1 [16]; CA4 is a serine/
threonine-rich region with an FXFP motif that binds ERK [14,17];
CA5 is kinase-like domain lacking the conserved lysine residue in
subdomain II that is required for phosphorylation [18,19].
3.1.1. Dual activity of KSR1: scaffold protein and protein kinase
Several groups showed that murine KSR1 (mKSR1) can bind to
MEK-1/2 and ERK but not Ras or Raf, and that mKSR1 in fact functions
as a scaffold protein suppressing the activity of MAPKs after different
stimulations such as growth factors and activated Ras [20–23].
Phosphorylation sites at Ser297 and Ser392 of KSR1 were shown to
regulate binding to 14-3-3 proteins in serum-free conditions and
the function of KSR1 depended on its expression levels. More specif-
ically, at low levels, KSR1 appeared to increase Ras-induced activity,
but inhibited the Ras pathway when expressed at higher levels [24].
This was conﬁrmed in KSR1(−/−) mouse embryo ﬁbroblasts, expres-
sing a range of KSR1 concentrations. With low KSR1 expression, ERK
activation was enhanced with a concomitant increase in cell growthand elevated RasV12 oncogenic transformation. Conversely with
higher KSR1expression all these activities were signiﬁcantly reduced
[25,26].
The structural similarity between KSR1 and the Raf kinase family
and its implications in cancer generated much interest in trying to
elucidate its potential kinase activity. TNFα and ceramide were ﬁrstly
reported to be capable of inducing KSR1 autophosphorylation and
phosphorylating Raf-1 at Thr269 both in vitro and in vivo [20]. The
same group showed that epidermal growth factor (EGF) acts as an
activator to increase the kinase activity of KSR1 in a two-stage
in vitro assay. Phosphorylation was only possible with an intact kinase
domain, as deletions at the C- and N-terminal domains rendered the
domain inactive. Meanwhile, its kinase ability did not rely on binding
to other kinases, such as MEK [21,22,27]. Furthermore, threonine
phosphorylation of Raf-1 by tumour necrosis factor α (TNFα) activa-
tion is regulated by KSR1. When mouse colon cells were transfected
to express a dominant-negative kinase-inactive KSR1, TNFα treat-
ment reduced survival and increased apoptosis, supporting the essen-
tial role of KSR1 in cell survival pathways in intestinal epithelial cells
[23,27,28].
Further insights on the function of KSR1 other than its kinase
activity have been gained, particularly as a scaffold protein in the
Ras–Raf–MAPKs signalling pathways. In quiescent cells, phosphoryla-
tion of KSR1 at Ser297 and Ser392 by Cdc25C-associated kinase
1 (C-TAK1) is required for KSR1 to remain in the cytoplasm through
binding to 14-3-3. Upon growth factor stimulation, KSR1 is depho-
sphorylated by protein phosphatase 2A (PP2A) resulting in the
release of 14-3-3. This exposes the CA3 domain of KSR1 leading to
cell membrane translocation, where a complex is formed with acti-
vated Ras, Raf-1 and MEK facilitating downstream MAPKs signalling
(Fig. 2) [24,29,30].
3.1.2. KSR1 in cancers: a potential therapeutic target?
Studies are beginning to elucidate the function of KSR1 regarding
the pivotal role of Ras–Raf–MAPKs module in cancer. In a Ras-
dependent breast cancer model, tumour inhibition was observed in
KSR−/− mice where KSR1 deﬁciency led to the loss of MEK and ERK
complexes [31]. Similarly, in a skin cancer mouse model Tg.AC
(v-Ha-ras mutated at codons 12 and 59), KSR1 was necessary for
Fig. 2. Schematic model for the function of KSR1. In inactive cells, phosphorylation of KSR1 at Ser297 and Ser392 by C-TAK1 allows it binding to 14-3-3, which maintains KSR1 in the
cytoplasm. KSR1 also constitutively interacts with MEK and ERK. Upon stimulation by growth factors such as EGF, KSR1 is dephosphorylated by PP2A at S392 resulting in the release
of 14-3-3 and exposure of the CA3 domain on KSR1. This leads to cell membrane translocation where KSR1 forms an active complex with phosphorylated Raf, MEK and ERK. The
activated ERK can in turn phosphorylate various substrates in the cytoplasm and nucleus regulating proliferation, cell cycle and apoptosis.
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therapeutic target in Ras-related cancers [32]. Continuous infusion
of KSR1 phosphorothioate antisense oligonucleotides into human
PANC-1 pancreatic and A549 non-small-cell lung carcinoma xeno-
grafts in nude mice produced signiﬁcant PANC-1 tumour shrinkage
and induced inhibition of A549 lung metastasis [33,34]. Furthermore,
KSR1 downregulation using antisense oligonucleotide sensitised
ionising radiation treatment in epidermal growth factor receptor
(EGFR)-dependent A431 and oncogenic K-Ras-driven A549 human
lung carcinomas in vivo [35]. Overexpression of wild-type KSR1 into
MCF-7 breast cancer cells increased cisplatin-related ERK activity
and enhanced cisplatin sensitivity [36]. A follow-up screen using a
collection of cancer cell lines and the NCI60 anticancer drugs also con-
ﬁrmed a correlation between KSR1 expression and drug sensitivity
[37].
KSR1 was also shown to interact with metastasis suppressor
Nm23-H1 in breast cancer cells. Nm23-H1 can phosphorylate KSR1
and promote its degradation resulting in decreased activities in the
ERK pathway [38,39]. In addition, KSR1 was necessary for cells to
recover from DNA damage in response to various agents such as
mitomycin C [40]. Recently, by performing a whole human kinome
screening using RNA interference, we identiﬁed that KSR1 is a novel
regulator of oestrogen receptor α (ERα) function. Knockdown of
KSR1 resulted in downregulation of known ERα regulated genes
such as TFF1 suggesting that KSR1 might play an important role in
ERα-dependent breast cancer [41].
3.1.3. Recent advances on KSR1 functions
There is still some argument whether KSR1 is an active kinase or
just a scaffold protein functioning in the Ras–Raf–MAPKs pathway.
Recent evidence suggests that KSR1 may possess dual activity. By
using puriﬁed and recombinant wild-type KSR1, two different groups
demonstrated that wild-type KSR1 was capable of directly phosphor-
ylating Raf-1 and MEK1, whereas mutated KSR1 was without activity
[42,43]. A further study on the catalytic activity of KSR1 was reported
by Hu et al. This group generated a mutant KSR1 construct (A587F) by
adding a bulky phenylalanine at the ATP binding pocket of KSR1 to
impair ATP binding. This mutant still maintained the closed active
conformation required for scaffold function allowing it to interact
with C-Raf and MEK constitutively. However, only the wild-typeKSR1 was able to phosphorylate MEK induced by C-Raf, which strong-
ly indicates that enzymatic activity of KSR1 might be speciﬁc to
certain substrates in a deﬁned context [44].
Other studies have supported the belief that KSR1 can directly
form a side-to-side dimer with Raf to regulate the activation of Raf
without the need of its catalytic activity. A potential dimer formation
was suggested based on crystal structure analysis of the conserved
residues within KSR1 and Raf. In addition, Raf activation was
impaired by residue mutations in the dimer interface of KSR1 [45].
Interestingly, McKay et al. found that some Raf inhibitors were prefer-
entially capable of inducing KSR1/B-Raf dimerisation compared to
C-Raf/B-Raf dimerisation, on the condition that they all had a com-
plete dimer interface. Furthermore, KSR1/B-Raf interaction abrogated
the activation of the ERK cascade pathway [46].
Collectively, these ﬁndings re-emphasise the crucial role of
KSR1 in modulating Ras–Raf–MAPKs signalling functioning both as
protein kinase and scaffolding protein.
3.2. HER3
HER3 belongs to the human epidermal growth factor receptor
family of receptor tyrosine kinases, which also include EGFR, HER2
and HER4 isoforms. A number of growth factors bind extracellularly
to these receptors resulting in the formation of dimmers leading to
the activation of downstream signalling pathways resulting in cell
proliferation and differentiation, whereas, abnormal activation
contributes to pathogenesis of many cancers [47,48]. Among these
diverse homodimer and heterodimer complexes, HER2–HER3 is
shown to be the most active form [49]. The uniqueness of HER3 is
that it has long been shown to be an inactive kinase because of
amino acid substitutions within the conserved kinase domain com-
pared to the other members in this family. Thus, HER3 can function
allosterically as a catalytic partner in order to activate the other
family members [50,51].
A recent study showed that the kinase domain of HER3 was able to
bind ATP and to trans-autophosphorylate its intracellular region by
forming a heterodimer between the intact intracellular kinase
domain and the kinase domain [10]. However, compared to other
EGFR family members, the kinase activity of HER3 was signiﬁcantly
decreased and no phosphorylation could be demonstrated when
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demonstrated that although HER3 lacked several key conserved
residues, it might employ a distinctive mechanism to transfer the
phosphate group by using the existing kinase-like conformation
instead of the catalytic base aspartate [10,11]. A further study sug-
gested that although the kinase activity of HER3 is far lower than
the other family members, it may still be adequate to activate
phosphatidylinositol-3-OH kinase (PI3K)/AKT pathway and contrib-
ute to the resistance of tyrosine kinase inhibitors (TKIs) [52]. Consid-
ering that HER3 may play a critical role in overcoming the resistance
to EGFR or HER2 inhibitors in cancers, more detailed functional and
mechanistic studies are needed to focus on the interaction between
family members and identiﬁcation of unique substrates.
3.2.1. HER3 and cancer
All members of the HER family are believed to be involved in
human cancers, including breast, skin, colon, lung and brain. Al-
though HER3 has not been proved to be an independent oncogene,
the allosteric function of HER3 as a dimer partner is widely implicated
in tumour development.
Much interest was generated after the HER3 gene was cloned and
its expression was detected in primary breast carcinomas. Its role in
breast cancer has been intensively studied [53,54]. The association be-
tween HER2 and HER3 expression in mammary carcinoma cells after
heregulin activation indicated that cancerous transformation required
them to function together [55,56]. Elevated HER2 expression and ac-
tivity were not sufﬁcient to drive tumour cell proliferation, without
forming a heterodimer with HER3 [57]. Consistent with this ﬁnding,
knockdown of HER3 inhibited HER2 tyrosine phosphorylation, de-
creased breast cancer cell proliferation and colony formation and re-
duced HER2-mediated tamoxifen resistance by suppressing PI3K/Akt
signalling [58]. In addition, HER3 was required in oestrogen-induced
breast cancer cell growth and activated HER2 tyrosine kinase, Akt,
and mitogen-activated protein kinase signalling [59]. Moreover, acti-
vation of the HER3-dependent pathway increased intravasation and
lung metastasis in orthotopic breast cancer models [60]. By analysing
paired patient specimens, increased HER3 expression and somatic
mutations in EGFR, HRAS, KRAS, NRAS or PIK3CA were observed com-
pared to primary breast tumours [61]. HER3 also played a critical role
in HER2-mediated paclitaxel resistance. In both transient and stable
HER3 overexpression models, cell growth inhibition and apoptosis
induced by paclitaxel were greatly reduced in breast cancer cells over-
expressing HER2, but not in cells with upregulated EGFR. Mechanistic
studies suggested that ampliﬁed HER3 contributed to HER2-mediated
paclitaxel resistance by upregulating Survivin via the PI3K/Akt/mTOR
signalling pathway [62]. Upregulation of HER3 was believed to play a
pivotal role to compensate for cell growth signals after treated with
PI3K or EGFR inhibitors [63,64]. In addition, Garrett and Cook et al.
showed that a combination of HER2, HER3 and PI3K inhibitors may
provide a better outcome in HER2 and PI3K dependent tumours, as
knockdown of HER3 by either siRNA or speciﬁc antibodies improved
the response to lapatinib in breast cancer cells both in vitro and
in vivo. Furthermore, ablation of both HER2 and HER3 produced a
greater inhibition of PI3K/Akt activity compared to single inhibitor
[65,66].
Further studies demonstrated that HER3 was involved in EGFR
dependent non-small cell lung cancer, mainly through the ability of
somatic mutant EGFR to phosphorylate kinase-defective HER3, lead-
ing to activation of PI3K/AKT cell growth pathways [67]. Although
patients treated with EGFR inhibitors, such as geﬁtinib or erlotinib,
initially showed a good response, acquired resistance and tumour
relapse due to secondary mutations soon developed [68–72].
Recently, a novel mechanism for geﬁtinib resistance involving HER3
was reported. Engelman et al. described that upregulated proto-
oncogene MET can trigger the activation of HER3 downstream path-
ways that contributes to geﬁtinib resistance in lung cancer [73,74].Apart from the central role of HER3 in cell survival and mediation of
drug resistance, it was also shown that phosphorylated HER3 is
signiﬁcantly increased in lung cancer brain metastases relative to pri-
mary tumours, supporting its possible role in invasion and distant
metastasis [75].
HER3 has also been shown to be upregulated in other types of
malignancies, including melanoma, ovarian and colorectal cancers.
Elevated HER3 correlated with poor prognosis in melanoma and colo-
rectal cancers [76–78] while HER3 overexpression was associated
with decreased survival in patients with ovarian cancer [79]. Blockade
of HER3 suppressed melanoma cell proliferation, migration, and
invasion in vitro [76]. A neuregulin (NRG1)/HER3 autocrine signal-
transducing loop was found to play an important role in ovarian can-
cers, and use of either siRNA against HER3 or a monoclonal antibody
targeting HER3 signiﬁcantly reduced ovarian cancer cells proliferation
in vitro and inhibited tumour growth in vivo [80]. Although some
questions have been clariﬁed on functions of HER3 in tumour prolif-
eration, invasion and metastasis, further understanding will help us
to develop novel therapies.
3.3. CASK
Calcium/calmodulin-dependent serine protein kinase (CASK) is a
pseudokinase belonging to the membrane-associated guanylate
kinase protein family (MAGUK) that function as multiple domain
adaptor (scaffolding) proteins [81]. CASK (LIN2) was originally
reported in C. elegans and in Drosophila (Caki) [82,83]. CASK is one
of the 10 subfamilies consisting of a PDZ domain, a catalytically
inactive guanylate kinase (GUK) domain and a Src Homology 3
(SH3) domain [84] and acts as a scaffold protein playing a role in
protein organisation. In mammals, it is located at cell junctions and
synapses and is thought to play a critical role in brain development
and central nervous system function [85,86]. It can bind to more
than 20 cellular proteins in different subcellular regions of neurons
and form protein complexes for the interaction with the trans-
membrane protein neurexin at pre-synaptic sites leading to down-
stream events [87]. Mutations lead to brain malformation, mental
retardation and neonatal lethality [88]. In a single study, it was dem-
onstrated that CASK functions as an active protein kinase that phos-
phorylates neurexins providing further evidence to suggest that at
least some “pseudokinases” retain kinase activity in addition to scaf-
fold properties [8].
3.3.1. CASK, and its role in cell proliferation and cancer
To date, there are only a few studies that associate CASK with can-
cer, although it has been implemented in the regulation of cell prolif-
eration. Human CASK was reported to bind inhibitor of DNA binding 1
(Id1) via its kinase domain to inhibit cell growth of ECV304 cells.
Over-expression of human CASK resulted in a reduced rate of cell
growth while a reduction of CASK levels using siRNA led to an
increase of cell proliferation. CASK was also shown to regulate
p21waﬁ/cip1 at the mRNA and protein level [89]. In another study,
Ojeh et al. showed that CASK is able to regulate proliferation and ad-
hesion of epidermal keratinocytes. CASK is localised in nuclei of basal
keratinocytes in newborn rodent skin and developing hair follicles.
Knockdown of CASK led to increased proliferation in cultured kerati-
nocytes and in skin raft cultures [90].
In one study, matched normal tissues were compared to human
oesophageal carcinoma samples taken from patients that did not re-
ceive treatment. CASK and its target gene Reelin were signiﬁcantly
up-regulated in human oesophageal carcinoma at the mRNA and pro-
tein level. In contrast, mRNA expression patterns of CASK in gastric
and colon carcinomas were up-regulated in approximately 50% of
cases but Reelin mRNA levels did not differ from matched normal
tissue. The interaction between CASK and Reelin appeared to differ
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oesophageal cancer [91].
A differential expression of CASK in high-risk non-relapsed versus
relapsed non-determinant chromosomal translocation (NDCT) acute
lymphobastic leukaemia patients has been reported. Gene expression
levels were 3 times higher in non-relapsed versus relapsed NDCT
patients [92].
Finally, using laser capture dissection and gene expression
proﬁling, CASK was found to be elevated in squamous cell carcinomas
samples when compared to either adenocarcinomas, small cell lung
cancers or normal lung tissue [93].
3.4. ILK
Integrin-linked kinase (ILK), a serine/threonine kinase, was origi-
nally discovered using a yeast two-hybrid screening system and was
found to interact with the cytoplasmic domain of β1 integrin [94].
ILK has an N-terminal ankyrin repeat domain, a pleckstrin-
homology (PH)-like domain and a C-terminal catalytic domain [95].
The ankyrin repeat domain binds to LIM (Lin11, Isl-1 and Mec-3)
found in scaffold protein domains of the interestingly novel cyste-
ine–histidine rich protein PINCH family. The C-terminal domain
reacts with parvin forming the ILK–PINCH–Parvin (IPP) complex,
which forms a scaffold with other factors [96]. ILK has an important
role in cell adhesion by linking integrin to the actin cytoskeleton
[96,97].
The argument as to whether ILK is a pseudokinase or it possesses
kinase activity has recently been discussed by Hannigan et al., as
there has been some debate in recent years relating to its true func-
tion [98]. In some studies, no substrates were identiﬁed for ILK and
it was considered to be a pseudokinase as it lacks the HRD and DFG
motifs in its kinase domain [96]. Furthermore, the crystal structure
of the kinase domain, differs from those of active kinases [97]. How-
ever, as shown by Hannigan et al., ILK has been shown to phosphory-
late a variety of different substrates, including glycogen synthase
kinase 3 (GSK3) and AKT [99]. Taking everything into consideration,
it is most plausible that ILK is a true kinase and therefore requires
re-classiﬁcation, while it is likely to have a novel mode of activity
resulting from changes to its catalytic domain.
ILK has many important functions in signal transduction pathways
associated with cell survival, migration, cell adhesion and extracellu-
lar matrix, differentiation, cell survival and angiogenesis and is
essential for embryonic development and tissue homeostasis, as
deregulation leads to abnormal tissue development [95].
3.4.1. ILK and cancer
ILK was originally described as a putative oncogene [100]. There is
little doubt that the expression of ILK is strongly associated with
tumour progression in the clinical context and unequivocally shown
to be associated with tumorigenesis in cell lines and tumour models
[101–104]. In a prostate cancer model, inhibition of ILK reduced the
rate of growth and decreased the metastatic potential of DU145
cells [105]. ILK siRNA has also been shown to inhibit cell attachment,
growth and invasion of gastric cancer in vitro and in vivo models,
possibly through interference with tumour angiogenesis processes,
since vascular endothelial growth factor (VEGF) was decreased after
silencing [101]. Similar observations were made in human bladder
cancer cell lines [106,107] and melanoma [108].
In humanmalignancies, overexpression of ILK correlates with pro-
gressive disease. In tumour tissue, ILK protein levels were increased in
many different human cancers including melanoma, colon, gastric,
non small cell lung, thyroid, pancreatic, ovarian, prostate, and
primitive neuroectodermal tumours, as well as mesothelioma, Ewing
sarcoma and medulloblastoma [95,99]. For example, in a paired nor-
mal:tumour tissue analysis of human astrocytoma, positive staining
was found in 208 of 228 histological specimens and ILK wassigniﬁcantly overexpressed at the mRNA level. Moreover, overexpres-
sion of ILKwas associated high grade tumours and shorter patient sur-
vival [109]. ILK was shown to phosphorylate AKT leading to the
activation of anti-apoptotic pathways [110–112]. Immunohistochem-
istry analysis showed that ILK and phosphorylated AKT protein levels
were overexpressed in laryngeal squamous cell carcinomas, although
no correlation was found with stage of disease [113]. Similarly, ILK
overexpression and AKT activationwere found in hepatocellular carci-
noma, where no correlation was found between expression levels and
patient survival [114,115].
In ovarian carcinoma, ILK expression was correlated with tumour
grade and expression was absent in normal ovarian epithelium
[116]. Likewise, no ILK was detected in normal bronchial epithelium,
while it was expressed in human basal cell carcinoma [117] as well as
in 68.5% of squamous cell carcinoma and 61.5% adenocarcinoma cases
respectively [118]. ILK has also been reported to upregulate the tran-
scription factor Twist1 which is associated with several aggressive
forms of breast, prostate, gastric and oesophageal cancers [118].
Interestingly, observations in paediatric rhabdomyosarcoma were
different to those for other malignancies. In these cases, ILK was
found to act as a tumour suppressor protein and this was linked to
overexpression of c-jun amino terminal kinase-1 (JNK1) and not to
any ILK mutations. Conversely in alveolar rhabdomyosarcoma, ILK
acts as a proto-oncogene [119,120].
In conclusion, since the involvement of ILK in cancer has been
clearly demonstrated, inhibition of ILK may provide a possible novel
cancer treatment. To this end, several small molecule ILK inhibitors
have been evaluated as possible anticancer agents [95,99,121,122].
3.5. JAKs and cancer
The Janus tyrosine kinase (Jaks) family has four members (Jak1,
Jak2, Jak3 and Tyrosine kinase 2 (Tyk2)). This family is composed of
seven Jak homology (JH) domains, named JH1–JH7 from the carboxyl
to amino terminus. Interestingly, JH1 is a typical tyrosine kinase do-
main whereas the neighbouring JH2 region is a pseudokinase domain
serving regulatory functions of Jaks activity through binding to JH1
[123–125]. Because of the differing domains, it is difﬁcult to classify
these as pseudokinases. Jaks normally interact with cytokine recep-
tors on the cell surface becoming active and can in turn phosphory-
late the cytoplasmic domain of the receptors. This results in the
recruitment of downstream signalling molecules such as signal trans-
ducers and activators of transcription (STATs) whose activation is
widely implicated in many cancers [126–129].
Jak members are highly associated with hematopoietic malignan-
cies. For example, a gain-of-function mutation (V617F) in the JH2 do-
main of Jak2 correlates with myeloproliferative neoplasias [130–133].
Jak1 mutations were also reported in patients with acute myeloid leu-
kaemia (AML) and acute lymphoblastic leukaemia(ALL) [134,135]. In
one study, approximate 18% of patients with the T cell precursor ALL
were shown to have Jak1 mutations, which associates with poor
response to therapy and overall prognosis. Three gain-of-function
mutations identiﬁed were implicated in contributing to interleukin-
9 (IL-9) independent resistance to apoptosis of T cell lymphoma
BW5147 cells [134]. In addition, Jak3 pathway genes were shown to
be elevated in B-lineage acute lymphoblastic leukaemia and the in-
creased expression of these genes correlates with steroid resistance
and relapse [136].
Jak family members have also been suggested to play a role in
solid tumour growth. In breast cancer, Jaks were shown to interact
with Src tyrosine kinase contributing in constitutive activation of
Stat3. Inhibition of Jaks by tyrosine kinase selective inhibitors
resulted in reduced growth and increased programmed cell death in
breast cancer cells [137]. In prostate cancer, Jaks inhibitor, tyrphostin
AG490, can suppress Stat3 activation and inhibit the growth of
human prostate cancer cells. This indicates that Jaks–Stat3 pathway
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[138]. Furthermore, erythropoietin was capable of activating Jak2–
Stat5 signalling leading to metastasis in head and neck squamous
cell carcinoma [139]. The Jaks–Stats pathway is also involved in
lung cancer. Gao et al. showed that in EGFR constitutively activated
human lung adenocarcinoma-derived cells, a pan-Jaks inhibitor (P6)
signiﬁcantly reduced Stat3 phosphorylation. Additionally, P6 sup-
pressed tumorigenesis of human lung adenocarcinoma cells in vitro
and in vivo. Results from this study conclude that Stat3 phosphoryla-
tion in lung adenocarcinoma is dependent upon the IL-6/gp130/Jaks
pathway [140].
Numerous reviews on the role of Jaks in cancer have been
published recently [141–146]. Involvement of Jak kinases in the
development of malignancies has resulted in a great number of inhib-
itors currently being evaluated in clinical trials [147–149].
4. Pseudokinases that exert allosteric regulation and
scaffolding function
4.1. STRADα
STE-20-related adaptor α and β (STRADα and STRADβ) isoforms
(also known as STLK5 and STKL6), which belong to the STE20 protein
kinase family, also lack kinase activity [3]. These pseudokinases are
upstream components in signal-transduction pathways controlling a
wide range of biological processes. The function of STRADα is to allo-
sterically activate the tumour suppressor Liver Kinase B1 (LKB1) in a
complex with mouse protein 25 α (MO25α) scaffolding protein,
resulting in the activation of 5′-adenosine monophosphate activated
protein kinase (AMPK) family members. Similarly, the STRADβ and
MO25β isoforms also stabilise LKB1 [150,151]. Activation of AMPK
leads to the regulation of cellular energy status, fatty acid synthesis,
cell polarity and proliferation. The kinase domain structure of
STRADα consists of N and C lobes with a cleft between them making
up the active site. The activation loop is found in the C terminal lobe
and it is phosphorylated at speciﬁc sites when the kinase is in an
active state, allowing substrate binding. In turn, LKB1 is activated by
binding to STRADα thus not relying on activation by phosphorylation.
Direct interaction of their kinase domains strongly suggests an allo-
steric mechanism of activation [152]. ATP and MO25α binding to
STRADα changes its kinase domain to an active-like kinase conforma-
tion that is characterised by extending its A-loop, allowing STRADα to
bind LKB1. This results in the kinase domain of LKB1 to adopt an ac-
tive kinase conformation, which is further stabilised by the binding
of MO25α to the A-loop of LKB1 [153]. Moreover, its cellular distribu-
tion is determined by STRADα and MO25α. Re-localization of LKB1 is
induced by STRADα from the nucleus to the cytoplasm [154]. Mutant
forms of STRADα that are unable to bind MO25α and ATP fail to
activate LKB1 [155,156].
4.1.1. STRADα and cancer
Peutz–Jeghers Syndrome (PJS) is a rare autosomal dominant dis-
order where patients have greater chance of developing colon, breast,
pancreatic, stomach, and ovarian cancers [157]. PJS is characterised
by a predisposition to polyps and hyperpigmentation of the buccal
mucosa [158]. Most PJS can be linked to pathogenic LKB1 germline
mutations. It was hypothesised that aberrant STRADα activity may
lead to similar effects as those resulting from LKB1 inactivation. Loss
of heterozygosity (LOH) analysis was performed in 42 PJS associated
tumours (sporadic lung, colon, gastric, and ovarian adenocarcinomas)
using eight microsatellite markers on chromosome 17, including p53,
BRCA1, and STRADα. Loss of STRADαmarker near the locus was seen
in 13 of 29 patients, which included gastric adenocarcinomas. Speciﬁc
LOH of the STRADαmarker was found in only 4 cases and no somatic
mutations were identiﬁed. Furthermore, no germline STRADα muta-
tions were found in 10 patients with PJS and family members withoutLKB1 germline mutation. The authors concluded that STRADα is
unlikely to be a tumour suppressor. Alhopuro et al. reported that
germline mutations in STRADαwere not the cause of PJS [159]. Single
amino acid substitution mutants of LKB1 isolated from human
cancers have lost the ability to interact with STRADα and were unable
to induce G1 cell cycle arrest when overexpressed in cells, indicating
the importance of the STRADα–LKB1 interaction [160,161].
In another study, miR-451 was reported to regulate the LKB1/
AMPK pathway in glial tumour cells. It was proposed as a mechanism
for enabling tumour cells to adapt to conditions of hypoxia and low
energy levels conditions [162]. When glucose levels were not in
limited supply, elevated miR-451 levels led to reduced LKB1/AMPK
pathway activation, allowing cell growth, increasing mTOR activity
and reducing apoptosis. When glucose levels were depleted, miR-
451 levels declined allowing activation of AMPK by LKB1-mediated
phosphorylation. This promoted cell survival in response to metabolic
stress and activated pathways involved in glioma motility. Overex-
pression of LKB1 caused G1 arrest in Hela cells and the G361 melano-
ma cell line [163], whereas mutated LBK1 failed to do this allowing
proliferation to proceed. Several shorter STRADα transcripts were
identiﬁed in colorectal cancer cell lines but no full length transcripts
were found. Nevertheless, binding and activation of LKB1 was still
possible in vitro [158]. Mutations of LKB1 in cancer patients showed
that some mutations prevented binding to STRADα [160]. Aberrant
activity of LKB1 is associated with carcinogenesis through deregula-
tion of cell cycle, of which STRADα and MO25α co-factors are essen-
tial for its normal function.
4.2. Tribbles family
Tribbles was ﬁrst shown as a regulator in coordinating mitosis and
morphogenesis during Drosophila development. Through promoting
the degradation of Cdc25/String, tribbles blocked mitosis at a critical
point to control cell cycle progression [164–166]. There are three
mammalian trb isoforms (trb1, trb2 and trb3) homologues to the
Drosophila tribbles and they all share the highly conserved kinase
domain, which lacks catalytic residues.
Despite their conserved structure, their actions differ; trb1 and
trb2 are mainly involved in the development of leukaemia, while
trb3 is upregulated in non-haematopoietic malignancies. Dedhia
et al. generated mice using hematopoietic stem cells expressing all
three tribbles isoforms separately. Only those overexpressing trb1
or trb2 developed AML. In addition, this data also showed that trb1
and trb2, but not trb3, have the ability of promoting the degradation
of CCAAT/enhancer-binding protein-α (C/EBPα) by resulting in their
differential functions in leukemogenesis [167].
4.2.1. Trb1, trb2 and cancer
Trb1 is overexpressed in AML and proven to interact with Homeo-
box proteins Hox-A9 and Meis1 (Hoxa9/Meis1), which have been
demonstrated to induce AML in mice by Hoxa9/Meis1-transduced
bone marrow cells [168,169]. Moreover, trb1 appears to be involved
in the MAPKs pathway by binding to MEK1 via its C-terminal
ILLHPWF motif contributing to myeloid leukemogenesis [170]. Trb2
was described as an oncogene contributing to pathogenesis of AML
in mice via suppressing C/EBPα activity, a key transcriptional regula-
tor of differentiation and frequently found mutated in AML while
Trb2 expression was also elevated in a group of AML patients [171].
Recently, Trb2 was also suggested to cooperate with HoxA9 and
Meis1 to accelerate the process from hematopoietic progenitors to
AML [172,173]. More recently, an in vitro and in vivo structural func-
tion analysis revealed that the trb2 kinase domain and the C-terminal
constitutive photomorphogenesis 1 (COP1)-binding domain are in-
dispensable in trb2 induced leukaemia for the activity of binding
and degrading C/EBPα [174]. Further studies are still needed to estab-
lish the functions of trb1 and trb2 in leukemogenesis.
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malignant melanoma, but not in other types of skin cancer using a
cancer-proﬁling array. Trb2 expression levels were associated with
cytoplasmic localization of Forkhead box O3a (FOXO3a). Decreased
trb2 reduced cell proliferation and colony formation and impaired
wound healing. In a melanoma xenograft model, tumour growth
was signiﬁcantly inhibited after trb2 knockdown [175]. Increased ex-
pression of trb2 was also identiﬁed in primary human lung tumours
and in non-small cell lung cancer cells and a further study suggested
that trb2 triggered lung tumorigenesis through degradation of
C/EBPα [176].
4.2.2. Trb3 and cancer
Trb3 is overexpressed in a variety of human cancers, including
lung, colon and breast tumours and by interacting with activating
transcriptional factor 4 (ATF4), it can reduce ATF4 levels to slow
down the cell cycle, thereby enabling tumour cells to adjust to
hypoxic conditions [177]. It has also been suggested that trb3 is
associated with CtBP-interacting protein (CtlP), a transcriptional
factor implicated in malignancy where trb3 mRNA expression
was increased in certain tumour tissues [178]. A recent study
showed that trb3 can induce tumour cell migration and invasion
through its kinase domain interacting with SMAD3 to regulate
transforming growth factor-β (TGF-β)-SMAD-mediated pathway
[179].
4.3. TRRAP
Transformation/transcription domain-associated protein (TRRAP)
is a member of the phosphatidylinositol 3-kinase-related kinase
(PIKK) family that shares a high homology to the PI3Ks [180,181].
TRRAP was originally discovered in 1998 where it was found to inter-
act with c-Myc and E2F oncoproteins [182]. In humans it is one of six
family members, which also include mammalian target of rapamycin
(mTOR), ataxia-telangiectasia mutated (ATM), ataxia- and Rad3-
related (ATR), DNA-dependent protein kinase catalytic subunit
(DNA-PKCs) and suppressor of morphogenesis in genitalia (SMG-1)
[183].
PIKK family possesses a conserved kinase domain regulated by
two C-terminal regions known as PIKK-regulatory domain (PRD)
and FRAP–ATM–TRRAP-C-terminal (FATC). TRRAP protein encom-
passes 4 domains: the FRAP–ATM–TRRAP (FAT) domain, the kinase
domain (KD), the PRD and the FATC domain [181].
TRRAP has a bipartite nuclear localization signal and is predomi-
nantly found in the nucleus. The function of the FAT domain has not
been elucidated whereas the FATC domain is necessary for kinase
activity within this PIKK family. TRRAP differs from other members
because it lacks the conserved amino acids required for ATP binding
and catalytic activity [184].
TRRAP has been reported to act as a scaffold protein for numerous
regulatory factors including GCN5, p53, BRCA1, E2F and c-Myc
[185,186]. It acts as a mediator, being part of several different histone
acetyltransferase (HAT) complexes [184,186–189]. In turn these com-
plexes act as a platform for different regulatory factors. Transcription-
al proﬁling revealed that TRRAP knockdown affected numerous
signalling pathways and cell cycle components. In one study TRRAP
was associated with repair of DNA double-strand breaks [186]. Collec-
tively, TRRAP plays a role in forming part of the complex necessary for
c-Myc oncogene activation and is involved in the regulation of
tumour suppressor gene p53.
4.3.1. TRRAP and cancer
TRRAP has been identiﬁed as a transcriptional cofactor of c-
Myc [190] playing an important role in cell cycle regulation
[191]. Deregulated function of TRRAP can lead to aberrant c-Myc
function resulting in abnormal cell proliferation. Normally, c-Mycrecruits TRRAP and the acetyltransferase enzyme GCN5, by inter-
acting with its N-terminal activation/transformation domain.
There is strong evidence showing that TRRAP is a co-activator of
c-Myc as preventing its recruitment leads to downregulation of
c-Myc-modulated genes [192]. In a gene inducible mouse model,
null mutation of TRRAP resulted in peri-implantation lethality,
and cell proliferation was inhibited because cells failed to com-
plete cytokinesis [193]. Studies have shown that TRRAP is
required for cellular transformation by c-Myc, where c-Myc over-
expression leads to deregulated cell growth and tumorigenesis
[182,194,195]. TRRAP was reported as a target of the adenovirus
E1A oncoprotein and to be important for oncogenic transforma-
tion mediated by viral oncoproteins [196,197]. TRRAP has also
been demonstrated to act as a docking platform for p53 and as
part of a multiprotein complex enabling p53 to directly activate
MDM2 expression [198].
In breast cancer, 70% of cases are ERα positive, where activated
receptor, bound by its ligand (oestrogen) drives cell proliferation.
Antisense TRRAP RNA inhibited oestrogen dependent breast cell
growth. It was found that 3 LXXLL motifs located around the middle
of the TRRAP protein normally bind to the phosphorylated surface
of ERα as well as other nuclear receptors [199].
Genetic mutations in the C-terminal transactivation domain of
BRCA1, as found in breast and ovarian cancer patients, caused the
loss of physical interaction between BRCA1 and TRRAP and signiﬁ-
cantly reduced the co-activation of BRCA1 transactivation function
by hGCN5/TRRAP [188,200].
TRRAP has also been studied in malignant melanoma. Whole-exon
DNA sequencing of 14 matched normal and metastatic melanoma
tumours from patients, who were not previously treated, showed
somatic mutations in TRRAP. The recurring mutation in TRRAP was
a cytosine to thymine change at position 2165 of the gene transcript,
resulting in a serine to phenylalanine substitution at amino acid
residue 722 of the protein. Knockdown of TRRAP had minimal effect
on the survival of cells expressing wild-type TRRAP but substantially
increased apoptosis rates of melanoma lines carrying mutant TRRAP
[201].
Glioblastoma multiforme is a highly aggressive form of brain
cancer which is believed to stem from poorly differentiated
brain tumour-initiating cells (BTICs). Several genes whose silenc-
ing induced differentiation of these cells were discovered using a
kinome-wide RNA interference screen. Knockdown using TRRAP
siRNA induced differentiation of cultured BTICs, sensitised the
cells to apoptotic stimuli, negatively affected cell cycle progres-
sion and signiﬁcantly inhibited tumour formation upon intracra-
nial BTIC implantation into mice. These ﬁndings show that
TRRAP was maintaining BTICs in a more tumorigenic state [202].
Deregulation of the Wnt signalling pathway is found in many
cancers leading to overexpression of oncogenes such as c-Myc. Loss
of TRRAP leads to hyperactivation of the Wnt pathway possibly lead-
ing to tumorigenesis [203]. The L11 ribosomal protein activates p53
by inhibiting oncoprotein MDM2 and c-Myc, leading to inhibition of
cell cycle progression. Overexpression of L11 inhibits c-Myc-induced
transcription and cell proliferation, while reduction of endogenous
L11 increases c-Myc activities. L11 competes with co-activator
TRRAP for binding to c-Myc [204,205].
A comparative genomic hybridization of 22 human pancreatic
cancer cell lines, using cDNA microarrays measuring 26,000
human genes, showed TRRAP to be signiﬁcantly ampliﬁed [206].
In a further study, 44 surgically resected pancreatic adenocarci-
nomas were assessed using array-based comparative genomic hy-
bridization. TRRAP at 7q22.1 was found to be ampliﬁed and
overexpressed in 36% of cases [207]. From these two studies
TRRAP was proposed as a putative oncogene in pancreatic cancer.
Disrupting the function of scaffolding protein TRRAP can change
signalling activities involved in cancer cell proliferation.
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Colon carcinoma kinase 4 (CCK4 or receptor tyrosine kinase 7,
RTK7) was originally isolated from colon carcinoma tissue but not
normal colon tissues. Sequence analysis identiﬁed CCK4 as an inactive
kinase belonging to the RTK family proteins [208]. A subsequent
study showed that CCK4 was also expressed in melanoma cell lines
and tumour biopsies. However, levels of CCK4 expression were signif-
icantly reduced or lost in advanced melanoma which indicated that it
might have a role in tumour metastasis [209]. A recent study
suggested that puriﬁed extracellular domain of CCK4 can undermine
the activity of endogenous CCK4 resulting in inhibition of vascular
endothelial growth factor (VEGF)-induced tube formation, cell
migration and angiogenesis of endothelial cells, which emphasise its
important role in metastatic processes [210]. Moreover, in a study
using an immunophenotyping screen of a large group of patients
treated for haematologic malignancies, CCK4 was shown to be
expressed in AML. A signiﬁcantly lower leukaemia-free survival and
greater resistance to anthracycline-based frontline therapy was
reported for CCK4 positive AML patients. Notably, this study
suggested that CCK4 could be an independent prognostic factor of
survival in certain sub-populations of patients [211]. CCK4 was also
involved in membrane type-1 matrix metalloproteinase (MT1-
MMP)-PTK7 axis, implicating its role in both cancer cell invasion
and normal embryogenesis in vertebrates [212]. Knockdown of
CCK4 in colon cancer cell line HCT116 inhibited proliferation and
increased apoptosis in a caspase-10 dependent pathway [213].
These ﬁndings indicate that CCK4 may be a novel therapeutic target
in malignancies.
4.5. VRK-3
Vaccinia-related kinase 3 (VRK-3) is one of three members
(including VRK-1 and VRK-2) belonging to the vaccinia related kinase
(VRK) family, which is a novel family of serine/threonine kinases
possessing a high homology to vaccinia virus B1R kinase [214,215].
Structural studies have shown that only VRK-3 has an inactive pseu-
dokinase domain due to amino acids changes within its binding site
not allowing ATP attachment [216]. The NH2-terminal region of the
VRK-3 contains a bipartite nuclear localization signal, enabling it to
migrate to the nucleus [214]. VRK-3 has been shown to activate vac-
cinia H1-related (VHR) phosphatase and can regulate the activity of
ERK [217,218]. In one study, VRK-3 was associated with phosphatase
activity in neuronal cells and after neurotoxic damage [219]. Further
work is needed to identify the biological effects of this pseudokinase.
4.5.1. VRK-3 and cancer
Both VRK-1 and VRK-2 have been linked to malignancies [220–
223]. However, to our knowledge only one study so far has shown
VRK-3 to be associated with cancer. Differential expression of VRK-3
was identiﬁed in colon cancer for the ﬁrst time using a comparative
kinome screen. In this study it was found that VRK-3 was signiﬁcantly
downregulated at the transcript level in both adenoma and adenocar-
cinomas when compared to normal colon tissue [224]. Any associa-
tion between VRK-3 and malignancy requires further evaluation.
5. Conclusions and perspectives
Our knowledge of this enigmatic family of protein kinases has in-
creased in recent years. To date, approximately 10% of these proteins
have been classiﬁed as pseudokinases. Their initial classiﬁcation was
largely based on sequence analysis and the discovery that pseudoki-
nases lacked at least one highly conserved amino acid within their
kinase domain. Based on our current knowledge, it appears that
pseudokinases can have different regulatory roles and functions.
Some provide a ‘molecular platform’, steering enzymes and theirsubstrates into critical positions allowing cellular reactions to
proceed, while others are able to allosterically activate kinases. In
addition, some pseudokinases, although they have evolved “inactive”
kinase domains, still exhibit catalytic activity by various unique
mechanisms, indicating they are evolutionary counterparts of protein
kinases. New experimental facts will allow a more precise classiﬁca-
tion of pseudokinases in the future.
New insights gained from structure analysis of WNK, CASK and
HER3 suggest that it would be interesting to re-evaluate the remain-
ing pseudokinases to delineate possible novel mechanisms in regulat-
ing phosphorylation. Thus, uncovering their three-dimensional
structure will improve our understanding of their intramolecular
interactions, their involvement in signal transduction and possibly
this will result in re-classifying some of them into active protein
kinases. Re-instating known active domains within pseudokinases
may shed more light on their functions. In addition, further evidence
on elucidating the pathways they participate in and the exact role of
proteins they cooperate with may reshape our perspectives on their
biological functions.
Herein, we review the literature on various pseudokinases, includ-
ing KSR1, HER3, CASK, ILK, JAKs, STRADα, the Tribbles family, TRRAP,
CCK4, VRK-3, accounting approximately for 30% of all known pseudo-
kinases, whose role and/or involvement in cancer has already been
reported. Irrespective of their mechanism of action, either as scaffold
proteins, allosteric activators or as ‘partly’ active kinases, they have
already been shown to play a critical role in human diseases including
cancer. Deciphering an interacting signalling network for individual
pseudokinase will provide us with potentially novel prognostic
tumour markers and targets for cancer therapy and shed new light
on addressing cancer-drug resistance in future.
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Abstract
Protein kinases play a pivotal role in regulatingmany aspects of biological processes, including development,
differentiation and cell death. Within the kinome, 48 kinases (∼10%) are classiﬁed as pseudokinases owing
to the fact that they lack at least one conserved catalytic residue in their kinase domain. However, emerging
evidence suggest that some pseudokinases, even without the ability to phosphorylate substrates, are
regulators of multiple cellular signalling pathways. Among these is KSR1 (kinase suppressor of Ras 1),
which was initially identiﬁed as a novel kinase in the Ras/Raf pathway. Subsequent studies showed that
KSR1 mainly functions as a platform to assemble different cellular components thereby facilitating signal
transduction. In the present article, we discuss recent ﬁndings regarding KSR1, indicating that it has dual
activity as an active kinase as well as a pseudokinase/scaffolding protein. Moreover, the biological functions
of KSR1 in human disorders, notably in malignancies, are also reviewed.
Introduction
KSR (kinase suppressor of Ras) 1 was originally dis-
covered more than 15 years ago as a novel protein kinase
evolutionarily conserved in Drosophila and Caenorhabditis
elegans functioning between Ras and Raf in the Ras
signalling pathway [1,2]. However, mammalian KSR1 has
been extensively referred to as a pseudokinase, because of
the mutation in the lysine residue in the catalytic domain,
which is required for its kinase activity. Subsequently,
the role of KSR1 as a scaffolding protein was revealed.
Murine KSR1 was first reported to co-operate with activated
Ras to facilitate MEK [MAPK (mitogen-activated protein
kinase)/ERK (extracellular-signal-regulated kinase) kinase]
and MAPK activation, thereby promoting Xenopus oocyte
maturation and cellular transformation [3]. In addition, KSR1
was observed to translocate from the cytoplasm to the plasma
membrane in the presence of activated Ras, where it forms
a complex involving Raf-1, MEK1 and 14-3-3 protein. This
in turn led to the activation of Raf-1, which is independent
of its enzymatic activity, highlighting its role as a scaffold in
the MAPK pathway [4,5]. Meanwhile, the notion of KSR1
as an active kinase was described from the finding that
TNFα (tumour necrosis factor α) and ceramide were shown
to significantly increase KSR1 autophosphorylation and its
capacity to phosphorylate and activate Raf-1 [6]. These data
thus support the dual activity of KSR1 as an active kinase as
well as a scaffold protein in the Ras/Raf/MAPK pathway.
Key words: cancer, kinase, kinase suppressor of Ras 1 (KSR1), phosphorylation, pseudokinase.
Abbreviations used: AMPK, AMP-activated protein kinase; CC, coiled coil; C-TAK1, Cdc25C-
associated kinase 1; EGF, epidermal growth factor; ERα, oestrogen receptor α; ERK, extracellular-
signal-regulated kinase; IFNγ , interferon γ ; iNOS, inducible nitric oxide synthase; KSR, kinase
suppressor of Ras; MAPK, mitogen-activated protein kinase; MARK2, microtubule afﬁnity-
regulating kinase 2; MEF, mouse embryonic ﬁbroblast; MEK, MAPK/ERK kinase; mTOR,
mammalian target of rapamycin; NK, natural killer; PPARγ , peroxisome-proliferator-activated
receptor γ ; PP2A, protein phosphatase 2A; SAM, sterile α-motif; TNFα, tumour necrosis factor α.
1Correspondencemay be addressed to either of these authors (email h.zhang10@imperial.
ac.uk or g.giamas@imperial.ac.uk).
In the present article, we discuss the recent advances in
unravelling its structure and function, especially in cancers.
Structure of KSR1
The KSR family members, namely KSR1 and KSR2, are
conserved from invertebrates to mammals. From sequence
comparison, the similarity of amino acids between KSR1
and KSR2 is approximately 61%. KSR1 is closely related
to the Raf kinase family containing five conserved areas
named CA1–CA5. The CA1 domain is located in the N-
terminus encompassing 40 amino acids which are exclusive
to KSR1, but absent from KSR2; CA2 is a proline-rich
domain with undetermined function; CA3 is a cysteine-
rich atypical C1 motif mediating its membrane recruitment
with phospholipids [5]; CA4 is a serine/threonine-rich region
with an FXFP (Phe-Xaa-Phe–Pro) motif that interacts with
ERK [3,7]; and CA5 is a putative kinase domain in which
the conserved lysine residue required for phosphorylation
is lacking [7]. One recent study identified another domain
composed of a CC (coiled coil) and a SAM (sterile α-motif) in
KSR1. In fact, by binding directly to micelles and bicelles, the
CC–SAM domain guided KSR1 to certain sites at the plasma
membrane upon growth factor stimulus. Furthermore, NMR
spectroscopy and in vitro assays demonstrated that the helix
α of the CC motif is essential for modulation of membrane
binding, indicating that, combined with the atypical C1
domain, the CC–SAM domain is indispensable for KSR1
cellular translocation [8].
KSR1 as a scaffold protein
The scaffolding function of KSR1 has been well described in
numerous cellular contexts in various conditions, although
different binding partners or even contradictory downstream
C©The Authors Journal compilation C©2013 Biochemical Society Biochem. Soc. Trans. (2013) 41, 1078–1082; doi:10.1042/BST20130042B
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Figure 1 KSR1 regulation in the canonical Ras/Raf/MAPK pathway
In non-stimulated cells, KSR1 is sequestered in the cytosol through 14-3-3 protein binding after phosphorylation by C-TAK1
at Ser297 and Ser392. Meanwhile, KSR1 constitutively interacts with MEK and ERK. Upon growth factor stimulation, activated
Ras triggers the dephosphorylation of KSR1 at Ser392 by PP2A, leading to the release of 14-3-3 protein from its binding sites.
This in turn allows KSR1 to translocate to the cell membrane, where KSR1 forms a complex with Raf, MEK and ERK. KSR1
thus potentially enhances the phosphorylation of Raf, MEK and ERK, facilitating the upstream signalling transduction as well
as regulating multiple cellular functions by activation of various substrates.
effects have been reported, compared with the initial notion
as a positive regulator in MAPK pathway. KSR1 was shown
to co-operate with MEK1/2, but not Ras or Raf-1, and
this interaction resulted in an inhibition of proliferation of
embryonic neuroretina cells induced by Ras [9]. Another
group described that KSR1 can interact directly with MEK-1
and ERK, and expression of KSR1 in COS-7 cells inhibited
serum-stimulated MAPK activation [10]. KSR1 was also able
to suppress EGF (epidermal growth factor) and Ras-induced
phosphorylation of ternary complex factors, which are sub-
strates of MAPK [11]. In addition, phosphorylation of KSR1
at Ser297 and Ser392 was shown to affect its binding capacity
to 14-3-3 protein in serum-starved medium, whereas MAPK
was able to phosphorylate KSR1 at Thr260, Thr274 and Ser443
depending on activatedRas [12]. The scaffolding role ofKSR1
is supported further by its effects on the Ras/Raf/MAPK
pathway depending on the levels of its expression. Indeed, at
a higher expression, KSR1 appeared to decrease Ras-induced
activity, but increased the Ras pathway when expression
was lower [12]. A further study in Ksr1− /− mouse embryo
fibroblasts confirmed this observation when titrating the
levels of KSR1 expression. With low KSR1 expression, ERK
activity was enhanced as well as cell growth and RasV12
oncogenic transformation. Likewise, all of these effects were
markedly reduced with higher KSR1 expression [13,14].
More studies have revealed a dynamic interplay showing
that KSR1 is acting as an allosteric regulator in the
Ras/Raf/MAPK signalling cascade. In non-stimulated cells,
C-TAK1 (Cdc25C-associated kinase 1) phosphorylates
KSR1 at Ser392, which creates the binding site for 14-
3-3 protein, resulting in sequestration of KSR1 in the
cytosol, where it constitutively interacts with MEK and
ERK. Upon growth factor stimulation, activated Ras triggers
the dephosphorylation of KSR1 at Ser392 by PP2A (protein
phosphatase 2A), leading to the release of 14-3-3 protein from
its binding sites. This in turn allows KSR1 to translocate
to the cell membrane, where KSR1 forms a complex with
Raf, MEK and ERK. KSR1 thus potentially enhances
the phosphorylation of Raf, MEK and ERK, facilitates the
upstream signalling transduction as well as phosphorylation
of multiple substrates in the cytoplasm and nucleus, and,
through this manner, regulates proliferation, cell cycle and
apoptosis [15–17] (Figure 1).
Recent advances in KSR1 structure demonstrated further
its involvement in multiple scaffold complexes. Upon growth
factor stimulation, a functional CA1 region of KSR1 was
reported tobenecessary for the assemblyof a ternary complex
with B-Raf and MEK, resulting in activation of MEK and
ERK. This in turn allows ERK to phosphorylate KSR1
andB-Raf on several feedback serine/threonine phosphoryla-
tion sites, which leads to the dissociation of KSR1 from the
plasmamembrane [18]. Rajakulendran et al. [19] showed that,
by forming side-to-side KSR1–Raf heterodimers, KSR1 can
regulate Raf activation directly, despite its lack of catalytic
function.Moreover, mutations in the dimer interface ofKSR1
suppressed the activity ofRaf [19]. The case for the scaffolding
role of KSR1 is supported further by the observation that
Raf inhibitors can trigger KSR1–B-Raf complex formation,
dependent on conserved dimer interface residues in each
partner [20]. In addition, this study demonstrates that KSR1
competes with C-Raf for inhibitor-induced dimerization to
B-Raf, thereby modulating downstream ERK signalling [20].
C©The Authors Journal compilation C©2013 Biochemical Society
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KSR1 as an active kinase
Mounting evidence supports the concept of KSR1 as
an active kinase, despite suggestions of an incomplete
catalytic domain. Initial in vitro kinase assays reported that
different concentrations of natural ceramide induced KSR1
autophosphorylation and transactivated Raf-1 at Thr269 [6].
Afterwards, EGF was shown to be able to stimulate the
kinase activity of KSR1 in a two-stage kinase assay. In
addition, only full-length KSR1 was capable of signalling
c-Raf-1-dependent activity, but not kinase-inactive and C-
and N-terminal deletion mutants [21]. The same group
proposed further that phosphorylation of c-Raf-1 on Thr269
by KSR1 is required for optimal activation in response to
EGF stimulation. The kinase activity of KSR1 appears
to act independently of KSR1-binding to MEK [22,23].
Direct phosphorylation of Raf-1 by KSR1 is essential for
TNFα-induced ERK1/2 activation in intestinal epithelial
cells, revealing a protective role of KSR1 in inflammation
process, which requires its regulatory kinase activity [24,25]
New biochemical techniques such as protein purification
and molecular modelling have enabled further aspects of
KSR1 function to be probed, generating new perspectives
on its catalytic functions. By using a specific monoclonal
antibody against phospho-Raf-1 (Thr269), the purified KSR1
was shown to be capable of phosphorylating BSA-conjugated
Raf-1 peptide [26]. Consistently, recombinant wild-type
KSR1, but not kinase-inactive KSR1, can autophosphorylate
its serine residues and directly activate MEK1 through
phosphorylation, regulating cell survival in response to
TNFα [27]. Furthermore, in order to distinguish between
the scaffold and kinase function of KSR1, Hu et al. [28]
generated a KSR1 mutant construct (A587F) by adding a
bulky phenylalanine residue at the ATP-binding pocket of
KSR1 to impair ATP binding. However, this mutant can
still maintain a closed active conformation, but is unable to
interact with ATP. Indeed, the KSR1 mutant was not able
to phosphorylate MEK, although it can constitutively bind
to MEK as a scaffold. On the other hand, the wild-type
KSR1 was shown to phosphorylate MEK induced by c-Raf,
indicating a requirement of an active kinase activity in this
process [28]. Crystal structure studies of the kinase domain
of KSR2 illustrated that the side-to-side interaction between
KSR2 and MEK1 is through their respective activation
segments and C-lobe αG helices. Upon ATP binding to its
catalytic site, KSR2 was shown to phosphorylate MEK1 by
in vitro kinase assays and chemical genetics [29].
Taken together, these findings support dual function
of KSR1 as a scaffolding protein and active kinase in
orchestrating the Ras/Raf/MAPK signalling cascade.
The roles of KSR1 in various biological
processes
KSR1 in cancers: a therapeutic target?
As KSR1 plays an essential role in the Ras/Raf/MAPK
module, which is one of the well-known oncogenic
pathways, studies are beginning to explicate its biological
characteristics in different cancers. In a v-Ha-Ras-mediated
skin cancer mouse model, KSR1 was shown to contribute
to tumorigenesis through the Raf-1/MAPK cascade [30].
Subsequentwork from the same group reported that targeting
KSR1 by continuous infusion of phosphorothioate antisense
ODNs (oligodeoxynucleotides) reduced tumour growth of
K-Ras-dependent humanPANC-1 pancreatic andA549 non-
small-cell lung carcinoma xenografts in nudemice, suggesting
inhibition of KSR1 as a potential therapeutic target in Ras-
dependent malignancies [31]. Similarly, the introduction of
KSR1 intoKsr1− /− MEFs (mouse embryonic fibroblasts) in-
duced cell proliferative and oncogenic potential, and removal
of KSR1 inhibited Ras(V12)-dependent transformation [13].
In addition, KSR1was involved in cell sensitivity to cisplatin-
induced apoptosis. Specifically, in comparison with wild-
type MEFs, KSR1 depletion in MEFs correlated with
reduced ERK activation by cisplatin and elevated resistance
to cisplatin-stimulated apoptosis. Moreover, transduction of
KSR1 into Ksr1− /− MEFs and MCF7 cells increased ERK
activation and sensitivity to cisplatin [32]. A further screen
to characterize KSR1 expression on drug sensitivity using a
collection of cancer cell lines and theNCI60 anticancer drugs
suggested an important role for KSR1 in defining cellular
sensitivity [33]. In human acute myeloid leukaemia cells,
KSR1 was revealed to be down-regulated by the oncoprotein
Cot1, thus providing extended information of its involvement
in non-solid tumours [34]. Metastasis suppressor Nm23-H1
can bind directly to KSR1 and phosphorylate KSR1 at Ser392,
and can therefore facilitate its degradation as a result of
decreased ERK activation [35,36]. KSR1 was also required
for cell-cycle reinitiation in response to DNA-damage
agents such as mitomycin C [37]. Additionally, through
modulation of PGC1α [PPARγ (peroxisome-proliferator-
activated receptor γ ) co-activator 1α] and ERRα (oestrogen-
related receptor α), KSR1 was demonstrated to induce
oncogenic Ras-dependent anchorage-independent growth
[38].
The inactivation of KSR1 in Myc (v-Myc myelocyto-
matosis viral oncogene homologue)-overexpressing mice led
to an enhancement in B-cell apoptosis as well as an impedi-
ment in the onset of B-cell tumorigenesis, suggesting further
that KSR1 modulates the co-operation of Ras/MAPK sig-
nalling pathway and Myc to drive oncogenic transformation
[39]. Of note, a recent study has revealed that KSR2 controls
tumour metabolism and cell growth in an AMPK (AMP-
activated protein kinase)-dependent manner [40]. The forced
expression of KSR2 in Ksr1-null MEFs resulted in augmen-
ted proliferation and induction of anchorage-independent
growth, whereas the introduction of AMPK restores the
transformed phenotype and tumourmetabolic activities upon
KSR2 depletion. Interestingly, our kinome screen using
RNAi on identifying novel regulators of ERα (oestrogen
receptor α) revealed a potential contribution of KSR1 to
ERα-dependent breast cancer [41].These results indicate a
significant role of KSR1 in various cancers and it might be a
potential therapeutic target in Ras-dependent cancers.
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KSR1 in immune regulation
KSR1 is an important regulator of immune function. Ksr1-
null mice displayed impairment in MEK and ERK activities,
thus resulting in a marked reduction in T-cell proliferation
[42]. A recent study has established a relationship between
MAPK and mTOR (mammalian target of rapamycin)
pathways through the involvement of KSR1 in T-cells.
Although KSR1 modulates mTORC1 (mTOR complex 1)
activity, KSR1 deficiency has no obvious effects in mTOR-
dependent T-cell differentiation [43]. As for NK (natural
killer) cells, it was shown that the loss of KSR1 in NK
cells perturbed NK cell cytolytic capacity. Upon T-cell
activation, KSR1 was recruited to NK lytic synapse that in
turn regulated the localization of active ERK to the synapse
[44]. Several studies have documented the protective role of
KSR1 against cytokine-induced apoptosis such as TNFα in
intestinal inflammatory conditions [25,45]. Ksr1− /− Il10− /−
mice were shown to be susceptible to an early manifestation
of colitis [46]. Additionally, elevated expression of IFNγ
(interferon γ ) in T-cells was detected in the double-knockout
mice and the inhibition of IFNγ was able to reduce the
extent of severity in colitis. KSR1 has also been shown to
be a protective factor against bacterial infection. In fact,
Ksr1-deficient mice were highly vulnerable to pulmonary
Pseudomonas aeruginosa infection, compared with wild-type
mice. Upon infection, KSR1 was capable of iNOS (inducible
nitric oxide synthase) and Hsp90 (heat-shock protein 90)
recruitment resulting in increased iNOS activity and NO
release to eliminate bacteria [47]. These findings underscore
an important role of KSR1 in immune responses.
KSR1/2 in metabolism
Both KSR members are involved in the maintenance of
cellular metabolism in which metabolic abnormalities were
evident in Ksr1- and Ksr2-deficient mice. Phenotypically,
Ksr1− /− mice exhibited adipocyte hypertrophy, whereas
Ksr2− /− counterparts were obese and glucose-intolerant
[14,48].The initiation of adipocyte differentiation relied
indirectly on suitable amounts of KSR1 that orchestrated
the temporal co-ordination of Raf/MEK/ERK and RSK
(ribosomal protein S6 kinase) signalling, and, in this manner,
controlled the activities of adipogenic transcription factors
such as C/EBPβ (CCAAT/enhancer binding protein β)
and PPARγ [14]. A key study by Costanzo-Garvey et al.
[48] has also revealed a direct interaction between the
two KSR isoforms and AMPK, a prominent energy sensor
for metabolic processes. The disruption of this interaction
prevented AMPK activation and phosphorylation that is
imperative to induce fatty acid oxidation and regulate
glucose uptake. Apart from the role of KSR2 in insulin
homoeostasis, KSR1 has also been recently implicated in
regulating glucose tolerance and insulin sensitivity via the
interplay between KSR1 and MARK2 (microtubule affinity-
regulating kinase 2) [49]. The mode of action in which
MARK2 acts as a negative modulator in insulin sensitivity
relies on the direct phosphorylation on Ser392 of KSR1 [49].
Collectively, these studies have underlined the significance
of KSR1/2 in regulating cellular metabolism and in energy
homoeostasis, and KSR1/2 could be potential therapeutic
targets in metabolic disorders, such as obesity.
Closing remarks
Comprehensive insights regarding the structural and func-
tional studies of KSR1 have started to redefine our previous
knowledge, as it is becoming obvious now that the original
classification of KSR1 as a pseudokinase may not be
representative of its exact biological behaviour. Advances
made in the last few years have changed our perspectives
in the functions of KSR1, whereas a more complicated
conception of KSR1 as a scaffold protein and an active
kinase is established. Nevertheless, numerous gaps remain
to be filled in order to understand the complexity of KSR1
biological actions. First of all, physiological substrates of
KSR1 and its catalytic activity need to be identified further
and validated in differential cellular contexts, as well as its
subcellular localization where it performs certain functions.
Moreover, as a scaffold protein, it is crucial to determine its
binding partners in dynamic scenarios since the subsequent
interaction will eventually contribute to various biological
outcomes. Finally, the inquiry as to whether KSR1 is an
attractive therapeutic target in malignancies that are confined
to be Ras-dependent tumours requires further clarification.
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SILAC-based phosphoproteomics reveals an
inhibitory role of KSR1 in p53 transcriptional
activity via modulation of DBC1
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Background: We have previously identified kinase suppressor of ras-1 (KSR1) as a potential regulatory gene in breast cancer.
KSR1, originally described as a novel protein kinase, has a role in activation of mitogen-activated protein kinases. Emerging
evidence has shown that KSR1 may have dual functions as an active kinase as well as a scaffold facilitating multiprotein complex
assembly. Although efforts have been made to study the role of KSR1 in certain tumour types, its involvement in breast cancer
remains unknown.
Methods: A quantitative mass spectrometry analysis using stable isotope labelling of amino acids in cell culture (SILAC) was
implemented to identify KSR1-regulated phosphoproteins in breast cancer. In vitro luciferase assays, co-immunoprecipitation as
well as western blotting experiments were performed to further study the function of KSR1 in breast cancer.
Results: Of significance, proteomic analysis reveals that KSR1 overexpression decreases deleted in breast cancer-1 (DBC1)
phosphorylation. Furthermore, we show that KSR1 decreases the transcriptional activity of p53 by reducing the phosphorylation of
DBC1, which leads to a reduced interaction of DBC1 with sirtuin-1 (SIRT1); this in turn enables SIRT1 to deacetylate p53.
Conclusion: Our findings integrate KSR1 into a network involving DBC1 and SIRT1, which results in the regulation of p53
acetylation and its transcriptional activity.
Kinase suppressor of ras-1 (KSR1), initially described more than 15
years ago as a novel protein kinase in the Ras-Raf pathway
(Kornfeld et al, 1995; Therrien et al, 1995) is an essential
scaffolding protein that co-ordinates the assembly of the
mitogen-activated protein kinase (MAPK) complex, consisting of
the MAPK kinase MEK and the extracellular signal-regulated
kinase (ERK) to facilitate activation of MEK and thus ERK
(Kolesnick and Xing, 2004; Zafrullah et al, 2009; Goettel et al,
2011). KSR1 has been extensively referred to as a pseudokinase,
because of its lack of a key catalytic residue (Zhang et al, 2012).
However, emerging evidence suggests that KSR1 functions as an
active kinase as well as a scaffold protein. Using recombinant wild-
type KSR1, different groups have shown that KSR1 is capable of
directly phosphorylating Raf-1 and MEK1 (Zafrullah et al, 2009;
Goettel et al, 2011; Hu et al, 2011). On the other hand, crystal
structure analysis suggests a direct interaction between KSR and
Raf that enables KSR1 to regulate Raf activation independent of its
catalytic activity (Rajakulendran et al, 2009). Such findings add
complexity to the simple view of ERK spatio-temporal pathway
control and identify pseudokinases such as KSR1 as potential targets.
Given the role of KSR1 in the Ras–Raf–MAPKs cascade,
intensive efforts have focused on Ras-dependent cancers. For
instance, recent studies reported that KSR1 regulates the
proliferative and oncogenic potential of cells and inhibition of
KSR1 abrogates Ras-dependent pancreatic cancer growth (Xing
et al, 2003; Kortum and Lewis, 2004). Similarly, KSR1 is required
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for tumour formation in a skin cancer mouse model (Lozano et al,
2003). As Ras mutations are rare in breast cancer, the involvement of
KSR1 may not depend on the canonical Ras–Raf–MAPKs pathway.
Using a short interfering RNA (siRNA) kinome screen, we identified
KSR1 as a novel regulator of the transcriptional activity of oestrogen
receptor alpha (ERa; Giamas et al, 2011). Moreover, we show that
KSR1 expression is significantly correlated with overall and disease-
free survival in patients with breast cancer (our unpublished data).
However, its biologic functions in this setting have remained
unexplored, as are its major partner proteins and pathways including
those connected to p53, which we implicate here.
The p53 tumour suppressor is well known to have a central role
in cell growth arrest, apoptosis and cellular response to genotoxic
stress (Levine, 1997; Vogelstein et al, 2000). Its transcriptional
activity is highly regulated by post-transcriptional modifications
including acetylation (Brooks and Gu, 2003; Tang et al, 2008).
Previous data demonstrate that deleted in breast cancer 1 (DBC1)
directly interacts and negatively regulates the deacetylase SIRT1
resulting in an increase of p53 acetylation (Kim et al, 2008; Zhao
et al, 2008). Furthermore, phosphorylation of DBC1 is necessary
for its interaction with SIRT1, while it inhibits the activity of SIRT1
in response to DNA damage (Yuan et al, 2012; Zannini et al, 2012).
Herein, we present a KSR1-regulated phosphoproteomic profile
in breast cancer cells using a stable isotope labelling of amino acids
in cell culture (SILAC) approach. Furthermore, we identify a role
of KSR1 in the regulation of p53 transactional activity by reducing
its acetylation via the modulation of DBC1–SIRT1 interaction.
MATERIALS AND METHODS
SILAC cell culture. SILAC dialysed calf serum and custom
Dulbecco’s modified Eagle’s medium (DMEM) mediums contain-
ing either unlabelled [12C6,
14N4]-arginine (Arg) and [
12C6]-lysine
(Lys) (R0K0 –‘light’) or labelled [13C6,
15N4]-Arg and [
13C6]-Lys
(R10K8 –‘heavy’) were purchased from Dundee Cell Products
(Dundee, UK). MCF7 cells were grown in these custom DMEM
mediums along with 10% dialysed fetal calf serum (FCS) and 1% of
antibiotics (penicillin and streptomycin). The cells that were grown
for at least seven passages were used for this experiment.
Protein digestion and peptide fractionation. Equal amounts of
protein from unlabelled and labelled samples were combined
before protein digestion. Briefly, samples were reduced in 10mM
dithiothreitol (DTT) and alkylated in 50mM iodoacetamide before
boiling in loading buffer, and then separated by one-dimensional
sodium dodecyl sulphate (SDS)–PAGE 4–12% Bis-Tris Novex
mini-gel from Invitrogen (Paisley, UK) and visualised by colloidal
Coomassie staining from Invitrogen. The entire protein gel lanes
were excised and cut into 10 slices each. Every gel slice was subjected
to in-gel digestion with trypsin overnight at 37 1C. The resulting
tryptic peptides were extracted by formic acid (1%) and acetonitile,
lyophilised in a speedvac and resuspended in 1% formic acid.
Protein digestion and phosphopeptide enrichment. FASP
procedure was performed as previously described (Wisniewski et al,
2009). In all, 500ul FASP 1 (8M urea, 20mM DDT in 100mM Tris/HCL
pH 8.5) was added to B2mg protein lysate to dilute SDS
concentration and transferred to a Vivacon 500, 30k MWCO HY
filter from Sartorius Stedim Biotech (Epsom, UK). The sample was
buffer exchanged using FASP 1 several times by spinning the tube
at 7000 g to remove detergents. The protein lysate was concen-
trated by centrifugation and diluted in FASP 2 (100mM Tris/HCl
pH 8.5) ready for trypsin digestion. The sample was reduced using
50mM fresh IAA in FASP 2 in the dark for 30min. Lysates were
spun down to remove excess IAA and buffer exchanged into FASP
3 (100mM triethyl ammonium bicarbonate). Trypsin was dissolved
in FASP 3 to give a 1 : 200 enzyme to protein ratio and added in a
volume of at least 100 ml for 4–6 h. This was repeated with fresh
trypsin for a further overnight incubation. Lysates were spun
down and washed with 0.5 M NaCl and 150 ml 10% TFA added to
reduce the pH. A standard desalting procedure was used
(Thingholm et al, 2006).
Hydrophilic interaction chromatography (HILIC) fractionation:
A TSKgel Amide-80 separation column with a TSKgel Amide
guard column was used for HILIC separation of FASP peptides.
Buffer A: 80% ACN, 0.1% formic acid and buffer B: 0.1% formic
acid was used for the gradient at a flow rate of 0.6mJmin–1. The
sample was separated into 45 fractions, collected 2mins per vial
and dried using a speed vac.
TiO2 enrichment was performed as previously described
(Thingholm et al, 2006). TiO2 beads were washed and
re-suspended in buffer B at 50 mg ml–1 and added to tubes to give
1mg per tube. The sample was re-suspended in loading buffer,
added to beads and incubated at RT for 20min. After washing,
using buffers A and B samples were eluted using aliquots of 0.5%
NH4OH. Elutions were pooled and 10 ml of 20% FA added to
adjust the pH. Samples were dried and re-suspended in 1% FA.
Mass spectrometry methods. Trypsin-digested peptides were
separated using an Ultimate 3000 RSLC nanoflow LC system
from Thermo Scientific (Cramlington, UK). On average 0.5 mg was
loaded with a constant flow of 5 ml min–1 onto an Acclaim
PepMap100 nanoViper C18 trap column (100mm inner-diameter,
2 cm; Thermo Scientific). After trap enrichment, peptides were
eluted onto an Acclaim PepMap RSLC nanoViper, C18 column
(75 mm, 15 cm; Thermo Scientific) with a linear gradient of 2–40%
solvent B (80% acetonitrile with 0.08% formic acid) over 65min
with a constant flow of 300 nlmin–1. The HPLC system was
coupled to a linear ion trap Orbitrap hybrid mass spectrometer
(LTQ-Orbitrap Velos, Thermo Scientific) via a nano electrospray
ion source (Thermo Scientific). The spray voltage was set to 1.2 kV,
and the temperature of the heated capillary was set to 250 1C. Full-
scan MS survey spectra (m/z 335–1800) in profile mode were
acquired in the Orbitrap with a resolution of 60 000 after
accumulation of 1 000 000 ions. The 15 most intense peptide ions
from the preview scan in the Orbitrap were fragmented by
collision-induced dissociation (normalised collision energy, 35%;
activation Q, 0.250; and activation time, 10ms) in the LTQ after
the accumulation of 10 000 ions. Maximal filling times were
1000ms for the full scans and 150ms for the MS/MS scans.
Precursor ion charge state screening was enabled, and all
unassigned charge states as well as singly charged species were
rejected. The lock mass option was enabled for survey scans to
improve mass accuracy. Data were acquired using the Xcalibur
software from Thermo Scientific.
Quantification and bioinformatics analysis. The raw mass
spectrometric data files obtained for each experiment were collated
into a single quantitated data set using MaxQuant (Cox and Mann,
2008) and the Andromeda search engine software (Cox et al, 2011).
Enzyme specificity was set to that of trypsin, allowing for cleavage
N-terminal to proline residues and between aspartic acid and
proline residues. Other parameters used were: (i) variable
modifications, methionine oxidation, protein N-acetylation, gln
- pyro-glu; (ii) fixed modifications, cysteine carbamidomethyla-
tion; (iii) database: target-decoy human MaxQuant (ipi.HU-
MAN.v3.68); (iv) heavy labels: R6K4 and R10K8; (v) MS/MS
tolerance: FTMS – 10 p.p.m., ITMS – 0.6Da; (vi) maximum
peptide length, 6; (vii) maximum missed cleavages, 2; (viii)
maximum of labelled amino acids, 3; and (ix) false discovery rate,
1%. Peptide ratios were calculated for each arginine-containing
and/or lysine-containing peptide as the peak area of labelled
arginine/lysine divided by the peak area of non-labelled arginine/
lysine for each single-scan mass spectrum. Peptide ratios for all
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arginine-containing and lysine-containing peptides sequenced for
each protein were averaged. Data are normalised using 1/median
ratio value for each identified protein group per labelled sample.
Cell lines, reagents, antibodies and plasmids. MCF7, ZR75-1,
SKBR3, MDA-MB-231 (MDA231) and p53þ /þ HCT116 cells were
maintained in DMEM supplemented with 10% FCS and 1% penicillin/
streptomycin/glutamine. All cells were incubated at 37 1C in
humidified 5% CO2. FuGENE HD transfection reagent was obtained
from Roche (Burgess Hill, UK). siKSR1 were purchased from Qiagen
(Crawley, UK) and verified. Plasmids containing human wild-type
KSR1 (pCMV6-KSR1) and empty vector (pCMV6-vector) were
obtained from OriGene (Cambridge, UK). Mutant KSR1 R502M
was generated using QuikChange Site-Directed Mutagenesis Kit were
from Stratagene (Stockport, UK) and confirmed by plasmid sequence.
MCF7-parental and MCF7-KSR1 stable cells were generated by
transfection of either pCMV6-vector or pCMV6-KSR1 in MCF7 cells
and selected in the presence of G418 (1mgml–1). KSR1 overexpression
was confirmed by RT–qPCR and western blotting. Etoposide was
purchased from Sigma Aldrich (Gillingham, UK). The Dual-Glo
Luciferase Assay System was purchased from Promega (Southampton,
UK). The following antibodies were used: KSR1 rabbit polyclonal from
Cell Signaling (Hitchin, UK), anti-Flag mouse monoclonal (Sigma
Aldrich), p53 mouse monoclonal DO-1 from Santa Cruz (Wiltshire,
UK), acetylated-p53 and phospho-p53 Ser15 rabbit polyclonal (Cell
Signaling), SIRT1 rabbit polyclonal (Santa Cruz), DBC1 and phospho-
DBC1 Thr454 rabbit polyclonal (Cell Signaling) and b-actin mouse
monoclonal from Abcam (Cambridge, UK). The following p53-target
gene promoter–reporter constructs previously described (Vikhanskaya
et al, 2007) were a kind gift from Professor Kanaga Sabapathy: AIP-1-
luciferase (luc), IGFBP3-luc, R2-luc and cyclinG1-luc. The renilla
luciferase reporter vector (pRL-TK) was purchased from Promega.
Protein extraction and western blotting. NP40 lysis buffer
(50mM Tris-HCl, pH 8.0, 150mM NaCl, 10% (v/v) glycerol, 1%
NP40, 5mM DTT, 1mM EDTA, 1mM EGTA, 50 mM leupeptin and
30 mgml–1 aprotinin) was used to extract whole-cell lysates. Cell
pellets were mixed thoroughly with NP40 lysis buffer, and then
incubated in ice for 15min before centrifuging at 15 000 r.p.m. for
15min at 4 1C. Nuclear and cytoplasmic extracts were prepared
from whole-cell lysis using NE-PER Nuclear and Cytoplasmic
Extraction Kit (Thermo Scientific). Protein concentration was
measured by the bicinchoninic acid (BCA) protein assay from
Pierce (Epsom, UK). Lysates were heated with 5 SDS sample
buffer at 95 1C for 5min before they were loaded to 10% SDS–
PAGE. Samples were then transferred to Hybond ECL super
nitrocellulose membranes from GE Healthcare (Little Chalfont,
UK). Subsequently, the membranes were blocked in TBS contain-
ing 0.1% (v/v) Tween20 and 5% (w/v) non-fat milk for 1 h. The
primary antibodies were probed with membranes overnight at
4 1C. The membranes were then washed three times in TBS/Tween
for 15min following incubation with HRP-conjugated secondary
antibodies (1 : 3000 dilution) for 60min. The membranes were
then washed three times again and were detected with enhanced
chemiluminescence (ECL). Films were developed using a Konica
SRX-1001A X-ray developer (Banbury, UK). Alternatively, mem-
branes were incubated with IRDye donkey anti-mouse or donkey
anti-rabbit secondary antibodies for 60min and visualised by
Odyssey Fc Imaging System from LI-COR (Cambridge, UK).
RNA extraction and RT–qPCR. RNeasy kit (Qiagen) was used to
isolate total RNA. Reverse transcription was performed using high-
capacity cDNA reverse transcription kit from Applied Biosystems
(Warrington, UK). RT–qPCR analysis was performed on a
7900HT Thermocycler (Applied Biosystems) using TaqMan
mastermix and primers for TP53 and GAPDH cDNAs, purchased
from Applied Biosystems.
Luciferase reporter assay. In all, 8 104 per well MCF7 cells were
seeded into 24-well plate and transfection was performed using
FuGENE HD transfection reagent according to the manufacturer’s
instructions. Cells were transfected with different p53 constructs,
and pCMV6-KSR1 or pCMV6-vector and together with renilla
luciferase reporter vector (pRL-TK). Cell lysates were collected
after 24-h transfection and firefly and renilla luciferase activities
were measured by the Dual-Glo Luciferase Assay kit as per the
manufacturer’s protocols described. The transcriptional activity of
various p53 constructs were determined by firefly luciferase activity
and normalised against renilla luciferase activity, which was served
as control for transfection efficiency.
Immunofluorescence staining. MCF7 cells seeded on glass
coverslips in 6 cm dishes were transfected with pCMV6-KSR1 or
pCMV6-Vector using FuGENE HD. Cells were fixed in 4% w/v
paraformaldehyde at 37 1C for 15min, permeabilised with 0.1%
Triton-X for 10min and incubated in immune-fluorescent
blocking buffer (10% AB-serum in PBS) for 1 h, followed by
incubation with p53 antibody (DO-1). After washing with PBS,
coverslips were incubated for 45min at 37 1C with anti-mouse-IgG
Alexa Fluor  555 antibody (Invitrogen). DNA was visualised by
DAPI staining. Cells were examined on an Axiovert-200 laser
scanning inverted microscope from Zeiss (Welwyn Garden City,
UK) as previously described (Giamas et al, 2011).
Cell proliferation assay. Sulphorhodamine B (SRB) assay was
performed to determine the growth of breast cancer cell lines in
96-well plates. After siRNA knockdown of KSR1 at indicated time
points, plates were collected for the following protocol. Cells were
fixed by adding 100 ml per well of ice-cold 40% trichloroacetic acid
(TCA) to each culture for 1 h and incubated in the fridge. Plates
were then washed  5 times in running tap water (allow the water
to fill wells indirectly). Cells were stained with 100 ml of 0.4% (w/v)
SRB from Sigma Aldrich in 1% acetic acid for 30min and plates
were washed five times in 1% acetic acid and left to air dry
overnight. On the day of plate reading, bound dye was solubilised
by adding 100 ml of 10mM Tris base to all the wells and plates were
measured at 492 nm using Tecan microplate reader (Reading, UK).
Neddylation assay. MCF7 cells plated on 15 cm dishes were
transfected using FuGENE HD with 8 mg pcDNA3-HA-NEDD8
from Addgene (Cambridge, MA, USA), 8 mg pCMV6-KSR1 or 8 mg
pCMV6-vector constructs as indicated. After 24 h, cells were lysed
in radio-immunoprecipitation assay (RIPA) buffer (Sigma Aldrich)
supplemented with protease inhibitors. Total protein was quanti-
fied by the BCA assay (Pierce). In all, 2 mg mouse IgG or p53 (DO-
1) was pre-incubated with protein agarose beads for 2 h to form IP
matrix complex (ImmunoCruz IP/WB Optima C System, Santa
Cruz). In total, 2mg protein lysate was added into the beads and
was incubated on a rotator overnight at 4 1C. Beads were washed
with RIPA buffer for three times and were heated in SDS loading
buffer. Neddylated p53 were detected by western blot using p53-
specific DO-1 antibody or NEDD8 antibody (Cell Signaling) as
described before (Xirodimas et al, 2004; Abida et al, 2007).
Statistical analysis. Each experiment was repeated at least three
times. Student’s t-test was two-sided at a 0.05 significance level and
performed using SPSS 16.0 statistical software (SPSS Inc., Chicago,
IL, USA).
RESULTS
Phosphoproteomics analysis of KSR1-regulated proteins using
SILAC. In order to obtain the KSR1-regulated phosphoproteome
profile, a necessary step to understand its integrated signalling
pathways in breast cancer, we first performed a quantitative
proteomic analysis.
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Here, MCF7 cells were maintained for seven cell divisions in
either R0K0 ‘light’ medium, containing unlabelled [12C6,
14N4]-
arginine (Arg) and [12C6]-lysine (Lys) amino acids, or in R10K8
‘heavy’ medium, containing labelled [13C6,
15N4]-Arg and [
13C6,
15N2]-Lys. Labelled cells were then transfected with either the
pCMV6 vector (R0K0, control) or with a pCMV6-KSR1 plasmid
(R10K8) that encodes for the full-length KSR1. After 24 h, proteins
were extracted, mixed 1 : 1, separated on SDS–PAGE, trypsin-
digested, fractionated and analysed by LC-MS/MS using Max-
Quant software (Cox and Mann 2008; Figure 1A).
We identified a total of 2504 proteins out of which 2032 were
quantified (false discovery rate o1%). Similarly, we found 1409
phosphopeptides from 891 phosphoproteins out of which 1165
phosphopeptides from 812 phosphoproteins were quantified. After
normalisation, we determined the phosphorylation vs total protein
level ratio between control and KSR1-overexpressed samples.
Based on our data, we obtained information about the phospho-
rylation change of 379 potential sites that correspond to 240
proteins, as several proteins had more than one potential
phosphorylation sites. Among these modulated sites, 341 phos-
phoserine (pS), 37 phosphothreonine (pT) and 1 phosphotyrosine
(pY) sites were included (Supplementary Excel File 1).
Surprisingly, only 3 out of the 379 identified phospho-sites were
induced 450% while most of them (233 out of 379) were actually
decreased (o50%) after KSR1 overexpression. These data partly
support the characterisation of KSR1 as a pseudokinase, emphasising
its primary role as a scaffold protein not a kinase. The values from
total and phosphorylated proteins were plotted to create a graph
showing the log2 normalised ‘total proteins’ vs the log2 ‘phosphory-
lated proteins’ ratios (Figure 1B).
Ontology analysis of differentially regulated KSR1 phosphoproteins.
We then performed gene ontology (GO) analysis and classification
(using the ‘Panther’ software; Mi et al, 2013) to assign the
KSR1-regulated phosphoproteome according to (i) molecular
functions, (ii) biological processes and (iii) cellular components
(Figure 1C). We found significant enrichment for GO molecular
functions terms related to binding (GO: 0005488), catalytic activity
(GO: 0003824), structural molecule activity (GO: 0005198), as well
as transcription regulator (GO: 0003824) and enzyme regulator
(GO: 0030234) activities. Our phosphoproteomics analysis facili-
tated the identification of biological processes associated with cell
cycle (GO: 0007049) and communication (GO: 0007154) along
with metabolic (GO: 0008152), cellular (GO: 009987) and
transport (GO: 0006810) processes. Finally, regarding the localisa-
tion of the identified KSR1-regulated phosphoproteins, there was a
similar distribution between membrane/cytoplasmic and nuclear
cell components, resulting from the direct and indirect effects of
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Figure 1. Identification of KSR1-regulated phosphoproteome in breast cancer cells. (A) Experimental schematic outline of SILAC experiment.
(B) Scatter plot comparison of phosphosite ratios quantified from control vs KSR1-overexpressed MCF7 cells. (C) Gene ontology (GO)
Classification of the KSR1-regulated phosphoproteome in MCF7 cells according to molecular functions, biological processes and cellular
compartmentalisation.
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KSR1 abundance. This is by far the first ontology analysis of KSR1-
regulated phosphoprotein profile in cancer, which will for sure
enable extensive study of its functions in signalling pathways other
than the canonical Ras–Raf–MAPKs cascades.
Phosphoproteomics analysis reveals a downregulation of
phospho-DBC1 by KSR1. Further examination of the identified
KSR1-regulated phosphoproteins unveiled that some of these proteins
have been previously implicated in the development of breast
cancer. For instance, androgen-induced proliferation inhibitor
(APRIN), a protein phosphorylated by ATM (ataxia telangiectasia-
mutated) and ATR (ataxia telangiectasia and Rad3-related) kinases,
was described as a BRCA2-interacting protein required for genome
integrity and a predictor of outcome in response to chemotherapy
in breast cancer (Matsuoka et al, 2007; Brough et al, 2012). Rho
GTPase-activating protein 35 (ARHGAP35) was shown to be
phosphorylated by breast tumour kinase (Brk) leading to RhoA
inactivation, Ras activation and promotion of breast cancer growth
and migration (Shen et al, 2008). Phosphorylation of Hsp27 was
correlated with HER-2/neu status and lymph node positivity in
breast cancer, and phosphorylated Hsp27 was also linked to
invasiveness and drug resistance (Zhang et al, 2007; Fujita et al,
2011). Histone deacetylase 1/Sin3A complex phosphorylation has
been linked to ERa expression and hormonal therapy resistance in
breast cancer cells (De Amicis et al, 2011).
Interestingly, among the most significantly KSR1-regulated
phosphorylated proteins, was DBC1, whose involvement in the
regulation of p53 activity via SIRT1 has been described previously
(Kim et al, 2008; Zhao et al, 2008). Taking into consideration the
importance of p53 in breast cancer, we then assessed the
connection between KSR1 and p53 activity in vitro.
KSR1 regulates the transcriptional activity of p53. We first
examined the effects of KSR1 on p53 transcriptional activity by
performing luciferase reporter assays using various p53-dependent
gene promoter constructs (including p53-R2, p53-AIP1, p53-
IGFBP3 and p53-CYCLIN G1). MCF7 cells were co-transfected
with either pCMV6 or pCMV6-KSR1 plasmids and each individual
p53-dependent promoter construct, in the presence or absence of
etoposide, which can induce p53 activity. Interestingly, the
luciferase activity of all four different p53-regulated genes was
significantly repressed after overexpression of KSR1, suggesting an
oppressive role of KSR1 on p53 activation (basal levels and after
etoposide treatment; Figure 2A). As expected, silencing of KSR1
resulted in a marked increase in the activity of p53-dependent
promoter genes (Figure 2B). These results suggest a potential
involvement of KSR1 in p53 transcriptional activity regulation.
KSR1 does not affect the mRNA, protein, subcellular localisation
and neddylation levels of p53. In order to investigate the
potential mechanism resulting in the downregulation of p53
transcriptional activity, we initially evaluated the p53 gene and
protein expression after KSR1 overexpression. RT–qPCR and
western blotting analyses did not reveal any changes in the p53
mRNA and protein levels, respectively, after KSR1 transient
overexpression in MCF7 cells (Figure 3A). Similarly, no change
in p53 protein levels was observed in MCF7 stably overexpressing
KSR1 cells comparing with MCF7 parental cells (Figure 3A). As
the nuclear localisation of p53 is essential for its activity, we
examined whether KSR1 could affect p53 compartmentalisation.
Immunofluorescence and subcellular protein fractionation did not
reveal any cytoplasmic translocation of p53 upon KSR1 transient
overexpression (Figure 3B). Moreover, it has been recently
reported that neddylation of p53 can inhibit its transcriptional
activity (Xirodimas et al, 2004; Abida et al, 2007). However, our
neddylation assay did not show any significant changes following
KSR1 overexpression ruling out neddylation as the reason for the
observed p53 decreased activity (Figure 3C).
KSR1 decreases p53 acetylation by reducing phosphorylation of
DBC1 resulting in impaired DBC1–SIRT1 interaction. Post-
translational modifications of p53 such as phosphorylation and
acetylation are essential for p53 activity in response to genotoxic
stress (Brooks and Gu, 2003; Tang et al, 2008). To examine effects
of KSR1 on phospho-p53 and acetylated-p53, cells were transfected
with pCMV6 or pCMV6-KSR1 plasmids in the presence of
etoposide or doxorubicin. Although the phosphorylation levels of
p53 (Ser15) did not change, interestingly the acetylated-p53 was
reduced after KSR1 overexpression upon either etoposide
(Figure 4A) or doxorubicin (Supplementary Figure 1) treatment.
Similar results were confirmed in several other breast cancer cell
lines (including ZR75-1 and SKBR3) and one colon cancer cell line
HCT116 (Supplementary Figure 1).
It is already known that SIRT1 functions as an NAD-dependent
p53 deacetylase that affects p53 activation (Vaziri et al, 2001; Tang
et al, 2008). In addition, DBC1 can interact with and negatively
regulate SIRT1 resulting in increased p53 acetylation (Kim et al,
2008; Zhao et al, 2008). Taking this potential link into
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consideration, we decided to investigate the effects of KSR1 on
these two proteins.
Total SIRT1 levels were not affected by KSR1 upregulation
(Figure 4A). Based on the SILAC data regarding the effects of
KSR1 on the phosphorylation of DBC1 and the association
between DBC1 and SIRT1, we performed western blotting of
phospho-DBC1 (Thr454) revealing a decrease in the phospho-
rylation levels in basal and etoposide-induced conditions
(Figure 4A). Consistently, KSR1 silencing rescued the abolished
acetylation of p53 after etoposide treatment (Figure 4B).
Moreover, knock-down of KSR1 did not alter the total
proteins of SIRT1 and DBC1, but increased DBC1 phosphoryla-
tion at Thr454 (Figure 4B). These data further validate our
SILAC results and allow KSR1 to integrate into a known network
of p53 acetylation regulation involving phospho-DBC1 and
SIRT1.
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To further demonstrate that KSR1 regulates p53 acetylation
through DBC1, we studied the effects of KSR1 on p53 acetylation
after DBC1 knockdown upon etoposide treatment in MCF7 cells.
As shown in Figure 4C, western blotting experiments revealed that
acetylated p53 was consistently increased after silencing of KSR1,
whereas no change in p53 acetylation was observed after knocking
down both KSR1 and DBC1 upon etoposide treatment. This
suggests that KSR1 regulates p53 acetylation through DBC1, as
depleting DBC1 undermines the effect of KSR1 on acetylated p53.
Moreover, to examine whether the effect of KSR1 on DBC1
depends on its catalytic activity, we generated a KSR1 mutant
(KSR1/R502M) that encompasses a key amino-acid mutation
(arginine to methionine) within its kinase domain resulting in
impaired catalytic activity (Laurent et al, 2004). Consistently, wild-
type KSR1 decreased pDBC1, whereas mutant KSR1/R502M
sustained pDBC1 levels in comparison with the control
(Figure 4D). This result suggests that an intact catalytic domain
of KSR1 is essential for regulating DBC1 phosphorylation.
Phosphorylation of DBC1, induced by genotoxic stress, creates
binding sites and enhances the interaction between SIRT1 and
DBC1 (Yuan et al, 2012; Zannini et al, 2012), which subsequently
undermines the deacetylase activity of SIRT1 on p53. For this
reason, we tested whether KSR1 affects the stress-induced SIRT1–
DBC1 interaction. As shown in Figure 4E, upon etoposide
treatment, the interaction between SIRT1 and DBC1, determined
by co-immunoprecipitation (IP), was undermined after KSR1
overexpression in MCF7, which allows SIRT1 to interact more with
p53 resulting in declined p53 acetylation.
KSR1 is important for breast cancer proliferation and its
expression is altered in breast cancer. To study whether KSR1
affects breast cancer growth in vitro, cell proliferation assay was
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Figure 4. Mechanisms of KSR1-regulated p53 transcriptional activity. (A) Effects on p53 acetylation and phosphorylation of DBC1 after KSR1
overexpression followed by etoposide treatment. MCF7 cells were transiently transfected with pCMV6 (vector) or pCMV6-KSR1 plasmids for 24 h.
Subsequently, cells were treated with various concentrations of etoposide (20, 40, 80mM, 3 h). p53 acetylation and DBC1 phosphorylation at
Thr454 were assessed by immunoblotting with specific antibodies as indicated. (B) Effects on p53 acetylation and phosphorylation of DBC1 after
KSR1 silencing followed by a titration of etoposide treatment. MCF7 cells were transfected with control siRNA (siCT) or siKSR1 for 72 h followed by
etoposide treatment (20, 40, 80mM, 3 h). p53 acetylation and DBC1 phosphorylation at Thr454 were assessed by immunoblotting with specific
antibodies as indicated. (C) Effect of KSR1 on p53 acetylation is through DBC1. MCF7 cells were transfected with control siRNA (siCT) or siKSR1 in
concordance with siCT or siDBC1 for 72h followed by etoposide treatment (40mM, 3h). Acetylated p53, DBC1 and KSR1 protein levels were
assessed by immunoblotting with specific antibodies as indicated. (D) Effect of KSR1 on DBC1 phosphorylation is dependent on its intact kinase
domain. MCF7 cells were transiently transfected with vector, wild-type KSR1 or mutant KSR1 (R502M) plasmids for 24 h followed by etoposide
treatment (40mM, 3 h). DBC1 phosphorylation was measured by immunoblotting with specific antibody. (E) Interaction of DBC1 and SIRT1 after
KSR1 overexpression with etoposide treatment by immunoprecipitation (IP). MCF7 cells were transiently transfected with pCMV6 or pCMV6-KSR1
plasmids for 24 h. Subsequently, cells were treated with etoposide (40mM, 3 h). The interactions between SIRT1 and DBC1 were detected by IP of
SIRT1 or DBC1 followed by immunoblotting with DBC1 and SIRT1 antibodies respectively. Blots shown are representatives of at least three
independent experiments. Quantification of blots was analysed by ImageJ software (NIH, Bethesda, MD, USA). (F) Schematic model illustrating the
role of KSR1 on p53 transcriptional activity in breast cancer cells with (i) basal or (ii) up-regulated levels of KSR1. Abbreviation: IgG¼
immunoglobulin G.
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performed in four different breast cancer cell lines. As shown in
Figure 5, knockdown of KSR1 significantly reduced breast cancer
cell growth in MCF7, ZR75-1, SKBR3 and MDA231 after six days,
showing an important role of KSR1 in breast cancer cell
proliferation. This is also supported by further examination of
KSR1 expression in breast tumour tissues. Oncomine analysis
(Rhodes et al, 2004) was conducted to study the levels of KSR1 in
normal breast and cancer tissues from TCGA Breast database.
Indeed, KSR1 abundance is varied between normal breast and
various breast carcinomas, including invasive ductal breast
carcinoma and invasive lobular breast carcinoma (Figure 6).
Specifically, KSR1 expression is significantly upregulated in
invasive ductal breast carcinoma, lobular breast carcinoma and
invasive breast carcinoma.
DISCUSSION
KSR1 was originally identified as a novel protein kinase
evolutionarily conserved in Drosophila and Caenorhabditis elegans
functioning between Ras and Raf in the Ras–Raf–MAPKs
signalling pathway (Kornfeld et al, 1995; Therrien et al, 1995).
However, mammalian KSR1 has been extensively referred as a
pseudokinase, because of the mutation in the lysine residue in the
catalytic domain, which is essential for its kinase activity (Zhang
et al, 2012). Later, the role of KSR1 as a scaffolding protein was
discovered. Murine KSR1 was first reported to cooperate with
activated Ras to facilitate MAPK kinases activation thus stimulat-
ing Xenopus oocyte maturation and cellular transformation
(Therrien et al, 1996). At the same time, the idea of KSR1 as an
active kinase was described from the finding that TNF-a and
ceramide were shown to significantly increase KSR1 autopho-
sphorylation and its capacity to phosphorylate and activate Raf-1
(Zhang et al, 1997). Therefore, emerging evidence suggests dual
function of KSR1 as an active kinase as well as a scaffold protein
(Rajakulendran et al, 2009; Hu et al, 2011). Moreover, KSR1 has
been previously shown as an oncogene in Ras-dependent cancers,
such as pancreatic and lung carcinomas (Xing et al, 2003; Kortum
and Lewis, 2004). However, its biological functions and modulated
signalling pathways in breast cancer have remained undefined.
In this study, we performed a global comparative proteomic
analysis and for the first time reveal the complex KSR1-regulated
phosphoproteome in MCF7 breast cancer cells. Various new
KSR1-regulated proteins and signalling networks that KSR1 is
involved in were identified. Notably, our phosphoproteomic
analysis showed that the majority (233 out of 379) of the
identified phospho-sites were actually reduced after KSR1 over-
expression in comparison with a small number of increased
phosphorylations (3 out of the 379), suggesting its primary role as
a scaffold protein not a kinase at least in this context.
Interestingly, none of the previously described proteins including
MEK and ERK in the canonical Ras–Raf–MAPKs pathways have
been identified in our study. The possible explanation could be
that the Ras mutations are very rare in breast cancer (Adjei,
2001). Indeed, our recent work has also shown no significant
alteration in phosphorylation of the main components in the
Ras–Raf–MAPKs cascades upon overexpressing or silencing
KSR1 (unpublished work). Moreover, the KSR1-regulated phos-
phoproteins identified in this study illustrated a much more
extensive view of KSR1 involved biological functions, including
cell cycle, metabolism and apoptosis. Notably, some phospho-
proteins have been shown to have vital roles in multiple aspects of
breast cancer. For example, APRIN was reported as a BRCA2-
interacting protein essential for genome integrity and associated
with chemotherapy response in breast cancer (Matsuoka et al,
2007; Brough et al, 2012), whereas ARHGAP35 was shown to be
important in breast cancer growth and migration (Shen et al,
2008). Phospho-Hsp27 was related to invasiveness and drug
resistance in breast cancer (Zhang et al, 2007; Fujita et al, 2011).
Most importantly, the KSR1-regulated phosphoproteomic
1
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Figure 5. Effects of KSR1 silencing on breast cancer cell proliferation in vitro. SRB assays of MCF7, ZR75-1, SKBR3 and MDA231 cells after
transfection with 20nM of either siKSR1 or ‘non-targeting’ siRNA (control siRNA) or vehicle (Hiperfect) for 6 days. Error bars represent s.d. of three
experiements each in quintuplicates (*Po0.05, compared with control siRNA at day 6; Student’s t-test).
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analysis has identified phospho-DBC1 as a potential connection
to its modulation of p53 transcriptional activity here.
Deleted in breast cancer-1 was previously reported to be
involved in regulating p53 acetylation (Kim et al, 2008; Zhao et al,
2008), which is indispensable for p53 transcriptional activity (Tang
et al, 2008). Therefore, our work further investigated the effects of
KSR1 on p53 transcriptional activity, as well as the potential
mechanism on KSR1-mediated regulation of p53 transcriptional
activity, including p53 acetylation. Luciferase assays using different
p53-dependent gene promoter constructs showed that KSR1
overexpression suppressed p53 transcriptional activity in the
absence or presence of etoposide, whereas the opposite results
were observed after silencing of KSR1, indicating a regulatory role
of KSR1 in p53 activity. Mechanistic study demonstrated that
overexpression of KSR1 had no effect on p53 mRNA and total
protein levels, as well as subcellular localisation, phosphorylation
and neddylation, which are all potentially involved in p53 activity
modulation.
As expected, KSR1 overexpression reduced the acetylation of
p53, whereas silencing of KSR1 rescued the decreased p53
acetylation in the absence or presence of etoposide, suggesting
that KSR1 is involved in regulating p53 acetylation. It has already
been shown that DBC1 can interact with and negatively regulate
SIRT1, a NAD-dependent p53 deacetylase, resulting in increased
p53 acetylation (Kim et al, 2008; Zhao et al, 2008). Moreover,
phospho-DBC1, induced by genotoxic stress, is competent to
create binding sites and enhance the interaction between SIRT1
and DBC1, which subsequently undermines deacetylase activity of
SIRT1 on p53 (Yuan et al, 2012; Zannini et al, 2012). Consistently,
we demonstrated that KSR1 overexpression decreases the phos-
pho-DBC1 levels, whereas KSR1 silencing increases DBC1
phosphorylation. This provides us an explanation to the observed
effects of KSR1 on p53 acetylation and activity. Similar results were
obtained after overexpression or silencing KSR1 in different breast
cancer cell lines including ZR75-1 and SKBR3. Further co-IP
experiments proved that overexpression of KSR1 attenuates the
interaction of SIRT1–DBC1, which therefore allows SIRT1 to
interact more with p53 resulting in decreased p53 acetylation. Our
data herein are consistent with previous reports and in combina-
tion with our SILAC analyses enable KSR1 to integrate into a
known network together with DBC1 and SIRT1 on regulation of
p53 acetylation.
However, more evidence is still needed to elucidate the
mechanism of KSR1 on modulating DBC1 phosphorylation. The
work from Zannini et al (2012) demonstrated that ATM/ATR can
directly phosphorylate DBC1 on Thr454 upon DNA damage.
Phosphorylated DBC1 bound to and inhibited SIRT1, leading to
the separation of the SIRT1-p53 complex and an increase of p53
acetylation. Moreover, another group indicated that protein kinase A
and AMP-activated protein kinase was capable of inducing the
dissociation of SIRT1 from its endogenous inhibitor DBC1,
resulting in an alteration in downstream effects (Nin et al, 2012).
Therefore, whether the effect of KSR1 on DBC1 phosphorylation is
through ATM/ATR kinases or alternative pathways requires
further investigation.
Collectively, our SILAC analyses of the KSR1-regulated
phosphoproteome profile in cancer cells demonstrate its involve-
ment in multiple biological and molecular processes as well as
intricate signalling pathways. The identification of novel KSR1-
regulated proteins will shed light on new KSR1-modulated
signalling pathways implicated in breast cancer. In this work, we
propose a model (Figure 4F) where in cancer cells with basal levels
of KSR1, phosphorylated DBC1 directly interacts with SIRT1 and
reduces its deacetylase activity resulting in p53 activation and gene
expression initiation. However, in KSR1-transduced cells, KSR1
suppresses DBC1 phosphorylation, which undermines the direct
interaction between DBC1 and SIRT1. This in turn allows SIRT to
decrease p53 acetylation, which eventually inhibits p53 transcrip-
tional activity. Our study provides a new insight on the role of
KSR1 in p53 regulation and unveils an interesting mechanism for
its function in breast cancer development.
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Figure 6. KSR1 expression is altered in breast cancer tissues.Oncomine analysis was performed to examine KSR1 expression in breast normal and
cancer tissues using online TCGA microarray data (www.oncomine.org).
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